Research funding: Genetech, Adaptive Biotechnologies, Celgene,
Pharmacyclics, Seattle Genetics, and Astra Zeneca
376 |A PHASE 1, MULTICENTER, OPENLABEL STUDY OF CC
99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN
PATIENTS WITH RELAPSED OR REFRACTORY NONHODGKIN
LYMPHOMAS
J.M. Michot
1
, C. Carpio
2
, L. Nastoupil
3
, J. Chavez
4
, T. Feldman
5
, S.
Ferrari
6
, D. Morillo
7
, E. Bachy
8
, A. Pinto
9
, J. Kuruvilla
10
, T. J.
Buchholz
11
, S. Kasibhatla
12
, S. Carrancio
12
, C. Guarinos
13
, F. Wu
14
, S.
Li
15
, P. Patah
16
, M. Pourdehnad
16
1
Gustave Roussy Institute of Cancer, Département d'Innovation
Thérapeutique et d'Essais Précoces (DITEP), Villejuif, France,
2
Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall
d'Hebron, University Autònoma of Barcelona (UAB), Department of
Hematology, Barcelona, Spain,
3
MD Anderson Cancer Center,
University of Texas, Department of Lymphoma & Myeloma, Houston,
Texas, USA,
4
Moffitt Cancer Center, University of South Florida,
Department of Malignant Hematology, Tampa, Florida, USA,
5
Hackensack Meridian Health, Lymphoma Division, Edison, New
Jersey, USA,
6
Papa Giovanni XXIII Hospital, Dipartimento di
Ematologia, Bergamo, Italy,
7
Hospital Fundación Jiménez Díaz,
Department of Hematology, Madrid, Spain,
8
Hospices Civils de Lyon,
Department of Hematology, Lyon, France,
9
National Cancer Institute,
Fondazione G. Pascale, IRCCS, HematologyOncology & Stem Cell
Transplantation Unit, Napoli, Italy,
10
Princess Margaret Cancer
Centre, Cancer Clinical Research Unit, Division of Medical Oncology
and Hematology, Toronto, Canada,
11
Bristol Myers Squibb, Early
Clinical Development, Oncology, Princeton, New Jersey, USA,
12
Bristol
Myers Squibb, Translational Biology, Oncogenesis Therapeutic
Research Center, Princeton, New Jersey, USA,
13
Bristol Myers Squibb,
ONCTRC CITRE, Princeton, New Jersey, USA,
14
Bristol Myers Squibb,
Clinical Pharmacology, Early Clinical Development, Princeton, New
Jersey, USA,
15
Bristol Myers Squibb, Global Biometric Sciences,
Princeton, New Jersey, USA,
16
Bristol Myers Squibb, Early Clinical
Development, Hematology/Oncology and Cell Therapy, Princeton, New
Jersey, USA
Background: CC99282 is a novel, oral cereblon (CRBN) E3 ligase
modulator (CELMoD) agent that coopts CRBN to induce potent
and targeted degradation of Ikaros and Aiolos, transcription factors
that are known to be important for the normal differentiation and
function of multiple types of hematopoietic cells. NonHodgkin
lymphomas (NHL) comprise diverse lymphoma subtypes with
varying genomic alterations and clinical outcomes. Despite treat-
ment advances, management of aggressive relapsed or refractory
(R/R) NHL remains challenging. The ability of CC99282 to spe-
cifically target Ikaros and Aiolos for degradation provides a strong
biological rationale for studying it for the treatment of patients
with R/R Bcell NHL, both as a single agent and in combination
with rituximab, an approved humanized antiCD20 monoclonal
antibody. CC99282NHL001 (NCT03930953) is an ongoing,
phase 1, multicenter, openlabel, firstinhuman study evaluating
the safety, tolerability, and preliminary clinical activity of CC99282
alone and in combination with rituximab in patients with R/R Bcell
NHL.
Methods: Eligible patients include those with R/R NHL, including
diffuse large Bcell lymphoma (DLBCL), follicular lymphoma (FL),
mantle cell lymphoma, or primary central nervous system lym-
phoma (PCNSL), who have relapsed on or are refractory to 2
lines of therapy (or who have received 1 prior line of standard
therapy and are not eligible for any other therapy). This study is
conducted in 2 parts: dose escalation (Part A) and dose expan-
sion (Part B). Part A evaluates the safety and tolerability of
escalating CC99282 doses to determine the maximum tolerated
dose (MTD)/recommended phase 2 dose (RP2D) of CC99282
monotherapy. In Part A, patients with R/R DLBCL or R/R FL
receive oral CC99282 once daily on intermittent schedules per
28day cycle. Following the evaluation of the Bayesian logistic
regression model recommendation as well as the safety and
pharmacokinetic/pharmacodynamic data that are monitored
continually, decisions on dose escalations are made by the safety
review committee until the MTD/RP2D is reached. Part B will
evaluate the safety and efficacy of CC99282 administered at the
RP2D alone or in combination with rituximab to confirm the
RP2D of CC99282. Treatment efficacy is assessed according to
the Lugano Classification for NHL and the modified International
PCNSL Collaborative Group criteria. Correlations between various
biomarkers and clinical outcomes of treatment with CC99282,
alone or in combination with rituximab, will also be explored.
Adverse events are monitored until 28 days following the final
dose. Study treatments may be continued for up to 2 years, or
until significant disease progression, unacceptable toxicity, or
withdrawal.
The research was funded by: Bristol Myers Squibb
Keywords: Molecular Targeted Therapies, Ongoing Trials
Conflicts of interests pertinent to the abstract
JeanM. Michot
Consultant or advisory role: ASTEX, AstraZeneca, Bristol Myers
Squibb
Other remuneration: Investigator of clinical studies with Abbvie,
Agios, ARGENX, Bristol Myers Squibb, Forma, Genentech, Janssen,
Lilly, Roche, Sanofi, Xencor
C. Carpio
Consultant or advisory role: Novartis, Takeda, Regeneron
Educational grants: Bristol Myers Squibb, Novartis, Gilead, Takeda
L. Nastoupil
Consultant or advisory role: ADC Therapeutics, Bristol Myers Squibb,
Genentech, Janssen, Novartis
462
-
SUPPLEMENT ABSTRACTS
Honoraria: Bayer, Epizyme, Kite/Gilead, Pfizer, TG Therapeutics
Research funding: Bayer, Bristol Myers Squibb, Epizyme, Genentech,
Janssen, Novartis, TG Therapeutics
J. Chavez
Consultant or advisory role: Kite/Gilead, Novartis, Kymera, Kar-
yopharma, Abbvie, Janssen, ADC Therapeutics, Pfizer, TeneBio
Other remuneration: Speakers Bureau: Beigene, Morphosys, Epizyme
T. Feldman
Consultant or advisory role: AstraZeneca, ADC Therapeutics, Jans-
sen, Karyopharm, Kite, MorphoSys, AbbVie, Daiichi Sakyo
Honoraria: AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers
Squibb, Daiichi Sakyo, Janssen, Karyopharm, Kite, MorphoSys,
Pharmacyclics, Seattle Genetics, Takeda
Other remuneration: Speakers Bureau: AbbVie, Bristol Myers Squibb,
Janssen, Pharmacyclics, Seattle Genetics, Takeda
D. Morillo
Honoraria: AbbVie, Takeda, Janssen
Educational grants: AbbVie, Takeda, Janssen, Kite
E. Bachy
Consultant or advisory role: Roche, Bristol Myers Squibb
Honoraria: Roche, Gilead, Novartis, Sanofi, Amgen
Educational grants: AbbVie, Gilead, Sanofi
Other remuneration: Provision of Writing Assistance: Roche
A. Pinto
Honoraria: Roche, Servier, Takeda, Bristol Myers Squibb, MSD
J. Kuruvilla
Consultant or advisory role: AbbVie, Bristol Myers Squibb, Gilead,
Karyopharm, Merck, Roche, Seattle Genetics
Honoraria: Amgen, Antengene, AstraZeneca, Bristol Myers Squibb,
Gilead, Incyte, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche,
Seattle Genetics, TG Therapeutics
Research funding: Canadian Cancer Society, Leukemia and Lym-
phoma Society Canada, Princess Margaret Cancer Foundation,
Janssen, Roche, AstraZeneca
Other remuneration: Karyopharm (DSMB)
T. J Buchholz
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
S. Kasibhatla
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
S. Carrancio
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
C. Guarinos
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
F. Wu
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
S. Li
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
P. Patah
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
M. Pourdehnad
Employment or leadership position: Bristol Myers Squibb
Stock ownership: Bristol Myers Squibb
FIGURE 1 A) Activation signature and B) fold increase in PF of tablots after EBVspecific activation. C) Representative alluvial plot
illustrates the clonal expansion of TCRs associated with thecel manufacturing process and that the clonal expansion of TCRs associated with
the tabcel manufacturing process and that the TCR repertoire of tabcel is conserved within the functionally activated Tcell population
SUPPLEMENT ABSTRACTS
-
463
Other remuneration: Patents, Royalties, or Other Intellectual Prop-
erty: Bristol Myers Squibb
CART CELL THERAPY
377 |COMPREHENSIVE ACTIVATION PROFILING OF
TABELECLEUCEL, AN OFFTHESHELF, Allogeneic EBVSPECIFIC
TCELL IMMUNOTHERAPY
F. Ruiz
1
, T. Jehng
1
, T. Spindler
1
, D. Munson
1
, J. Karlen
1
, V. Thota
1
,
A. Wang
1
, J. Chuan
1
, M. Yedwabnick
1
, J. Dubovsky
1
, B. T. Aftab
1
1
Atara Biotherapeutics, Thousand Oaks, California, USA
Background: Tabelecleucel (tabcel) is an investigational offthe
shelf, allogeneic EpsteinBarr virus (EBV)specific Tcell immuno-
therapy. Tabcel has shown clinical activity in patients with EBV
+
posttransplant lymphoproliferative disease and other EBV
associated diseases. We aim to comprehensively profile tabcel
through highcontent immunophenotyping (IPT), Tcell receptor
(TCR) repertoire, cytokine polyfunctionality (PF), and differential
gene expression patterns (GEP) using resting and EBVantigen
stimulation states to model intrinsic effector responses associated
with engagement of EBV
+
disease. Using this approach, we aim to
identify corollaries associated with clinical outcomes.
Methods: IPT was performed using targeted flow cytometry activa-
tion profiling (CD25/CD69), and 40plex mass cytometry by timeof
flight (CyTOF). PF response and cytokine profiles were evaluated us-
ing the IsoLight singlecell PF strength assay. TCR repertoires were
assessed using TCRβimmunoSEQ and GEP were evaluated using a
custom Nanostring panel consisting of 333 Tcell lineage gene targets.
Results: Analyses for a subset of tabcel lots has been completed and
are described here. This subset of tabcel lots varied in their CD4/CD8
composition, with the majority having proportionally higher CD8+T
cells (>70%). Baseline control expression of activation markers of
8.5 ±2.1% increased to 65 ±3.9% postactivation with EBV
+
targets
(Figure 1A). Baseline control PF was 0.58 ±0.21%, and upon activation
tabcel demonstrated a 25.3fold average induction of PF (Figure 1B).
The resultant activated cytokine profiles are primarily comprised of
effector and chemoattractive cytokines including IFNγand MIP1β.
The tabcel manufacturing process effectively amplified and enriched
for EBVspecific TCRs that correspond back to a starting frequency of
0.52 ±0.8% of the initial donor TCR repertoire (Figure 1C). Notably,
cross comparison of tabcel enriched TCRs against publicly available
databases (VDJdb, McPasTCR) identified previously curated EBV
specific TCRβsequences as a component of the expanded reper-
toire. We are currently assessing the degree of convergence for TCR
sequences against common antigen motifs across donors and corre-
lation of IPT to postactivation PF. Analysis of postactivation GEP and
extended IPT by CyTOF are currently underway and will be reported
at the time of presentation.
Conclusions: The process for generating tabcel from unre-
lated donors enriches for known EBVspecific clones and results
in a net amplification of EBVtargeted Tcell clonality. Upon acti-
vation, tabcel exhibits a multifactorial activation profile
and demonstrates PF associated with secretion of effector
and chemoattractive cytokines. Altogether this multiomics
profiling will facilitate corollaries associated with clinical
outcomes.
EA previously submitted to regional or national meetings (up to
1000 attendees) and EBMT 2021.
The research was funded by: Atara Biotherapeutics
Keywords: Genomics, Epigenomics, and Other Omics, Cellular
therapies, Immunotherapy
Conflicts of interests pertinent to the abstract
F. Ruiz
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
T. Jehng
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
T. Spindler
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
D. Munson
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
J. Karlen
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
V. Thota
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
A. Wang
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
J. Chuan
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
M. Yedwabnick
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
464
-
SUPPLEMENT ABSTRACTS
J. Dubovsky
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
B. T. Aftab
Employment or leadership position: Atara Biotherapeutics
Stock ownership: Atara Biotherapeutics
378 |CLINICAL AND RADIOGRAPHIC FACTORS PRIOR TO CAR
TCELL THERAPY ACCURATELY IDENTIFY RELAPSED/
REFRACTORY LYMPHOMA PATIENTS AT HIGH RISK FOR
PROGRESSION AND POOR SURVIVAL
G. Jodon
1
, M. D. Colton
2
, A. R. Cai
3
, B. Haverkos
1
, R. Morgan
3
,
M. Kamdar
1
TABLE 1Clinical and Radiographic Characteristics at Baseline
SUPPLEMENT ABSTRACTS
-
465
1
University of Colorado Anschutz Medical Campus, Hematology/
Oncology, Aurora, Colorado, USA,
2
University of Colorado Anschutz
Medical Campus, Internal Medicine, Aurora, Colorado, USA,
3
University of
Colorado Anschutz Medical Campus, Radiology, Aurora, Colorado, USA
Introduction: Although chimeric antigen receptor (CAR) Tcell
therapy has drastically improved outcomes for relapsed/refractory
(R/R) lymphomas, a subset of patients will not respond to treatment
or will relapse quickly following an initial response. The identifica-
tion of predictive factors to identify which patients will benefit most
from this therapy is crucial to improve patient selection. The pur-
pose of this study is to further elucidate patient clinical and
radiographic variables that could be predictive of a response to
CART therapy.
Methods: We conducted a singlecenter retrospective review of all
R/R lymphoma patients who received infusion of CAR Tcells from
20172020 and had one PET scan posttreatment for response
evaluation. Clinicopathological and radiographic parameters were
identified apriori and collected through chart review. PET param-
eters included standardized uptake value (SUVmax) at baseline,
total metabolic tumor volume (TMTV), total lesion glycolysis (TLG),
and change in SUVmax from baseline to 9 months. For continuous
parameters without established cutoffs, variables were dichoto-
mized separately for time to progression and time to death using
the Contal and O'Quigley method. Risk factors for progression and
death were identified by constructing a Cox proportional hazards
model.
Results: Sixtyfour patients with R/R lymphoma were included in
the study. Median age at treatment was 65, 65% were males, and
87% DLBCL. Baseline characteristics are summarized in Table 1.
With a median follow up of 10.7 months, 36 patients (56.2%)
progressed, and 38 patients (59.4%) remain alive. Median
progression free survival (PFS) was 9.6 months and median overall
survival (OS) was 19.9 months. Univariate analysis for PFS iden-
tified stage III/IV (HR 3.59, p =0.016) and elevated CRP >11 (HR
3.32, p <0.001) as risk factors for disease progression, with trends
for elevated LDH (HR 1.87, p =0.066), tocilizumab administration
(1.83, p =0.079), and TMTV >10 (HR 1.97, p =0.093) as risk
factors. Univariate analysis for OS identified CNS involvement (HR
6.66, p =0.005) and elevated ferritin (HR 2.75, p =0.014) as risk
factors, with trends for stage III/IV (HR 3.29, p =0.053), elevated
ALC (HR 2.11, p =0.058), and elevated CRP (HR 2.18, p =0.054)
as risk factors. Multivariate analysis for PFS identified stage III/IV
(HR 3.02, p =0.04), elevated CRP (HR 3.32, p <0.001) and delta
SUV max >1 (HR 3.4, p = <0.001) as risk factors for disease
progression. Multivariate analysis for OS identified CNS involve-
ment (HR 3.9, p =0.04), elevated ferritin (HR 2.8, p =0.014) and
delta SUV max >6 (HR 2.5, p =0.02) as risk factors for death
following CART therapy.
Conclusions: Both clinical (advanced stage, elevated CRP and ferritin,
CNS involvement) and radiographic variables (delta SUVmax) identify
R/R lymphoma patients who are at high risk for progression and/or
poor overall survival after CAR Tcell therapy.
Keywords: Diagnostic and Prognostic Biomarkers, PETCT, Aggres-
sive Bcell nonHodgkin lymphoma
Conflicts of interests pertinent to the abstract
M. Kamdar
Consultant or advisory role: AbbVie, KaryoPharm, Kite, AstraZeneca,
Celgene/ BristolMyers Squibb, Adaptive Biotechnologies, Curio
Science
Research funding: TG Therapeutics, Genentech
Other remuneration: Speaker's Bureau: SeaGen
466
-
SUPPLEMENT ABSTRACTS
379 |LIFE AFTER CART CELLS: A PROSPECTIVE STUDY
EVALUATING THE PERSONAL, SOCIAL AND PROFESSIONAL
OUTCOMES AFTER CART CELL THERAPY IN LYMPHOMA
PATIENTS
A. Moignet
1
, A. Anota
2
, F. Colin
3
, L. Cherel
3
, B. Lorne
3
, T. Lamy
3
, S. De
Guibert
3
, L. Ysebaert
4
, R. Houot
3
1
University Hospital Rennes Pontchaillou, Hematology, Rennes, France,
2
IUCT Oncopole, Oncopole, Toulouse, France,
3
University Hospital Rennes
Pontchaillou, Hematology, Rennes, France,
4
IUCT Oncopole, Hematology,
Toulouse, France
Introduction: CD19 CART cells have been approved for the treat-
ment of relapse/refractory (R/R) diffuse large Bcell lymphoma
(DLBCL). With these adoptive immunotherapies, about 3040% of
patients achieve prolonged remissions, most of whom are likely to be
cured. However, little is known about life after CART cells. Thus, we
initiated a prospective study to evaluate the personal, social
and professional outcomes after CART cell therapy in lymphoma
patients.
Methods: This is a prospective, observational, multicenter study,
conducted at the University Hospitals of Rennes and Toulouse
(France). All adult patients treated with CART cells (Yescarta
®
or
Kymriah
®
) for R/R DLBCL are eligible. Primary objective is to
describe healthrelated quality of life (HRQoL) changes during the
first year after CART cell therapy using the EORTC QLQC30 and
FACTLym questionnaires. Secondary objectives are to describe the
dynamic changes of other personal, social, and professional pa-
rameters including anxiety and depression (HAD scale), cognitive
state (FACTCog), fatigue (FACTFatigue), sexuality (SqoL), post
traumatic stress disorder (PTSD), social and professional reinte-
gration, supportive care measures. These outcomes are correlated
with baseline characteristics of the patients and his disease, as well
as with response to therapy, adverse events, and biological
parameters.
Patients fill the questionnaires before leukapheresis, immedi-
ately before CART infusion, and then 3 months, 6 months and one
year after CART infusion. Adverse events are prospectively
collected by dedicated nurses who call patients daily until day 21,
twice a week until day 28, once a week until month 2, every other
week until month 3, once a month until month 6, and once every 3
months until month 12.
Results: This first patient was enrolled in November 2020. To date,
30 patients were included in the study: 19 male and 11 female,
median age is 65 years (range, 1975) and median number of prior
lines is 2 (range, 25). Median follow up is 3.2 months (range, 012)
for the entire cohort. Six patients have completed their 6 months
followup. Among the 5 patients with available HRQoL at 6 months, 3
patients (60%) presented a clinically significant improvement of their
global HRQoL level.
Conclusions: This prospective study will provide a better under-
standing of the personal, social, and professional outcomes of pa-
tients who have been treated with CART cells. These data will be of
importance to better inform patients who undergo CART cell ther-
apy, identify needs for improvement in quality of life after CART cell
therapy, and better appreciate the social and economic impact of
these treatments.
Our preliminary data suggest that HRQoL is improved in most
patients. These results will be updated at the meeting.
Keywords: Late Effects in Lymphoma Survivors
No conflicts of interests pertinent to the abstract.
380 |THE PATIENT AND CARER EXPERIENCE OF CHIMERIC
ANTIGEN RECEPTOR TCELL THERAPY FOR RELAPSED/
REFRACTORY BCELL LYMPHOMA AT A UK REGIONAL CENTRE
C. Stenson
1
, T. Menne
1
, W. Osborne
1
, A. Publicover
1
, H. Kennedy
1
, J.
Shaw
2
, F. Dewhurst
2
, R. Stocker
2
, J. Vidrine
1
1
Freeman Hospital, Clinical Haematology, Newcastle upon Tyne, UK,
2
Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne,
UK
Introduction: Chimeric Antigen Receptor Tcell therapy (CART) is
a potentially lifesaving treatment for refractory haematological
malignancies. Many UK CART services are in their infancy. Patient
perspectives on service delivery, treatment toxicity and impact on
health related quality of life (HRQoL) are lacking. This qualitative
evaluation aimed to explore the patient and carer experience of
CART and identify areas for service improvement.
Methods: Patients who received CART between April 2019 and
March 2021 at the Freeman Hospital, NewcastleuponTyne, who
attended primary or followup appointments between December
2020 and March 2021 were asked if they wanted to take part in the
evaluation. 16 semistructured qualitative interviews were carried
out with 10 patients and 4 carers at specific time points in the patient
journey: hospital admission prior to CAR Tcell infusion, day 28 post
infusion and routine followup appointments after treatment (8, 9, 12
and 18 months). Five patients completed 2 interviews (preinfusion
and day 28).
Results: The mean age of the patients was 54 and 60% were female.
Nine patients had diffuse large Bcell lymphoma and one had pri-
mary mediastinal Bcell lymphoma. Inductive thematic analysis
identified three main themes. The importance of the CART nurse
specialist as a point of contact was consistently identified by pa-
tients and carers as vital to navigating the treatment process. The
continuity of care and approachability associated with this role were
linked to patient satisfaction and perceived level of support
received. Reported treatment toxicity centred on fatigue, poor
SUPPLEMENT ABSTRACTS
-
467
appetite/weight loss and problems with memory and cognition.
Patients and carers were well prepared for side effects in the acute
treatment phase but some felt less prepared for prolonged impact
on physical function and cognition after discharge. CART therapy
was viewed as a ‘lifeline,' but the uncertainty of treatment outcome
caused significant anxiety, disruption to employment and family life,
and made it difficult to make future plans. Many responses were
framed by the COVID19 pandemic which increased feelings of
isolation and vulnerability and had a significant, negative impact on
HRQoL.
Conclusions: To our knowledge this is the first qualitative work
exploring the views of CART patients and carers at multiple points in
the patient journey, including perspectives on longterm treatment
impact. Considerations for service creation and development na-
tionally and internationally include: the importance of a dedicated
nurse specialist, preparing patients for and supporting them with
prolonged treatment side effects, and the psychological challenges
associated with prognostic uncertainty. Expanding indications of
CART therapy mean there is an urgent need for multicentre studies
incorporating patientreported outcome data to inform patient cen-
tred care and service delivery.
Keywords: Cellular therapies, Aggressive Bcell nonHodgkin
lymphoma
No conflicts of interests pertinent to the abstract.
IMAGING
381 |SURVIVAL INDEPENDENT PREDICTIVE VALUE OF
INTERIM FDG
18
PET IN NEWLY DIAGNOSED DIFFUSE LARGE B
CELL LYMPHOMA
S. Duarte
1
, C. Afonso
1
, B. Marques
1
, C. Barros Lima
1
, D. Neves
1
, A. C.
Lai
2
, M. J. Julião
2
, A. Roque
1
, L. Ruzickova
1
, J. Carda
1
, M. Gomes
1
, A.
Cipriano
2
, A. Espadana
1
1
Centro Hospitalar e Universitário de Coimbra, Clinical Hematology
Department, Coimbra, Portugal,
2
Centro Hospitalar e Universitário de
Coimbra, Pathology Department, Coimbra, Portugal
Introduction: Interim response evaluation by PET (iPET) in diffuse
large B cell lymphoma (DLBCL) is encouraged to rule out disease
progression and has been suggested to be predictive of survival.
FIGURE 1 Image A, B, C: PFS according to baseline SUVmax in relationship to FLIPI risk categories. Image D: PFS according to baseline
SUVmax and presence of at least 2 risk factors (bone marrow involvement, elevated LDH, elevated b2microglobulin, extranodal disease,
bulky disease and Bsymptoms)
468
-
SUPPLEMENT ABSTRACTS
However, treatment guidance by iPET is not yet recommended for
DLBCL in clinical practice. We aimed to assess the predictive value of
iPET in progression free survival (PFS) and overall survival (OS) in
DLBCL patients (pts).
Methods: Single centre retrospective analysis of pts diagnosed with
DLBCL from 2010 to 2019, uniformly treated with RCHOP/R
CHOPlike protocols (68 cycles) and submitted to iPET assessment
after 34 cycles of treatment. Negative iPET (iPET) was defined by
Lugano classification. Cox regression model was used to estimate PFS
and OS. Risk factors with p <0.1 in the univariate analysis were
included in the multivariate model.
Results: A total of 335 pts were diagnosed with DLBCL. Fortyone
percent (n =138) underwent iPET, 52% males, median age of 63
years old (2486). At diagnosis, 12% of the pts had an ECOG per-
formance status (PS) >1, 69% presented with advanced stage dis-
ease (AdS) and 47% with B symptoms (BS). About 44% of the pts
had intermediate/high risk International Prognostic Index (IPI)
score.
Considering early response evaluation by iPET, 73% (n =101) of
the pts had iPETand 27% (n =37) iPET+. ECOGPS >1 (OR 4.97,
p=0.001), AdS (OR 3.86, p =0.007), BS (OR 3.32, p =0.005),
elevated lactate dehydrogenase (OR 5.67, p <0.001), increased β2
microglobulin (OR 4.44, p =0.01), extranodal involvement (OR 3.14;
p=0.04) and IPI >2 (OR 5.32, p <0.001) were associated with higher
proportion of iPET+pts.
Primary refractory DLBCL (PrR) rate, defined as having a positive
posttreatment evaluation by PET (fPET), was 17%. iPET sensitivity
and specificity to predict PrR was 70% and 82%, respectively, for
positive and negative predictive values of 43% and 93%. fPET
demonstrated a significant frequency of positivity in pts who had
iPET+(OR 10.2, p <0.001).
For a median followup of 54 months, median PFS was not
reached (NR) and was higher in iPET(NR versus 10.9 months; HR
4.60, p <0.001), and iPET remains significant after multivariate
analysis (HR 5.17, p <0.001).
Median OS was NR and was superior in the iPETgroup (NR and
54.2 months; HR 4.15, p <0.001), also remaining significant after
applying a multivariate model (HR 4.85, p <0.001).
Conclusion: Our results showed iPET positivity is an independent
predictor of poorer PFS and OS in DLBCL, even after adjusting
for prognostic factors such as age, AdS and intermediate/
high IPI score. In addition, iPET showed a higher specificity
and negative predictive value, supporting iPET as a valuable tool for
early assessment of response in DLBCL, particularly of PrR.
Keywords: Diagnostic and Prognostic Biomarkers, PETCT, Aggres-
sive Bcell nonHodgkin lymphoma
No conflicts of interests pertinent to the abstract.
382 |FAVOURABLE PROGNOSTIC ROLE OF HIGH BASAL
MAXIMAL STANDARDIZED UPTAKE VALUE IN FOLLICULAR
LYMPHOMA
G. M. Assanto
1
, G. Ciotti
1
, M. Brescini
1
, R. Agrippino
1
, G. Lapietra
1
, M.
L. De Luca
1
, G. Annechini
1
, G. M. D'Elia
1
, A. Chiaravalloti
2
, I. Del
Giudice
1
, A. Pulsoni
1
1
Haematology, Department of Translational and Precision Medicine,
Sapienza University of Rome, Rome, Italy,
2
Nuclear medicine, Department
of Biomedicine and Prevention, Nuclear Medicine, University Tor Vergata,
Rome, Italy
SUPPLEMENT ABSTRACTS
-
469
Introduction: Follicular Lymphoma (FL) is an indolent disease: despite
the efficacy of treatment strategies in inducing remission, high risk
patients relapse within two years and others relapse on long term.
Despite encouraging studies on the prognostic role of Total Meta-
bolic Tumor Volume (TMTV) the role of SUVmax at baseline PET/CT
needs to be better defined.
Methods: Retrospective observational monocentric cohort study
performed at Sapienza University of Rome. All patients affected by FL
who underwent a basal staging PET/CT were included. Patients who
fulfilled GELF criteria received different treatment, according to
guidelines and clinical judgment. Patients were stratified according to
the SUVmax assessed at the onset. Two subgroups were identified and
compared in terms of PFS and OS: A) Basal SUVmax <6; B) Basal
SUVmax >6.
Results: Ninetyfour patients were included, 34 in group A (36,2%) and
60 in group B (63,8%). Fiveyear PFS in the whole cohort was 87,5%,
74,5% for group A and 95% for group B (p 0.005). Nevertheless, PFS at
two years was comparable in the two groups (97%). A correlation be-
tween PFS and baseline SUVmax was observed in patients in different
FLIPI risk categories. In lowrisk FLIPI patients (48.3%) a significantly
superior long term PFS was observed in group B compared to A, PFS at
followup was 92% and 66,7% respectively (p 0.012) (Figure 1AB). No
significant association between PFS and baseline SUVmax was
observed in the subgroup of intermediate (p 0.180) and highrisk FLIPI
(p 0.317). Multivariate analysis of all the parameters assessed,
confirmed the presence of a basal SUVmax >6 as an independent
favorable prognostic factor for PSF (OR 0.234; 95% IC 0.580.934; p
0.04) as well as a correlation between a BM involvement at diagnosis
and unfavorable PFS (odds ratio [OR] 5.98; 95% IC 1.523.3; p 0.011).
Was finally explored the PFS of groups A and B based on the presence
of at least two baseline features considered as an indicator of
aggressive disease (bone marrow involvement, elevated LDH, elevated
β2microglobulin, extranodal disease, bulky disease, presence of B
symptoms) (Figure 1D).
Conclusion: Our data demonstrate the independent prognostic role
of baseline SUVmax as a PFS predictor, especially in patients with
lowrisk FL. Even without other risk factors, patients with low tumor
metabolic activity exhibit a higher longterm relapse probability.
Baseline SUVmax evaluation, with its simple assessment, could help
identifying patients at risk for late relapse, requiring strict followup
and, potentially, MRD monitoring.
Keywords: Diagnostic and Prognostic Biomarkers, PETCT, Indolent
nonHodgkin lymphoma
No conflicts of interests pertinent to the abstract.
383 |FDGPET/CTGUIDED REBIOPSY MAY FIND CLINICALLY
UNSUSPICIOUS TRANSFORMATION OF AN INDOLENT
LYMPHOMA AT THE POINT OF DIAGNOSIS OR RELAPSE
A. Rajamäki
1
, K. Sunela
2
, H. Kuitunen
3
, M. Sorigue
4
, O. Kuittinen
5
1
Central Finland Central Hospital, Department of Oncology, Jyväskylä,
Finland,
2
Tampere University Hospital, Department of Oncology,
Tampere, Finland,
3
Oulu University Hospital, Department of Oncology,
Oulu, Finland,
4
ICOHospital Germans Trias i Pujol, Department of He-
matology, Badalona, Spain,
5
Kuopio University Hospital, Department of
Oncology, Kuopio, Finland
Introduction: Histologic transformation (HT) to an aggressive lym-
phoma is a welldescribed event in the clinical course of indolent
lymphomas. When HT occurs, it is common to find both low grade
and high grade lymphoma in different areas of the body. Purpose of
the study was to evaluate the benefit of a diagnostic FDGPET/CT
guided rebiopsy from the maximum standardized uptake value
(SUVmax) site in indolent lymphomas, to reveal HT not detected in
first biopsy.
Methods: 85 patients with indolent lymphoma (follicular lymphoma,
marginal zone Bcell lymphoma, or nodular lymphocytepredominant
Hodgkin's lymphoma) who had undergone a diagnostic FDGPET/CT,
were identified in Oulu university hospital in Finland. Principally,
FDGPET/CT was made to all patients who were referred to
hospital with a diagnosis of an indolent lymphoma or its
relapse. SUVmax 10 was mainly considered a limit for a new biopsy,
and rebiopsy was performed in the accessible site of highest
SUVmax.
Results: Median followup was 41 months (range: 1–407 months).
During the followup, 8 of 85 (9.4%) patients experienced a biopsy
confirmed HT which was detected with a diagnostic FDGPET/CT.
One of these patients had also a clinical suspicion of HT, 2 had
minor symptoms which might be suggestive, but first biopsy showed
indolent histology, and 5 presented clinically with an indolent dis-
ease. Median SUVmax in patients with HT vs. without HT was
27.1 (range, 10.534.9) vs. 9.0 (range, 1.824.9). 21.6% of patients
with SUVmax >10, and 66.7% of patients with SUVmax >20, had
a HT.
Conclusions: Our results suggest that a rebiopsy based on a high
SUVmax in a diagnostic FDGPET/CT is valuable in detecting HT
after the diagnosis or relapse of an indolent lymphoma.
Keywords: PETCT, Indolent nonHodgkin lymphoma
No conflicts of interests pertinent to the abstract.
384 |PROSPECTIVE VALIDATION OF RECIL RESPONSE
CRITERIA: RESULTS OF OBINUTUZUMABGDP AS SALVAGE
PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN
AGGRESSIVE B CELL LYMPHOMA
E. Lebel
1
, M. D. Jain
2
, A. Prica
1
, V. Kukreti
1
, R. Kridel
1
, R. C. Laister
1
,
L. Meng
1
, J. Delabie
1
, J. Weiss
1
, T. Panzarella
1
, M. Crump
1
, J.
Kuruvilla
1
1
Princess Margaret Cancer Centre, Division of Medical Oncology and
Hematology, Toronto, Canada,
2
Moffitt Cancer Center, Department of
Blood and Marrow Transplant and Cellular Immunotherapy, Tampa,
Florida, USA
470
-
SUPPLEMENT ABSTRACTS
TABLE 1Responses to second line OGDP by Lugano and RECIL criteria
SUPPLEMENT ABSTRACTS
-
471
Introduction: Obinutuzumab plus gemcitabine, dexamethasone
and cisplatin (OGDP) is a feasible outpatient salvage regimen
that enables autologous stem cell transplant (ASCT) in patients with
relapsed/refractory aggressive B cell lymphomas (NCT02750670;
Jain, ASH 2019, 4610). The RECIL criteria have been developed for
lymphoma (aligned with RECIST criteria for solid tumors) and are
based on unidimensional measurements of no more than 3 lesions for
response assessment (Younes, Ann. Oncol. 2017). We prospectively
evaluated responses to OGDP by RECIL criteria.
Methods: following 2 cycles of OGDP, patients (pts) were evalu-
ated for response by both Lugano criteria (Cheson, JCO 2014;
primary study endpoint) and RECIL criteria (predefined secondary
endpoint). Responsive pts by Lugano criteria proceeded to pe-
ripheral blood stem cell (PBSC) collection using the 3
rd
cycle of
OGDP as mobilizing chemotherapy, and subsequently had end of
salvage assessment by PETCT. Responsive pts by PETCT pro-
ceeded to ASCT.
Results: Of 30 pts treated with 2 cycles of OGDP, 18 (60%)
responded by Lugano criteria (all with partial response (PR)), 8 had
stable disease (SD) and 4 had progressive disease (PD). 25/29 pts
(86%) had a concordant response by RECIL criteria (table 1). Three
pts were responsive by RECIL and were SD by Lugano (pts 1,13,16); 2
of them (1,13) proceeded to transplant but developed PD. In 1 pt,
response was downgraded (Lugano PR, RECIL MR; 26), he is now
post ASCT in remission.
Conclusions: We prospectively show that RECIL criteria offer
easier response assessment and appear concordant to Lugano
criteria for most pts. Refinement of these criteria and defining
their utility in decision making requires further prospective
assessment.
Keywords: Imaging and Early Detection Other, Aggressive Bcell
nonHodgkin lymphoma, Chemotherapy
Conflicts of interests pertinent to the abstract
M. D. Jain
Consultant or advisory role: kite/Gilead, Novartis, BMS and Takeda
A. Prica
Honoraria: AstraZeneca, Gilead
R. Kridel
Research funding: Gilead Sciences and Roche
M. Crump
Honoraria: Novartis and Kite Gilead
Research funding: Roche
J. Kuruvilla
Consultant or advisory role: Abbvie, BMS, Gilead, Karyopharm,
Merck, Roche, Seattle Genetics
Honoraria: Amgen, Antengene, Astra Zeneca, BMS, Gilead, Incyte,
Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle Ge-
netics, TG Therapeutics
Research funding: Canadian Cancer Society, Leukemia and Lym-
phoma Society Canada, Princess Margaret Cancer Foundation,
Janssen, Roche, Astra Zeneca
Other remuneration: Karyopharm (DSMB)
385 |SPLENIC INCREASED 18FFDG UPTAKE IN PET SCAN
PERFORMED FOLLOWING TREATMENT WITH PEGGCSF
LIPEFILGASTRIM
A. Fe'
1
, M. Cimminiello
2
, A. Nicoletti
1
, A. Matturro
2
, G. Coralluzzo
2
, S.
P. Pascale
2
, R. Nuccorini
2
, L. Fabio
2
, S. Mancino
3
, T. Cavallo
4
1
AOR San Carlo, SIC di Medicina Nucleare, Potenza, Italy,
2
AOR San
Carlo, UOC Ematologia, Potenza, Italy,
3
AOR San Carlo, UOC Radiologia,
Potenza, Italy,
4
AOR San CarloPO Villa d'Agri, SSD Radiologia, Villa
d'Agri, Italy
Introduction: Lipegfilgrastim, is oncepercycle, a pegylated recom-
binant GCSF approved by the EMA in July 2013 for reducing the
duration of Chemotherapyinduced neutropenia which can lead to
febrile neutropenia in cancer patients (pts) receiving chemotherapy.
Methods: We retrospectively analyzed 18FDG PET TC scan at the
initial staging (sPET), interim time (iPET) and at end of therapy (ePET)
in 16 consecutive pts (9 DLBCL and 7 HL). None of these pts had
focal or diffuse splenic involvement at sPET. All patients were treated
with consolidated chemoteraphy scheme associated with a Lipegfil-
gastrim, oncepercycle. The time elapsed between Lipegfilgastrim
administration and iPET was on average 15 days.
Results: The 18FDG iPET did not show any pathological uptake in all
pts but showed a splenic diffuse,homogeneous increased uptake of
18FDG, greater than epatic 18FDG uptake in all pts,determining an
inversion of the hepatosplenic ratio uptake. The 18FDG ePET, per-
formed one month after the end of therapy, did not show any
pathological findings: normal spleen uptake lower than liver and
phisiological hepatosplenic ratio uptake.
Even if it is consolidated to perform an interim PET in HL and NHL
and it is consolidated to treat these pts with GCSF, we found a
diffuse, homogeneous increased splenic uptake of 18FDG greater
than epatic 18FDG uptake in all 16 pts treated with a Lipegfilgastrim,
oncepercycle.
In literature, some authors did not observe larger variations in
bone marrow and spleen uptake in the group of pts having received
lipegfilgastrim compared to filgastrim and lenogastrim group, despite
its longer halflife due to its PEGylated nature. The major determi-
nant for the occurrence of a bone or spleen hypermetabolism on
iPET/CT was the timelapse between the chemotherapy and the PET/
CT examination, which should be maintained greater than 15 days.
In our group of pts we did not observe any difference in the
increase of bone marrow uptake of 18FDG at the iPET compared
with pts received filgastrim or lenogastrim. The 18FFDG PET scan
performed at the end of therapy showed no pathological findings,
with a normal 18FFDG uptake in the spleen and bone marrow,
determining the benign and reactive nature of the splenic and bone
marrow 18FFDG increased uptake found in the previous iPET.
Conclusion: it is important to know that in pts who received
aggressive chemoteraphy protocol like HL and NHL associated with a
Lipegfilgastrim can have therapeuticrelated reactive splenic uptake
concurrent with bone marrow uptake secondary to administration of
GCSF for myelosuppression without influencing on the Deauville
score determination.
472
-
SUPPLEMENT ABSTRACTS
We think that the type of GCSF used, the time elapsed between
its last injection and interim PET/CT and the timelapse between the
chemotherapy and the PET/ CT examination must be evaluated when
performing a 18FFDG PET scan, to avoid falsepositive results.
Keywords: PETCT, Aggressive Bcell nonHodgkin lymphoma,
Hodgkin lymphoma
No conflicts of interests pertinent to the abstract.
386 |PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH
RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE
TREATMENT WITH ANTICD38 IMMUNOTHERAPY
G. Fouquet
1
, M. Wartski
2
, A. Dechmi
2
, L. Willems
1
, B. DeauFischer
1
,
P. Franchi
1
, J. Descroocq
1
, P. Deschamps
1
, J. Clerc
2
, D. Bouscary
1
,
S. Barreau
3
, N. Chapuis
3
, M. Vignon
1
, A.S. Cottereau
2
1
Cochin Hospital APHP, Paris, France, Hematology, Paris, France,
2
Cochin
Hospital, APHP, Paris, Nuclear Medicine, Paris, France,
3
Hôpital Cochin,
APHP, Service d'hématologie biologique, Paris, France
Introduction: Although immunotherapy with monoclonal antiCD38
antibody has improved prognosis of relapse/refractory multiple
myeloma (RRMM), some patients experience early relapse with a
dismal outcome. 18FFDG PET/CT is now recommended for the
visualization of disease activity in both newly diagnosed and
RRMM patients. It has also been used for the prediction of sur-
vival outcome in patients treated with allogeneic stem cell trans-
plant. This study evaluated the predictive impact of
PET parameters in RRMM patients before initiating antiCD38
therapy.
FIGURE 1 Kaplan Meier estimates of progression free survival
(PFS) and overall survival (OS) according to the presence of more
than 3 local lesions (FLs) or less/equal than 3 focal lesions
TABLE 1Patient characteristics and results
SUPPLEMENT ABSTRACTS
-
473
Methods: Consecutive RRMM patients who underwent baseline 18F
FDG PET /CT before antiCD38 based immunotherapy (Dar-
atumumab, Isatuximab) in our centre between June 2019 and
December 2020, were included. A focal lesions (FL) was defined as
focally increased FDG uptake greater than the physiologic bone
marrow uptake, with or without any underlying lesion. Extra-
medullary disease (EMD) was defined as FDGavid soft tissue not
contiguous to bone. Highrisk (HR) cytogenetics was defined as del
(17p), t(4;14), and t(14;16). Survival functions were calculated using
Kaplan Meier estimates, comparisons between categories were made
with the logrank test. MannWhitney U test was used to compare
PET variables in relation to beta2microglobuline (B2M).
Results: Thirtyeight patients (female n =19) with a median age at
relapse of 73 (range 58 87) were included. Median prior line of
treatment before antiCD38 immunotherapy was 3 (range 29) and
47% (n =18) had underwent autologous stem cell transplantation.
The ISS initial stage 1, 2 and 3 comprised 42% (n =16), 37% (n =14)
and 21% (n =8) respectively. 24% (n =8/33) had HR cytogenetic.
Before starting CD38 targeted therapy, 65% of the patients (n =25)
had at least one FL with a median SUVmax of 7.8, 49% (n =19) had
more than 3 FLs with a median SUVmax of 10.7. EMD was present in
19% (n =7) of all patients. Median PFS and OS for the entire cohort
were 12,5 months and 15,8 months. The presence of >3 FLs was
associated with significantly inferior PFS (p =0.0036) and OS
(p =0.025). A high SUV max 11.5 (n =8) was a predictor of PFS
(p =0.036) and OS (p =0.031). A median serum B2M level was
significantly higher in patients with >3 FLs compared with 13 FLs
(p =0.015). The initial ISS score was significantly associated with
both PFS (p =0.0045) and OS (p =0.0081). EMD and HR cytogenetic
did not significantly correlate with the PFS or the OS. In multivariable
analysis, ISS score and >3FLs were independent prognosticators for
PFS (p =0.010, p =0.025 respectively). Blood flow cytometry, per-
formed in 15 patients, detected 4 patients with abnormal plasma cells
among 3 had FLs >3 and one had a single bone lesion with EMD.
Conclusion: Presence of >3 FLs on PET/CT is a predictor of survival
outcomes in patients with relapse/refractory MM treated with CD38
targeted therapy and correlates with tumour burden biomarker.
Keywords: Immunotherapy, PETCT, Multiple Myeloma
No conflicts of interests pertinent to the abstract.
MISCELLANEOUS
387 |STEM CELL MOBILIZATION AFTER TREATMENT WITH
BENDAMUSTINE IN PATIENTS WITH HODGKIN AND BCELL
NONHODGKIN LYMPHOMAS. RESULTS AT DONOSTIA
UNIVERSITY HOSPITAL, SPAIN
B. Mendibil Esquisabel
1
, J. J. Ferreiro Martinez
1
, I. Zeberio
Etxetxipia
1
, A. Altuna Mongelos
1
, J. Iriondo Alzola
1
, A. Zumalde
Murua
1
, A. Arambarri Oyarzabal
1
, N. F. Rois Pego
1
, A. Alkorta
Eizagirre
1
1
Hospital Universitario Donostia, Hematology Department, Donostia,
Spain
Introduction: Salvage chemotherapy followed by an autologous
stemcell transplantation (ASCT) is the standard of care for patients
with either relapsed or refractory Hodgkin lymphomas (HL) or Bcell
nonHodgkin lymphomas (NHL). In the last decades treatment regi-
mens including bendamustine have shown efficacy in patients with B
cell NHL, both as frontline treatment or in subsequent lines, and in
patients with relapsed or refractory HL. Bendamustine is an alky-
lating agent that shares structural properties with purine analogs like
fludarabine, which are known to have a negative effect on peripheral
blood stem cell (PBSC) mobilization. This fact raised concern as to the
impact bendamustine could have on stem cell mobilization. Lately, a
retrospective multicenter study performed by Fondazione Italiana
Linfomi has shown that prior treatment with bendamustine does not
affect PBSC mobilization
1
.
Methods: We conducted a retrospective analysis of PBSC mobiliza-
tion in 31 patients with HL or NHL who had received treatment with
bendamustine, either in the same or previous lines, in our center.
Results: Patient characteristics and results are shown in Table 1. 31
patients underwent PBSC mobilization after treatment with bend-
amustine: 16 patients with follicular lymphoma, 14 patients with HL
and 1 patient with small lymphocytic lymphoma. Median age was 52
years. 27 patients received combinations with bendamustine as
secondline treatment and 4 patients received it as part of the first
line treatment. Median time from treatment with bendamustine to
PBSC mobilization was 2 months. All patients underwent mobiliza-
tion with GCSF and 14 required the use of plerixafor per protocol.
90% of the patients succeeded to mobilize in the first attempt. 27
patients obtained 2 x 10
6
CD34+/kg of body weight in the first
mobilization attempt and 1 patient required a second mobilization to
collect the CD34+target. 3 patients presented a mobilization failure,
2 of which underwent a second mobilization with GCSF with success
3 and 10 months later, respectively. Both patients were able to
collect the CD34+target. 11 patients required a second harvest to
achieve the CD34+target and only one patient required three har-
vests. The median number of CD34+obtained in each mobilization
was 3.06 x 10
6
/kg. 27 patients underwent ASCT with successful
engraftment.
Conclusions:
1. Consistent with previously published studies, our experience
shows that bendamustine does not impair PBSC mobilization.
2. Mobilization with GCSF alone has shown to be a successful
mobilization strategy in this subset of patients. No increased use of
plerixafor has been observed when compared to the usual rates in
our center.
REFERENCES:
1. Merli M, Luminari S, Farina L, Cocito F, Defrancesco I, Gini
G, et al. Stem cell mobilization after bendamustine in indolent
lymphomas: a multicenter study on behalf of the Fondazione
Italiana Linfomi. Bone Marrow Transplant. 2020 Dec;55
474
-
SUPPLEMENT ABSTRACTS
(12):23502353. doi: 10.1038/s41409-020-0967-5. Epub 2020
Jun 15.
Keywords: Hodgkin lymphoma, Indolent nonHodgkin lymphoma,
Stem Cell Transplant
No conflicts of interests pertinent to the abstract.
388 |COMPARATIVE EVALUATION OF RADIATION THERAPY
TECHNIQUES FOR MEDIASTINUM IRRADIATION IN LYMPHOMA
PATIENTS USING IMRT, BVMAT, 3DCRT
M. Fomintseva
1
, Y. Vinogradova
1
, N. Ilyin
1
, I. Shenderova
1
, L.
Storozhenko
1
, A. Vasilieva
1
1
A.M. Granov Russian Research Centre for Radiology and Surgical
Technologies, Department of Radiation and Combined Therapy, Saint
Petersburg, Russian Federation
Introduction: Radiation therapy is effective in treating mediastinal
lymphomas, but the question of its longterm radiation effects, such
as induced breast cancer, lung cancer, and heart disease, has been
increasingly raised in recent years. The aim of our work was to
compare the radiation doses that receive heart, lungs, and mammary
glands (MG) during irradiation of mediastinal lymphomas by 3
different techniques: IMRT, BVMAT, 3DCRT.
Methods:A radiation therapy plan was calculated for each of the
indicated techniques for 7 mediastinal lymphoma patients. Photon
energy: 6 MV, target dose: 30 Gy/15 fractions, planned target volume
(PTV) coverage: 98% PTV covered by at least 95% isodose. IMRT and
BVMAT plans were calculated by inverse planning, and 3DCRT by
direct planning using the Monte Carlo algorithm.
Each IMRT plan consists of 7 coplanar fields almost equally spaced
around a patient, using the ability not to pass through MG. BVMAT
plan is a composition of 3 noncoplanar VMAT arcs, couch
G330°÷G30°, couch G150°÷G180° +G181°÷G210° and couch 270°
G330°÷G30°. 3DCRT plan is a couple of APPA fields with an addition
of small portion of posterior oblique fields that lead to maximum dose
outside PTV avoidance without adding any significant dose to lungs.
An extra subvolume “heart inside PTV” was created for inverse
optimization in order to keep its dose theraputical and avoid any
possible maximum inside the heart.
Results:With a probability of p <0.05, the following parameters
were estimated. Average volumes of PTV (620 ±170) cc, MG (710 ±
660) cc, total lung (2950±420) cc and heart (590 ±90) cc. Dose
Volume relations are given in following table
Normal Structure parameter IMRT BVMAT 3DCRT
V
4
Mammary Gland, % 22±10 12±13 20±19
V
20
Lungs, % 25±3 21±4 24±4
mean dose to Lungs, Gy 14,5±7,6 13,0±8 10±1,5
V
5
Heart, % 44±24 55±24 46±24
(Continues)
(Continued)
Normal Structure parameter IMRT BVMAT 3DCRT
V
25
Heart, % 25±12 25±12 34±20
mean Heart dose, Gy 10,9±6 12,4±5 12,6±6
max Heart dose, Gy 31,8±0,4 32,0±1,2 32,8±0,6
Conclusions: With the stated above PTV coverage, the IMRT tech-
nique can significantly increase the conformity index of the plan and
lead to the lowest dose to the heart in all studied parameters, but
showed the highest dose to the lungs both mean dose and V
20
.
The BVMAT technique can significantly reduce V
4
MG while
maintaining minimum V
25
heart and V
20
lungs. At the same time,
despite the low mean dose to the heartinsidePTV, the mean dose to
the whole heart with this technique is higher compared to the IMRT
technique due to the increase in V
5
heart.
The standard 3DCRT technique achieves the lowest average
dose to the lungs, but has not shown any advantages in the rest of
considered critical organs. The scatter of the data is due to the large
variability of the physiological parameters of the patients, in order to
specify the obtained data the study is proceeded.
EA previously submitted to regional or national meetings (up to
1000 attendees).
Keywords: Late Effects in Lymphoma Survivors, Radiation Therapy
No conflicts of interests pertinent to the abstract.
389 |A NEW OPTION IN PAIN PREVENTION WITH BLISS©, A
DIGITAL THERAPEUTIC SOLUTION LEVERAGING VIRTUAL
REALITY: RESULTS OF A FRENCH OPENLABEL MULTICENTER
RANDOMIZED PHASE III STUDY (REVEH TRIAL)
A.L. Septans
1
, K. Le
2
, F. Maloisel
3
, H. Vanquaethem
4
, A. Schmitt
5
,
M. Le Goff
6
, M.P. Moles
7
, M. Zinger
8
, H. Bourgeois
1
, M. Peron
9
,
F. Denis
1
, S. Bouchard
10
1
ILC Jean Bernard, Oncohematology, Le Mans, France,
2
Confluent Pri-
vate Hospital, Hematology, Nantes, France,
3
Clinique SaintAnne, Hema-
tology, Strasbourg, France,
4
Hôpital dInstruction des Armées Bégin,
Médecin interne, Saint Mande, France,
5
Institut Bergonié, Hematology,
Bordeaux, France,
6
ILC Jean Bernard, Hematology, Le Mans, France,
7
CHU, Hematology, Angers, France,
8
ILC Jean Bernard, Onco
hematoloogy, Le Mans, France,
9
Effet Papillon, Quality of Life, Laval,
France,
10
Université du Québec en Outaouais, Psychoeducation and
Psychology, Gatineau, Canada
Introduction: The prevention of careinduced pain is a central concern
for healthcare teams in hematology units. Use of MEOPA (Oxygen
+Nitrous Oxide) is today a standard of care for relaxation procedure.
Distraction through immersion in virtual reality (VR) has already
documented its analgesic effects in several phase II trials but com-
parison with standard treatments in a large randomized study is
needed.
SUPPLEMENT ABSTRACTS
-
475
Methods: We conducted an openlabel multicenter randomized
phase III trial (ClinicalTrials.gov identifier: NCT03483194). We
assessed the safety and efficacy of Bliss© in prevention of pain and
anxiety before performing and during a bone marrow biopsy. Bliss©
is a new Digital Therapeutic/Virtual Reality solution with four
imaginary interactive environments in three dimensions (image and
sound) augmented by binaural sound. Efficacy was evaluated by pain
intensity with visual analog scale (score from 0 to 10) immediately
after the biopsy and anxiety by 2 questionnaires (fear of pain before
the biopsy and revised STAI questionnaire before and after the
biopsy). The primary end point was patientassessed pain intensity
after the bone marrow procedure.
Results: A total of 126 patients were enrolled with previously
untreated malignant hemopathy between September 6, 2018 and
May 18, 2020. They were randomly assigned in a 1:1 ratio to receive
prevention pain with MEOPA (n =63) or Bliss© (n =63). All patients
received a local anesthesia with lidocaïne before the biopsy. Median
age of the study population was 65.5 years old (range 18 to 87) and
54.2% were men. The average pain intensity was 3.5 (standard de-
viation 2.6) for the MEOPA group and 3.0 (SD 2.4) for the VR group
(p =0.26) without any significant difference according to age, gender
ord hemopathy. Concerning anxiety, 67.5% of patients were afraid
before the biopsy and anxiety scores were moderate to very high in
26.3% of patients before the biopsy (STAI questionnaire) and 9.0%
after the biopsy for all patients (17.3% of reduction in anxiety for the
MEOPA group and 17.2% for the VR group, p =0.83). Immersion in
VR was well tolerated in 100% of patients included in the VR group.
Physicians were very satisfied by the relaxation procedure in
64.9% of cases (52.5% in the MEOPA group and 77.6% in the
VR group, p =0.01) and recommended reuse of the technique
in 54.2% in the MEOPA group and 79.1% in the VR group (p =0.02).
Conclusion: The intensity of pain did not significantly differ in both
arms. Bliss©based relaxation method was well tolerated and the
satisfaction of patients and physicians was very high. This study vali-
dates the use of immersion in VR with Bliss© as a new Digital Thera-
peutic and support the integration of software in the panel of
supportive care.
EA previously submitted to ASCO and EHA 2021.
The research was funded by: Roche, Elsan group and France
Lymphome Espoir Association
Keywords: Therapeutics and Clinical Trials in Lymphoma Other
Conflicts of interests pertinent to the abstract
K. Le
Consultant or advisory role: Incyte, Abbvie
Research funding: Roche
Educational grants: Janssen, Roche
F. Maloisel
Honoraria: Pfizer, Agmen, Incyte, Abbvie
S. Bouchard
Other remuneration: president and part owner of In Virtuo, a com-
pany that distributes virtual reality environments
390 |NEGATIVE SYNERGISM BETWENN THE COMBINATION
OF STEROID AND LOW MOLECULAR WEIGHT HEPARIN (LMWH)
ON BONE METABOLISM, IN PATIENTS TREATED FOR LYMPHOMA
L. Pezzullo
1
, M. D'Addona
1
, C. Martorelli
1
, L. Mettivier
1
, V. Giudice
1
,
R. Fontana
1
, I. Ferrara
1
, S. Luponio
1
, R. Guariglia
1
, B. Serio
1
, C. Selleri
1
476
-
SUPPLEMENT ABSTRACTS
1
Salerno University, Hematology Division, Salerno, Italy
Low molecular weight heparins (LMWH) are widely used in throm-
bosis prophylaxis in treated lymphoma patients with central periph-
eral venous device (PVD). The negative effect of heparin on
osteogenesis is known, it is not clear how anticoagulants vit K in-
hibitors act while the role of LMWH is controversial. The negative
effect of steroids on osteogenesis is also documented but there are
no data on negative synergy related to the simultaneous intake of
steroids and LMWH.
The aim of our study is to evaluate the bone events (bone
fractures) observed retrospectively in a consecutive cohort of lym-
phoma patients treated with chemotherapy (with or without ste-
roids) from January 2014 to January 2021 with at least 6 months of
followup.
From January 2014 to January 2021 we observed 197 pa-
tients with a median followup of 38 months (range 685 months);
90 with NHL treated with CHOP or similar 34 f and 56 m with a
median age of 59 years (range 2377 years); 53 with NHL treated
with bendamustine based therapy; 23 f and 30 m with median
age of 65 years (range 4281 years) and 54 with HD treated
with ABVD or similar; 26 f and 28 m with a median age of 34
years (range 1675 years). All patients with PVD and all treated
in prophylaxis with LMWH (enoxaparin or nadroparin) 4000 U /
day.
In the NHL group treated with steroids and LMWH the
observed bone events (bone fractures) were 13 (14.5% of patients).
All patients had vertebral involvement and in 2 patients in addi-
tion to the vertebral problem, an event in the femur was docu-
mented. In the NHL group treated with LMWH but not steroids, the
observed bone events were 2 (3.8% of patients) while in the
HD group there were 2 (3.8% of patients), all with vertebral
involvement.
These data show a higher incidence of bone events in patients
receiving steroid and LMWH therapy. This evidence suggests a
negative synergism between the association of steroids and LMWH
on bone metabolism and also probably confirms that vitamin D
metabolism in patients with aggressive NHL may be implicated in the
prognosis of these lymphomas.
This evidence suggests the need to integrate vit D with or
without calcifying into the therapy of patients with aggressive NHL
and to evaluate the possibility of proposing prophylaxis for throm-
bosis not with LMWH but with the new oral anticoagulants.
A prospective study is needed which also includes the study of
calcium metabolism and bone mineralization both at diagnosis and
over time in the various subtypes of NHL and which supportive
treatments they have received.
EA previously submitted to EHA 2021.
Keywords: Late Effects in Lymphoma Survivors
No conflicts of interests pertinent to the abstract.
391 |RISK OF HEMOLYMPHOPOIETIC NEOPLASM BEFORE
AND AFTER THYROID CANCER. A POPULATIONBASED STUDY
IN ITALY, 19982012
V. Mattioli
1
, E. Crocetti
2
, L. Dal Maso
1
, C. Buzzoni
2
, S. Franceschi
1
,
D. Serraino
1
, S. Vaccarella
3
, S. Ferretti
4
, S. Busco
5
, U. Fedeli
6
,
M. Varvarà
7
, F. Falcini
8
, M. Zorzi
9
, G. Carrozzi
10
, W. Mazzucco
11
,
C. Gasparotti
12
, S. Iacovacci
5
, F. Toffolutti
1
, R. Cavallo
13
, F. Stracci
14
,
A. G. Russo
15
, A. Caldarella
16
, S. Rosso
17
, A. Musolino
18
,
L. Mangone
19
, C. Casella
20
, M. Fusco
21
, G. Tagliabue
22
, D. Piras
23
,
R. Tumino
24
, L. Guarda
25
, Y. M. Dinaro
26
, S. Piffer
27
, P. Pinna
28
,
G. Mazzoleni
29
, A. C. Fanetti
30
1
CRO Aviano, Cancer Epidemiology, Aviano, Italy,
2
AIRTUM Database,
Italy,
3
International Agency for Research on Cancer, Section of Cancer
Surveillance, Lyon, France,
4
IRCCS Istituto Romagnolo per lo Studio dei
Tumori (IRST) “Dino Amadori”, Meldola, ItalyAzienda Usl della Romagna,
Romagna Cancer Registry, Forlì, Italy,
5
ASL Latina, Cancer Registry of
Latina Province, Latina, Italy,
6
Azienda Zero, Epidemiological Department,
Padua, Italy,
7
Università degli Studi di Catania, Registro Tumori Integrato
CataniaMessinaSiracusaEnna, Catania, Italy,
8
Istituto Scientifico
Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Romagna
Cancer Registry, Meldola, Italy,
9
Veneto Region, Veneto Tumor Registry,
Padua, Italy,
10
Modena Cancer Registry, AUSL Modena, Public Health
Department, Modena, Italy,
11
Palermo and Province Cancer Registry,
Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone”, University
of Palermo, Clinical Epidemiology Unit with Cancer Registry, Palermo, Italy,
12
Brescia Health Protection Agency, Epidemiology Unit, Brescia Cancer
Registry, Brescia, Italy,
13
ASL Salerno, Cancer Registry, Salerno, Ita-
ly
14
University of Perugia, Public Health Section Dept. of Medicine and
Surgery, Perugia, Italy,
15
Agency for Health Protection of Milan, Cancer
Registry of Milan, Epidemiology Unit, Milan, Italy,
16
Institute for Cancer
Research, Prevention and Clinical Network (ISPRO), Tuscany Cancer Reg-
istry, Clinical Epidemiology Unit, Florence, Italy,
17
Azienda Ospedaliera
Universitaria Città della Salute e della Scienza di Torino, Piedmont Cancer
Registry, Torino, Italy,
18
Azienda Ospedaliera Universitaria di Parma,
Parma Cancer Registry, Oncology Unit, Parma, Italy,
19
AUSL ASMNIRCCS,
Azienda USL di Reggio Emilia, Reggio Emilia Cancer Registry, Epidemiology
Unit, Reggio Emilia, Italy,
20
IRCCS Ospedale Policlinico San Martino,
Liguria Cancer Registry, Clinical Epidemiology, Genova, Italy,
21
ASL Napoli
3 Sud, Cancer Registry, Napoli, Italy,
22
Fondazione IRCCS Istituto Nazio-
nale dei Tumori, Lombardy Cancer Registry, Varese Province, Cancer
Registry Unit, Department of Research, Milan, Italy,
23
Azienda Regionale
per la Tutela della Salute, North Sardinia Cancer Registry, Sassari, Italy,
24
Provincial Health Authority (ASP 7), Cancer Registry and Histopathology
Department, Ragusa, Italy,
25
Agenzia di Tutela della Salute (ATS) della Val
Padana, Mantova Cancer Registry, Epidemilogy Unit, Mantova, Italy,
26
Siracusa Cancer Registry, Health Unit of Siracusa, Siracusa, Italy,
27
Trento Province Cancer Registry, Unit of Clinical Epidemiology, Trento,
Italy,
28
ASSL Nuoro/ATS Sardegna, Nuoro Cancer Registry, RT Nuoro,
Nuoro, Italy,
29
Southtyrol Cancer Registry, Bolzano, Italy,
30
Health Pro-
tection Agency, Sondrio Cancer Registry, Sondrio, Italy
SUPPLEMENT ABSTRACTS
-
477
Introduction: The number of patients living after a cancer diagnosis is
increasing, especially after hemolymphopoietic and thyroid cancer
(TC). This study aims at evaluating both the risk of a second hemo-
lymphopoietic cancer in TC patients and the risk of TC as a second
cancer.
Methods: Two populationbased cohorts of cancer patients aged up
to 84 years were identified from 28 Italian cancer registries in the
1998–2012. The first included TC patients and the second hemo-
lymphopoietic cancers patients with cancers. Standardized incidence
ratios (SIR) of SPC were stratified by sex, age, and time since first
cancer. SPC diagnosed within 2 months since first are not included in
the computation of cancerspecific SIRs.
Results: 38,535 TC patients and 154,820 patients with hemolym-
phopoietic cancers were included. Overall SIR for hemolympho-
poietic cancer in TC patients was significantly increased (SIR=1.5 in
women and 1.3 in men), as well as for most of the hemolymphopoietic
subtypes (SIR=2.7 for acute lymphoid leukemia, 1.6 for follicular non
Hodgkin lymphomas, 1.5 for chronic lymphoid leukemia, and 1.4 for
myelomas for both sexes). The overall SIR for hemolymphopoietic
cancer in TC patients was significantly higher in all three age groups
(034 years: 2.0, 3554: 1.4 and 55+: 1.4 for both sexes). The risk of
TC cancer was significantly increased after Acute Lymphoid Leuke-
mia (10 cases, SIR=6.1), Hodgkin lymphomas (38, 2.8), and all
hemolymphopoietic neoplasms (183, 1.8). The risk of TC after any
hemolymphopoietic cancer was particularly higher for the age groups
034 and 3554 (SIR 4.3 and 1.8 respectively).
Conclusions: TC patients have both an increased risk of developing a
second hemolymphopoietic cancer as TC to be a second cancer. An
elevated risk of second primary tumors from the use of radioactive
iodine (RAI) therapy in TC patients, in particular in pediatric and
young adult patients, may explain the elevated incidence of acute
lymphoid leukaemias and hemolymphoiectic neoplasms overall. The
present finding may help in designing surveillance programs for
hemolymphopoietic cancers in TC patients and vice versa keeping
into consideration the possibility of overdiagnosis of TC.
Keywords: Prevention and Cancer Interception
No conflicts of interests pertinent to the abstract.
392 |LATE TOXICITIES AND LONGTERM MONITORING IN
CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE BCELL
LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS
OF THE FONDAZIONE ITALIANA LINFOMI
C. Minoia
1
, C. Gerardi
2
, E. Allocati
2
, V. De Sanctis
3
, S. Franceschetti
4
,
S. Viviani
5
, M. A. Annunziata
6
, A. Bari
7
, T. Skrypets
1
, S. Oliva
8
, A.
Puzzovivo
9
, S. Di Molfetta
10
, V. Caccavari
11
, A. Di Russo
12
, G.
Loseto
1
, A. Daniele
13
, L. Nassi
14
, G. Gini
15
, A. Guarini
1
1
IRCCS Istituto Tumori “Giovanni Paolo II”, Hematology Unit, Bari, Italy,
2
Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Centro
Politiche Regolatorie in Sanità, Milan, Italy,
3
Faculty of Medicina e
Psicologia, Sant'Andrea Hospital, University of Rome "La Sapienza",
Department of Radiation Oncology, Rome, Italy,
4
ASST Ovest Milanese, U.
O.C. Ematologia, Legnano, Italy,
5
IEO European Institute of Oncology,
IRCCS, Division of HematoOncology, Milan, Italy,
6
Centro di Riferimento
Oncologico di Aviano (CRO), IRCCS, Unit of Oncological Psychology,
Aviano, Italy,
7
Università di Modena e Reggio Emilia, UO Terapie Mirate in
Oncoematologia ed Osteoncologia, Dipartimento di Scienze Mediche e
Chirurgiche MaternoInfantili e dell'Adulto, Modena, Italy,
8
IRCCS Istituto
Tumori "Giovanni Paolo II", Cardiology Unit, Bari, Italy,
9
IRCCS Istituto
Tumori "Giovanni Paolo II, Cardiology Unit, Bari, Italy,
10
University of Bari
"Aldo Moro", Department of Emergency and Organ Transplantation,
Section of Internal Medicine, Endocrinology, Andrology and Metabolic
Diseases, Bari, Italy,
11
Istituto Clinico Città Studi, Assisted Reproduction
Unit, Milan, Italy,
12
Fondazione IRCCS Istituto Nazionale dei Tumori,
Radiotherapy Unit, Milan, Italy,
13
IRCCS Istituto Tumori "Giovanni Paolo
II", Experimental Oncology and Biobank Management Unit, Bari, Italy,
14
Careggi Hospital and University of Florence, Lymphoma Unit, Hema-
tology Department, Florence, Italy,
15
AOU Ospedali Riuniti AnconaUni-
versità Politecnica delle Marche, Clinic of Hematology, Ancona, Italy
Background: In the current years it is estimated that cancer survivors
are more than 16 million and it is predicted to reach 22 million by
2030. Up today there is a paucity of data on late toxicities affecting
lymphoma survivors, thus we still need more data from literature to
follow late sequelae of these patients and to set up an organized and
evidence based followup strategy.
Aim: Researchers belonging to the Fondazione Italiana Linfomi
drawn a series of systematic reviews with the aim to :i) evaluate
available data and develop homogeneous indications for lymphoma
survivors' monitoring using a systematic approach; ii) find a balance
between the unmet medical need and the sustainability of health-
care system.
Methods: The research work was carried out by a multidisciplinary
team of 16 researchers of the Fondazione Italiana Linfomi under
the methodological supervision of 3 Researchers of the Istituto di
Ricerche Farmacologiche “Mario Negri”, in Milan. The systematic
reviews focused on six topics: cardiotoxicity, secondary cancers,
endocrinemetabolic sequelae, fertility and neurological/ cognitive
toxicities, healthy lifestyles. The following specific questions were
analyzed, considering the population of classical Hodgkin lymphoma
(cHL) and Diffuse large Bcell lymphoma (DLBCL) survivors treated
at adult age (18 years old): i) incidence of the longterm toxicity;
ii) comparison with more recent therapies (e.i. modern radiation
therapy); iii) best monitoringof longterm sequelae. The search was
conducted on 3 bibliographic databases (PubMed, Embase and the
Cochrane Library) with also hand searching up to December, 2020.
Selection process and data extraction were conducted according to
the Preferred Reporting Items for Systematic reviews and Meta
analyses (PRISMA) guidelines.
Results: Six independent systematic reviews were conducted accord-
ing to the topics of research. A global number of 170 full text papers
resulted eligible for data extraction and were included in the final
sample. They concerned: cardiotoxicity (n =22), secondary cancers
(n =21), endocrinemetabolic sequelae (n =9), fertility (n =46),
478
-
SUPPLEMENT ABSTRACTS
neurologic and cognitive toxicity (n =62), healthy lifestyles (n =10).
The optimal detection and monitoring was found out for: i) early left
ventricular ejection fraction dysfunction, coronary artery disease,
valvular heart disease; ii) secondary acute myeloid leukemias/ myelo-
displastic syndromes and solid tumors; iii) metabolic syndrome, thy-
roid, gonadal, and mineral bone disorders; iv) peripheral neuropathy,
fatigue, cognitive impairment, anxiety and depression. Fertility pres-
ervation and correction of unhealthy lifestyles were also examined.
Conclusion: The final documents could be a reasonable bridge from
evidence to decision in order to improve the clinical practice and
customize the general followup approach of cHL and DLBCL
survivors.
EA previously submitted to EHA 2021.
Keywords: Late Effects in Lymphoma Survivors
No conflicts of interests pertinent to the abstract.
393 |HEALTHCARE RESOURCE UTILIZATION IN PATIENTS
WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC
LEUKEMIA USING REALWORLD DATA FROM FIVE COUNTRIES
C. Cool
1
, C. Feng
2
, S. Wade
3
, R. Rau
1
, K. Ching
1
, L. Nyamutswa
2
,
H. Viswanathan
1
, B. Kharabi
2
, A. Duvall
4
1
Precision Value & Health, PRECISIONheor, New York, New York, USA,
2
Kite Pharma, A Gilead Company, Global Health Economics and
Outcomes Research, Santa Monica, California, USA,
3
Wade Outcomes
Research and Consulting, Health Economics, Salt Lake City, Utah, USA,
4
University of Chicago, Department of Medicine, Section of Hematology/
Oncology, Chicago, Illinois, USA
Introduction: About half of acute lymphoblastic leukemia (ALL) pa-
tients relapse, and outcomes are poor in relapsed or refractory (R/R)
ALL patients with the current standard of care. Healthcare resource
utilization (HRU) by line of therapy (LoT) in R/R ALL patients is not
well studied. This study aims to assess their HRU by LoT.
Methods: A retrospective review of R/R ALL patient charts by 243
oncologists in the United Kingdom, France, Germany, Italy, and Spain
was conducted. Patients were treated at secondline (2L) or thirdline
(3L) between January 2015 and December 2018. HRU including hos-
pitalizations, length of stay (LoS), Intensive Care Unit (ICU) days, and
Emergency Room (ER) visits was assessed and stratified by patients' R/
R status [primary refractory, relapsed without Stem Cell Transplant
(SCT), or relapsed post SCT] and LoT. Baseline characteristics and in-
duction regimens were summarized. HRU for induction or SCT was
excluded.
Results: Data on 725 and 309 R/R ALL patients who started 2L and 3L
respectively were analyzed (Table 1). Sample size varied by outcome.
Median ages were 53 years (2L) and 50 years (3L). The majority were
male (2L: 72.1%; 3L: 64.1%), and about a quarter were Philadelphia
positive (2L: 25.2%; 3L: 25.6%). 34.5% (2L) and 47.6% (3L) of pa-
tients were treated with new regimens (blinatumomab or inotuzu-
mab). Over the duration of therapy (DoT) (2L: 7.7 months, 3L: 7.4
months), the percent of patients hospitalized ranged over varying R/R
status from 27.1% to 39.7% (2L) and 27.4% to 47.6% (3L). For both 2L
and 3L, relapsed patients post SCT had higher hospital and ER use
compared to primary refractory and relapsed patients without SCT.
Conclusions: HRU is substantial for R/R ALL. Relapsed patients post
SCT had more hospitalizations and ER visits compared to other R/R
ALL patients. There is a need for more effective therapies with po-
tential to reduce HRU for R/R ALL.
The research was funded by: Kite Pharma, A Gilead Company
Keywords: Cancer Health Disparities, Molecular Targeted Therapies,
Combination Therapies
Conflicts of interests pertinent to the abstract
C. Cool
Employment or leadership position: PRECISIONheor
C. Feng
Employment or leadership position: Kite Pharma, Boston Scientific
Stock ownership: Kite Pharma/Gilead, Boston Scientific, Sanofi, Pfizer
TABLE 1HRU of R/R ALL by R/R status and LoT
SUPPLEMENT ABSTRACTS
-
479
Educational grants: Kite Pharma/Gilead; Boston Scientific
S. Wade
Consultant or advisory role: Kite Pharma
R. Rau
Employment or leadership position: PRECISIONheor
K. Ching
Employment or leadership position: PRECISIONheor
L. Nyamutswa
Employment or leadership position: Kite Pharma
Stock ownership: Kite Pharma/Gilead
H. Viswanathan
Employment or leadership position: PRECISIONheor
B. Kharabi
Employment or leadership position: Kite Pharma
Stock ownership: Kite Pharma, GSK, Immatics, Novartis, BMS, Roche
Educational grants: Kite Pharma
TABLE 1Subtypes of malignant lymphomas in Ukraine, according to 2016 WHO classification
480
-
SUPPLEMENT ABSTRACTS
394 |BURDEN OF MULTIPLE MYELOMA IN CHINA: AN
ANALYSIS OF THE GLOBAL BURDEN OF DISEASE, INJURIES, AND
RISK FACTORS STUDY 2019
W. Liu
1
, J. Liu
2
, L. Mi
1
, C. Cai
3
, T. Gong
4
, J. Ma
4
, L. Wang
2
1
Peking University Cancer Hospital & Institute, Department of
Lymphoma, Beijing, China,
2
National Center for Chronic and
Noncommunicable Disease Control and Prevention, Chinese Center for
Disease Control and Prevention, National Center for Chronic and
Noncommunicable Disease Control and Prevention, Beijing, China,
3
Beijing Institute of Survey and Mapping, Beijing Municipal Key
Laboratory of Urban Spatial Information Engineering, Beijing Institute
of Survey and Mapping, Beijing, China,
4
Harbin Institute of
Hematology & Oncology, Harbin Institute of Hematology & Oncology,
Harbin, China
Background: The burden of multiple myeloma (MM) is increasing
over time in China. However, there is limited data to evaluate
comprehensively the epidemiological characteristics of MM.
Methods: Following the general analytical strategy used in Global
Burden of Disease, Injuries, and Risk Factors Study 2019, we ana-
lysed the burden of MM including incidence, mortality, prevalence
and disabilityadjusted life years (DALYs) with 95% uncertainty in-
terval (UI) in China. Trends in burden of MM from 1990 to 2019 were
evaluated.
Results: There were an estimated 347.45 thousands DALYs with an
agestandardized DALYs rate of 17.05 (95% UI, 12.3120.77) per
100,000 population in 2019. The estimated incidence case and
deaths of MM were 18.79 thousands and 13.42 thousands, with age
standardized incidence and mortality rates of 0.93 (95%UI, 0.67
1.15) and 0.67 (95%UI, 0.500.82) per 100 000 population. The age
specific DALYs rates per 100,000 population increased more than 10
at age group 4044 and reached a peak (93.82) at age group 7074.
Males had higher burden than females with about 1.52 folds sexual
differences in agespecific DALYs rates in all age groups. From 1990
to 2019, the DALYs number of MM increased by 134% with changing
from 148.48 thousands in 1990 to 347.45 thousands in 2019.
Conclusion: The burden of MM increased doubly during the past 3
decades, which highlighted the need of establishment of effective
disease prevention and control strategies in both national and pro-
vincial levels.
Keywords: Multiple Myeloma
No conflicts of interests pertinent to the abstract.
395 |SUBTYPES OF MALIGNANT LYMPHOMAS IN UKRAINE,
ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY
REPORT OF THE UKRAINIAN LYMPHOMA REGISTRY
T. Skrypets
1
, Y. Stepanishyna
2
, G. R. Galli
3
, M. Manni
4
, A. Hubareva
5
,
I. Tytorenko
2
, A. Martynchyk
2
, O. Aleksik
2
, N. Shudrak
2
,
Y. Pastushenko
2
, O. Novosad
2
, K. Filonenko
2
, T. Kadnikova
2
,
Y. Kushchevyi
2
, M. Federico
4
, I. Kriachok
2
1
University of Modena and Reggio Emilia, PhD Program in Clinical and
Experimental Medicine, Modena, Italy,
2
National Cancer Institute,
Department of Oncohematology, Kyiv, Ukraine,
3
Associazione Angela
Serra, Associazione Angela Serra for Cancer Research, Lecce, Italy,
4
University of Modena and Reggio Emilia, CHIMOMO, Modena, Italy,
5
Ukrainian Lymphoma Study Group, Ukrainian Lymphoma Study Group,
Kyiv, Ukraine
Introduction: According to the Ukrainian National Cancer Registry,
Malignant Lymphoma (ML) represent the 9th most frequent type of
cancer, with agestandardized rates of 8.4 for males and 6.6 for fe-
males. Unfortunately, no data on subtypes of ML are reported
neither by WHO2008 nor the updated WHO2016 classification.
There is a lack of information on real incidence, clinical presentation,
outcome of different subtypes, and performances of the healthcare
system in Ukraine. In 2019, the Ukrainian lymphoma registry (ULR)
was established and here we report the preliminary analysis of the
first 432 cases registered, based on local histological diagnosis.
Methods: The ULR prospectively collects information on baseline
clinical and disease characteristics, firstline treatment, and response
evaluation of new cases of ML classified according to the most recent
WHO2016 classification. Registration was performed online on a
secured dedicated database. Electronic Case Report Forms were
reviewed and verified by the ULR team.
Results: ULR was launched in October, 2019. So far, 432 patients
with newly diagnosed ML were registered. The median age is 45.9
years (range 1799), 40,6% were male, and 59,4% female. By age
distribution, 20,6% of patients were under 30 years old, 37,8% be-
tween 30 49, 22,7% in 5064, while 18,9% were over 65. Overall,
64% of the population is affected by mature Bcell neoplasms, 32%
by Hodgkin lymphoma and 4% by mature T and NKcell neoplasms.
As reported in Table 1, DLBCL (24.7% of cases) represents the most
frequent subtype of Bcell malignancies, followed by CLL/SLL (7.7%)
and FL (7.6%). A high incidence of PMBCL (7.0%) and PCNSL (4.6%),
was observed. With respect to mature T and NKcell lymphomas,
ATLL and AITL resulted the most frequent subtypes.
Conclusions: Our preliminary ULR data provides the first compre-
hensive analysis on the distribution pattern of ML in Ukraine, clas-
sified according to the recent WHO classification. As expected
considering the Ukrainian population age structure, a high percent-
age of ML are represented by HL, while a limited number of FL have
been found, suggesting a possible different genetic predisposition to
this subtype in the Ukrainian population. In conclusion, regardless its
very young age, ULR is recruiting very well and may help to better
investigate the outcome of patients with ML outside clinical trials, in
the real world.
The research was funded by: Associazione Angela Serra for
Cancer Research, Italy
Keywords: Pathology and Classification of Lymphomas
SUPPLEMENT ABSTRACTS
-
481
No conflicts of interests pertinent to the abstract.
396 |THE SURVIVAL OF 2852 PATIENTS WITH LYMPHOMA: A
SINGLE CENTER STUDY FROM CHINA
L. Zhang
1
, Z. Sun
1
, X. Fu
1
, W. Wan
1
, J. Ge
1
, Y. Xia
1
, D. Xu
1
, F. Nan
1
, H.
Yu
1
, M. Zhang
1
, L. Li
1
, X. Li
1
, Z. Li
1
, X. Wang
1
, Y. Chang
1
, J. Yan
1
, X.
Wu
1
, Z. Zhou
1
1
The First Affiliated Hospital of Zhengzhou University, Department of
Oncology, Zhengzhou, China
Background: Hospital type can also affect the treatment outcome
and prognosis of patients with lymphoma. This study was to describe
the survival of lymphoma patients admitted to an academic center in
China over the past decade.
Methods: The survival and prognosis of 2852 patients with lym-
phoma admitted to an academic center in China in the past decade
were retrospectively analyzed.
Results: The 5year OS for 269 patients with Hodgkin lymphoma
(HL) were 91.3%. In 1744 patients with mature BCL, the patients
with follicular lymphoma (FL) had the highest 5year OS rate (75.3%),
followed by Burkitt lymphoma (71.2%), diffuse large Bcell lymphoma
(62.0%), small lymphocytic lymphoma/chronic lymphocytic leukemia
(60.5%), and mantle cell lymphoma (50.7%). In 712 patients with
mature T and NK cell lymphomas, the 5year OS rate was highest in
ALK+anaplastic large cell lymphoma (68.6%), followed by natural
killer/Tcell lymphoma (61.4%), ALKanaplastic large cell lymphoma
(43.0%), peripheral Tcell lymphoma not otherwise specified (40.4%)
and angioimmunoblastic Tcell lymphoma (37.1%). In 127 patients
with lymphoblastic lymphoma, the 5year OS rate were 36.3% and
32.1% in B cell lymphoblastic lymphoma and T cell lymphoblastic
lymphoma, respectively.
Conclusion: The survival rate of patients with natural killer/Tcell
lymphoma or HL in our center are numerically higher than that of
other domestic and foreign centers (currently reported). The sur-
vival rate of patients with mature BCL is similar with other
centers.
The research was funded by: National Natural Science Founda-
tion of China(Grant No. 81970184)
Keywords: Lymphoid Cancers Other
No conflicts of interests pertinent to the abstract.
397 |COCHRANE HAEMATOLOGY REVIEWS TO INFORM
WORLD HEALTH ORGANIZATION'S LIST OF ESSENTIAL
MEDICINES ON CLINICAL VALUE OF HIGHPRIORITY CANCER
MEDICINES
V. Piechotta
1
, C. Hirsch
1
, M. Ernst
1
, M. Goldkuhle
1
, L. Moja
2
, N.
Skoetz
3
1
University of Cologne, Cochrane Haematology, Department I of
Internal Medicine, Center for Integrated Oncology Aachen Bonn
Cologne Duesseldorf, Faculty of Medicine and University Hospital,
Cologne, Germany,
2
World Health Organization, Department of
Essential Medicines and Health Products, Geneva, Switzerland,
3
University of Cologne, Cochrane Cancer, Department I of Internal
Medicine, Center for Integrated Oncology Aachen Bonn Cologne
Duesseldorf, Faculty of Medicine and University Hospital, Cologne,
Germany
Introduction: Essential medicines aim to satisfy the priority health
needs of a population. In 2019, cancer medicines made up 12% of
all listed medicines in the World Health Organization's Essential
Medicines List (EML). Every other year, scientists and stakeholders
worldwide are invited to prepare evidencebased applications for
the inclusion of novel medicines, and changes to or deletion of
currently listed medicines in order to refine and update the EML.
Our aim is to illustrate the value of Cochrane Haematology sys-
tematic reviews for the revision of antineoplastic therapeutics listed
in the EML.
Methods: As part of a prioritisation within Cochrane Haematology
and the EML cancer medicines working group,we identified a need
to systematically review multiple antineoplastic therapeutics for
the treatment of multiple myeloma and Bcell lymphomas. We
prepared five Cochrane reviews according to standard Cochrane
methodology to review the efficacy and safety of the treatments in
question, and integrated the results as evidence body into three
EML applications.
Results: Based on the results of the Cochrane reviews, we prepared
EML applications for the inclusion of four individual medicines
(bortezomib, daratumumab, lenalidomide, and thalidomide) for the
treatment of multiple myeloma. A fifth review contributed to the
work of the EML Committee providing information on the benefits,
harms, production, and access to CART therapies, suggesting to
monitor these treatments over time. A potential candidature of CAR
T cell therapies for diffuse large Bcell lymphoma might be possible in
the near future.
Bortezomib, lenalidomide, and thalidomide were included in the
21st EML that was published in 2019. Proposals on daratumumab
and CART cells are available for public review on the WHO website
and will be discussed during the 23rd WHO Expert Committee on the
Selection and Use of Essential Medicine in June 2021.
Conclusions: Using Cochrane Haematology reviews to inform the
EML allows to adequately consider potential biases and un-
certainties in the available evidence in order to identify essential
treatment options in haematooncology. The EML process is also
an opportunity for Cochrane to expand on dimensions such as
medicine development, logistics and purchase and procurement
agreements.
EA previously submitted to EHA 2021.
Keywords: Cancer Health Disparities
No conflicts of interests pertinent to the abstract.
482
-
SUPPLEMENT ABSTRACTS
398 |PRIORITISATION OF RELEVANT COCHRANE REVIEW
TOPICS IN THE FIELD OF HAEMATOLOGY
C. Hirsch
1
, T. Jakob
1
, E. Tomlinson
2
, L. Estcourt
3
, S. Theurich
4
, S.
Ocheni
5
, N. Skoetz
6
, V. Piechotta
1
1
Cochrane Haematology, Department I of Internal Medicine, Center
for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty
of Medicine and University Hospital, University of Cologne, Cologne,
Germany,
2
Cochrane Cancer Network, Royal United Hospital, Bath, UK,
3
Cochrane Haematology, Haematology/Transfusion Medicine, NHS
Blood and Transplant, Oxford, UK,
4
Department of Medicine III,
University Hospital LMU, LudwigMaximiliansUniversität München,
Munich, Germany,
5
Department of Haematology & Immunology,
University of Nigeria, ItukuOzalla Campus, Enugu, Nigeria,
6
Cochrane Cancer, Department I of Internal Medicine, Center for
Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of
Medicine and University Hospital, University of Cologne, Cologne,
Germany
Background: Cochrane Haematology produces, publishes and
maintains systematic reviews in the field of haematology. The group
wants to ensure that their limited resources and efforts are being
used to produce Cochrane reviews addressing topics that are of
utmost importance to their endusers. According to one of
Cochrane's key principle ‘striving for relevance' the group initialised
their first priority setting exercise engaging stakeholders worldwide
to identify the top priority topics for Cochrane Haematology re-
views. The aim was to identify the top ten priority topics for review
updates and the top five priority topics for new Cochrane Haema-
tology reviews as part of Cochrane Haematology's priority setting
exercise.
Methods: The priority setting exercise consisted of two phases. In
phase one, potential priority topics were generated by identifying
trends (analysing review metrics) and gaps (screening for priority
topics of the American Society of Hematology (ASH), the Euro-
pean Hematology Association (EHA), the German Society for
Hematology and Oncology (DGHO) and the James Lind Alliance
(JLA) in the field of hematology) in the current review portfolio.
In the second phase, the identified topics were then prioritised
by various stakeholders in an online survey. Respondents were
asked to select the topics they deemed to be of high priority and
rank them afterwards from highest to lowest priority. An average
score was then calculated for each ranked topic. Topics with the
highest average score were identified as being the top priority
topics.
Results: The online survey was open between July 6th 2020 to
August 28th 2020. A total of 160 responses were collected, of which
63 respondents (39%) provided complete responses. Most of the
respondents identified themselves as physician (34%), someone who
is or has been affected by haematological disease (31%), or researcher
(24%) and were distributed across 21 countries. The highest number
of respondents resided in the United Kingdom (n =72), Germany (n =
20) and Canada (n =11). The top ten priority topics for reviews that
need updating were related to interventions in multiple myeloma,
hodgkin lymphoma and topics from the areas of stem cell trans-
plantation and supportive care for haematological diseases. The top
five priority topics for new reviews addressed mainly myelodysplastic
syndrome (MDS), relapse of disease posthaematopoietic stem cell
transplant and longterm survival in cancer.
Conclusion: The priority setting process engaged various stake-
holders and identified the most relevant review topics, published on
Cochrane Haematology's website. These topics, some of them are
open to new authors, will now guide the group's future scope of work
and ensure that the most important reviews are updated. New pri-
ority reviews will close gaps within the review portfolio of Cochrane
Haematology.
EA previously submitted to regional or national meetings (up to
1000 attendees) and EHA 2021.
Keywords: Cancer Health Disparities, Lymphoid Cancers Other
No conflicts of interests pertinent to the abstract.
399 |CLINICAL, LABORATORY, IMAGING FINDINGS AND
TREATMENT OF 60 CASES WITH CASTLEMAN'S Disease
Q. Siyu
1
, Z. Xudong
1
1
The First Affiliated Hospital of Zhengzhou University, Oncology
Department, Zhengzhou, China
Purpose: Castleman disease is a rare lymphoproliferative disorder
with low prevalence, the clinical study of CD is mainly among case
reports and small series trials. We want to provide more detailed
clinical information of this rare disease to offer some insight for the
management and treatment of CD patients.
Methods: We retrospectively collected the clinical information of 60
CD patients diagnosed in the First Affiliated Hospital of Zhengzhou
University with unbridged followup data.
Results: We analyzed the detailed information of 60 patients (19
with UCD and 41 with MCD). The most common pathology type of
UCD is HV, whereas PC and Mix much expresses for MCD.
Asymptomatic and lymphadenopathy are more common in UCD,
whereas fever is more common in MCD. MCD patients were more
likely to show anemia, hypoproteinemia, abnormal A/G, abnormal
platelet count, as well as elevation of LDH and urinary protein
than UCD patients according to laboratory test information. In
addition, EBV and cytomegalovirus were found positive in
approximately 87.0% of the tested patients with MCD more than
UCD (75.0%). The most common region of lymphadenopathy in
MCD patients is neck (80.5%), the UCD patients (65.0%) as well.
SUVmax of PETCT was significantly higher in MCD than in the
UCD group (6.8±4.2 and 2.8±0.7, respectively). Thrombocytopenia,
splenomegaly and elevated β2MG were defined as the
SUPPLEMENT ABSTRACTS
-
483
independent poor prognosis factor of CD. Surgical resection is the
first choice for the treatment of UCD, and there is no standard
treatment for MCD.
Conclusions: The present work increase understanding on the dif-
ference between UCD and MCD from clinical various aspects which
provide a comprehensive evaluation of CD patients for better diag-
nosis and treatment.
The research was funded by: The paper is supported by National
Natural Science Foundation of China (Grant No.82070209) and
(Grant N0.82070210).
Keywords: Diagnostic and Prognostic Biomarkers, PETCT, Pathology
and Classification of Lymphomas
No conflicts of interests pertinent to the abstract.
484
-
SUPPLEMENT ABSTRACTS
DOI: 10.1002/hon.2882
SUPPLEMENT ABSTRACT
INDUSTRY PROGRAM SATELLITE SYMPOSIUM AGENDA
Friday, June 18
Time Channel Session Article/ abstract nr.
12:00 13:30 Channel 1 Janssen Oncology Pharmaceutical Companies of Johnson & Johnson
PRECISION MEDICINE IN LYMPHOMA: WHAT DOES IT MEAN?
Chair: John Gribben, London (UK)
The power of precision medicine lies in its ability to guide health care decisions toward the
most effective treatment strategy for a given patient, and thus, improve the quality of
patient care. In this symposium, the expert faculty will evaluate what precision
medicine means for the management of patients with Bcell lymphomas. Professor John
Gribben will lead a structured roundtable discussion with Professor Steven le Gouill,
Professor Steve Treon and Professor Catherine Thieblemont to consider how aspects
of precision medicine can be applied in different lymphomas to improve patient care
and clinical outcomes. EM61522
Welcome and introduction
John Gribben, London (UK)
Structured roundtable discussion: What does precision medicine mean for the
management of lymphoma now and in the future?
Steven Le Gouill, Nantes (France)
Catherine Thieblemont, Paris (France)
Steve Treon, Boston (USA)
All faculty, moderated by John Gribben, London (UK)
Q&A live session
All faculty, moderated by John Gribben, London (UK)
Closing remarks
John Gribben, London (UK)
12:00 13:30 Channel 2 AstraZeneca
EVOLVING STRATEGIES USING BTK INHIBITORS IN CLL: A SELECTIVE APPROACH TO
IMPROVE PATIENT OUTCOMES
Chair: Paolo Ghia, Milan (Italy)
In this CMEcertified, live webinar on 18 June 2021 at 12.00 CEST, Drs. Paolo Ghia, George
A. Follows, and Veronique Leblond will discuss the evolving global strategies around
using BTK inhibitors in CLL, including the current role of BTKi in CLL, safety concerns,
and a discussion of patient cases. Attendees will have the opportunity to have questions
answered by these experts, enhancing the interactivity of this webinar.
(Continues)
All session times for the 16ICML Virtual edition follow the Central European Summer Time (CEST)
© 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Hematological Oncology. 2021;39(S2):485493. wileyonlinelibrary.com/journal/hon
-
485
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
The Current Role of BTK Inhibitors in CLL
Paolo Ghia, Milan (Italy)
A Focus on Safety of BTK inhibitors in the Management of CLL
George Follows, Cambridge (UK)
Practical Case Discussions: Selecting BTK inhibitor Therapy in CLL
Véronique Leblond, Paris (France)
12:00 13:15 Channel 3 MSD
EXPLORING THE UTILITY OF NOVEL TARGETS IN LYMPHOMAS
Chair: Ulrich Jaeger, Vienna (Austria)
Educational Objectives
Review the most recent data and the actual treatment landscape in cHL
Review the treatment options with BTK inhibitors in CLL and NHL
12:00 12:10 Welcome and introduction
Ulrich Jaeger, Vienna (Austria)
12:10 12:35 Current treatment landscape in Classical Hodgkin‘s Lymphoma
Jane Winter (USA)
12:35 13:00 Bruton‘s Tyrosine Kinase (BTK) inhibition: past, present, future
Paolo Ghia (Italy)
13:00 13:10 Q&A Live Panel Discussion
All faculty
13:10 13:15 Closing remarks
Ulrich Jaeger, Vienna (Austria)
12:00 13:30 Channel 4 ADC Therapeutics
ELEVATE YOUR KNOWLEDGE ON NOVEL ANTIBODYBASED THERAPIES TO TREAT
R/R DLBCL
Chair: Carmelo CarloStella, Milan (Italy)
Although firstline chemoimmunotherapy for diffuse large Bcell lymphoma (DLBCL) is
highly effective, a substantial proportion of patients develop relapsed or refractory
(R/R) disease, which is associated with poor survival outcomes. While current salvage
treatments can provide effective disease control in eligible patients with R/R DLBCL,
treatment options are limited, and many patients still experience disease progression.
Join this year’s ADC Therapeutics Satellite Symposium where a panel of experts,
chaired by Prof. Carmelo CarloStella, discuss the evolving treatment landscape in R/R
DLBCL and the role novel antibodybased therapies might have in meeting this urgent
unmet need.
12:00 Welcome and Introduction
Carmelo CarloStella, Milan (Italy)
12:01 12:20 Aiming to meet the unmet need in R/R DLBCL with novel antibodybased therapies
Sonali Smith, Chicago, IL (USA)
12:20 12:45 CD19 as a target in DLBCL
Weiyun Z. Ai, San Francisco, CA (USA)
12:45 13:10 Clinical data on CD19targeted antibodybased therapies in R/R DLBCL
486
-
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
Carmelo CarloStella, Milan (Italy)
13:10 13:30 Live Q&A Discussion and Closing Remarks
14:00 15:30 Channel 1 Bristol Myers Squibb
ARE WE GOING TOWARDS A NEW CARE PARADIGM IN FL AND CLL?
Chair: Stefano Luminari, Reggio Emilia (Italy)
Please join this Bristol Myers Squibb supported Satellite Symposium on the changing
treatment landscape of Follicular Lymphoma (FL) and Chronic Lymphocytic Leukemia
(CLL) at the 16th ICML Virtual Edition. During the Symposium, Prof. Luminari and Dr.
Kittai will address the parameters to define the treatment goals in patients with FL and
CLL respectively and discuss the current treatment options including chemotherapy
free approaches in FL and CLL. In addition, the question whether chemotherapyfree
regimens will replace chemotherapy at least for some subgroups of patients will also be
addressed. After the presentations, you are encouraged to join the discussion with the
expert speakers during the live Q&A session.
14:00 14:05 Welcome and Introduction
Stefano Luminari, Reggio Emilia (Italy)
14:05 14:30 Follicular Lymphoma: resetting the treatment goals and is chemotherapy here to stay in
FL?
Stefano Luminari, Reggio Emilia (Italy)
14:30 14:55 Chronic Lymphocytic Leukemia: resetting the treatment goals and is chemotherapy here
to stay in CLL?
Adam S. Kittai, Columbus, OH (USA)
14:55 15:30 Q&A and discussion
All faculty, moderated by Stefano Luminari
Closing remarks
Stefano Luminari, Reggio Emilia (Italy)
14:00 15:30 Channel 2 Medscape (supported by an independent educational grant from Takeda)
SPOTLIGHT ON LYMPHOMA: ADDRESSING REAL WORLD CLINICAL CHALLENGES
FOR HL AND PTCL
Chair: Timothy Illidge, Manchester (UK)
In this live virtual symposium, three expert faculty will navigate the changing landscape for
the treatment of HL and PTCL. The faculty will explore factors to consider when
choosing among the available treatment options for both frontline and relapsed/
refractory HL, with an emphasis on how to best sequence these treatments. The faculty
will also discuss newly available therapies for the frontline treatment of PTCL, including
how to manage adverse effects related to their use. Patient cases will be presented to
illustrate these concepts, and the faculty panel will discuss evidencebased
management of these challenging cases.
14:00 14:05 Welcome and Introductions
Timothy Illidge, Manchester (UK)
14:05 14:40 Spotlight on the Treatment of HL: Which Regimen, for Which Patient?
Martin Hutchings, Copenhagen (Denmark) and Anna Sureda, Barcelona (Spain)
14:40 15:10 Spotlight on the Treatment of Newly Diagnosed PTCL: Incorporating New Therapies Into
the Treatment Paradigm
Timothy Illidge, Manchester (UK)
(Continues)
-
487
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
15:10 15:30 Shifting Focus: What Do You and the Experts Think?
Q&A Live Session
Timothy Illidge, Manchester (UK), Martin Hutchings, Copenhagen (Denmark) and Anna
Sureda, Barcelona (Spain)
Adjourn
14:00 15:30 Channel 3 AbbVie
NOT ALL BISPECIFIC ANTIBODIES ARE CREATED EQUAL
Chair: Gilles Salles, New York, NY (USA)
We will consider how bispecific antibodies offer a novel approach and treatment paradigm
for patients with nonHodgkin lymphoma (NHL). The science and rationale for bispecific
antibodies in NHL will be discussed as we take a look at the mechanistic differences in
the bispecific CD3xCD20 class. We will then review the latest preclinical and early
phase data, consider where bispecific antibodies fit into the future treatment algorithm,
and finish by opening the floor for questions from the audience.
Welcome and Introduction
Gilles Salles, New York, NY (USA)
Bispecific antibodies: a mechanistic review of the pipeline
John Gribben, London (UK)
Emerging clinical data for bispecific antibodies in NHL
Sarit Assouline, Montreal, Quebec (Canada)
Future perspectives on bispecific antibodies in NHL
Gilles Salles, New York, NY (USA)
Live Q&A session and closing remarks
All speakers
14:00 15:30 Channel 4 Pfizer Oncology
COVID19 IN CLL AND B CELL MALIGNANCIES
Chair: Toby Eyre, Oxford (UK)
Introductory remarks on COVID 19 Perspective on hematological malignancies patients
and clinical research in the era of COVID19
Toby Eyre, Oxford (UK)
Clinical outcomes of CL patients with COVID19
Lindsey Roeker, New York, NY (USA)
Clinical outcomes of B cell lymphoma patients with COVID19
Toby Eyre, Oxford (UK)
Vaccine efficacy in patients with B cell malignancies and impact of anti CD20 antibodies
and other targeted therapies on humoral immunity
David Knorr, New York, NY (USA)
16:00 17:30 Channel 1 Kite, a Gilead Company
BUILDING ON SURVIVAL IN CELL THERAPY: FOCUS ON THE FUTURE
Chair: John Gribben, London (UK)
CAR Tcell therapy continues to reshape the R/R NHL landscape, with multiple CAR Tcell
products now licensed in Europe and the US. Despite successes, questions remain on
the future of CAR Tcell therapy. During this interactive symposium, our faculty will
discuss how we define survival in lymphoma, examine the impact of CAR T product on
survival and share insights into patient management optimisation. Finally, they will
488
-
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
explore future directions and advances in cell therapy. We encourage you to take the
opportunity to participate in the voting questions and live Q&A, where the faculty will
discuss questions submitted by the audience.
Welcome and introduction: We have come so far…
John Gribben, London (UK)
How is CAR T reshaping survival in lymphoma?
Armando LópezGuillermo, Barcelona (Spain)
What is the impact of the CAR T product on achieving survival?
Frederick Locke, Tampa, FL (USA)
How can we optimise patient management?
John Gribben, London (UK) and Marion Subklewe, Munich (Germany)
New directions: What does the future hold?
Caron Jacobson, Boston, MA (USA)
Live audience Q&A
All faculty
16:00 17:30 Channel 2 Incyte
PEARLS OF KNOWLEDGE: EXPERT PERSPECTIVES IN THE TREATMENT OF R/R DLBCL
Patients with relapsed or refractory (R/R) diffuse large Bcell lymphoma (DLBCL) who are
transplantineligible tend to have very poor outcomes. There is no standard of care, and
the currently available treatments generally result in responses that are not durable. In
this symposium, we address key unmet needs for these patients with a series of short
videos from DLBCL experts outlining various aspects of how they treat their patients
with R/R DLBCL.
What is your goal for secondline treatment and further for patients with transplant
ineligible R/R DLBCL?
Pier Luigi Zinzani, Bologna (Italy)
What is the role of chemofree regimens for the treatment of R/R DLBCL?
Marco Ladetto, Alessandria (Italy)
How do you decide which treatment option to use for patients with transplantineligible
R/R DLBCL? What is the role of new molecules with targets other than CD20?
Georg Lenz, Münster (Germany)
What are your expectations of median PFS and DoR for patients with nontransplant
eligible R/R DLBCL with the current treatment options? What would you consider to be
a good response? When would you consider a patient to be cured?
Johannes Düll, Würzburg (Germany)
Which therapies would you consider (will be considering) for patients with transplant
ineligible R/R DLBCL with CNS involvement?
Martin Dreyling, Munich (Germany)
What is your approach to the treatment of patients with doubleor triplehit R/R DLBCL?
Guillaume Cartron, Montpellier (France)
In your experience, are most transplantineligible patients also ineligible for CAR Tcell
therapy?
Roch Houot, Rennes (France)
(Continues)
-
489
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
What challenges have you experienced with the early identification of patients eligible for
CAR Tcell therapy?
Eva González Barca, Barcelona (Spain)
Which adverse events are of concern to you when treating patients with transplant
ineligible R/R DLBCL?
Christopher Fox, Nottingham (UK)
In what way does your approach to treatment differ for patients with transplantineligible
R/R DLBCL who relapse early compared with those who relapse at a later stage?
Armando LópezGuillermo, Barcelona (Spain)
16:00 17:30 Channel 3 Regeneron
EVOLVING TREATMENT PARADIGM FOR RELAPSED/REFRACTORY DIFFUSE LARGE B
CELL LYMPHOMA
Chair: Pier Luigi Zinzani, Bologna (Italy)
The treatment landscape for patients with relapsed/refractory (R/R) diffuse large Bcell
lymphoma DLBCL has expanded with therapeutic advances involving novel targets and
modalities. New agents under investigation for R/R DLBCL include bispecific antibodies,
which are designed to facilitate Tcell activation against tumor cells by binding targets
on T cells and tumor cells simultaneously. This symposium will highlight considerations
for treating patients with R/R DLBCL using newly available therapies, and discuss the
potential impact of emerging bispecific agents on the treatment paradigm in DLBCL. A
questionandanswer session will provide the opportunity for participants to engage
with faculty experts.
Current Landscape and Recent Therapeutic Advances in the Management of R/R DLBCL
Pier Luigi Zinzani, Bologna (Italy)
Considerations for Evaluating Treatment Options for Patients with R/R DLBCL
John Kuruvilla, Toronto (Canada)
Understanding Emerging Bispecific Therapies
Jeremy Abramson, Boston, MA (USA)
Panel Discussion: Exploring the Potential Impact of Bispecific Therapies on the DLBCL
Treatment Paradigm
Pier Luigi Zinzani, Bologna (Italy)
John Kuruvilla, Toronto (Canada)
Jeremy Abramson, Boston, MA (USA)
17:15 17:30 Live Q&A session
John Kuruvilla, Toronto (Canada) and Jeremy Abramson, Boston, MA (USA)
16:00 17:30 Channel 4 Bayer
THE EVOLVING TREATMENT LANDSCAPE AND EMERGING NOVEL THERAPIES IN
INDOLENT NONHODGKIN’S LYMPHOMA (iNHL)
Chair: Martin Dreyling, Munich (Germany)
Despite the recent advances in the treatment of iNHL, many patients with advanced
disease experience relapse and resistance to ongoing therapies, underscoring the need
to identify novel treatment options and appropriate treatment combinations. In this
Bayersponsored symposium, our esteemed faculty will explore the evolving treatment
landscape and promising therapies for iNHL, including various chemotherapyfree
treatment options such as targeted therapies (eg, PI3K inhibitors), CART therapy, and
bispecific antibodies. Current and emerging treatment options for relapsed follicular
lymphoma (FL) and marginal zone lymphoma (MZL) will be discussed in detail, with a
490
-
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
focus on recent key clinical data and ongoing clinical trials. A live Q&A session will
provide an opportunity for participants to interact with the faculty experts.
Welcome and Opening Remarks
Martin Dreyling, Munich (Germany)
Current Treatment Landscape and Emerging Therapies in iNHL
Gilles Salles, New York, NY (USA)
The Evolving Therapeutic Options for Patients With Follicular Lymphoma After First
Relapse
Pier Luigi Zinzani, Bologna (Italy)
How to Treat Relapsed Marginal Zone Lymphoma? Challenges and Clinical Considerations
Christian Buske, Ulm (Germany)
Live Q&A live session
All panelists, led by Martin Dreyling, Munich (Germany)
18:00 19:30 Channel 1 Bristol Myers Squibb
ADVANCEMENTS OF CAR T CELL THERAPIES IN BCELL MALIGNANCIES
Chair: David Maloney, Seattle WA (USA)
Please join this Bristol Myers Squibb supported Satellite Symposium on the Advancements
of CAR T cell therapies in Bcell malignancies at the 16th ICML Virtual Edition. During
the Symposium, Dr. Maloney and Prof. Mateos will present an overview of the latest
data on the use of CAR T cell therapy in DLBCL and Myeloma respectively; how use of
CAR T therapy could be optimized and could shape the treatment landscape in Bcell
malignancies. Dr. Michael Hudecek will then share his translational insights, with a
specific focus on improving patient selection and optimizing outcome. Following the
presentations, there will be an opportunity to interact with the faculty at the live Q&A
session.
18:00 18:05 Welcome and Introduction
David Maloney, Seattle WA (USA)
18:05 18:25 Evolution of the CAR T treatment paradigm in DLBCL
David Maloney, Seattle WA (USA)
18:25 18:45 Prime time for CAR T cell therapy in multiple myeloma
MariaVictoria Mateos, Salamanca (Spain)
18:45 19:05 Understanding scientific advancements with CAR T cell therapy
Michael Hudecek, Wurzburg (Germany)
19:05 19:30 Q&A and discussion
All faculty, moderated by David Maloney, Seattle WA (USA)
Closing remarks
Davide Maloney, Seattle WA (USA)
18:00 19:30 Channel 2 F. HoffmannLa Roche
UNLOCKING THE FUTURE: SEARCHING FOR A CURE IN DLBCL
Chair: Georg Hess, Mainz (Germany)
In this forwardlooking symposium, a vision of how novel therapies, and future advances in
DLBCL may improve patient care in the next five years will be presented by an expert
panel. Interactive discussions, in the form of patient cases and knowledge exchange, will
revolve around current treatment pathways and challenges, and how future integrated
(Continues)
-
491
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
care solutions may help raise the bar to cure more patients with DLBCL. You will have
plenty of opportunities to vote on the cases, and interact with the renowned faculty on
the insights and clinical experiences they will share.
Where are we now?
Georg Hess, Mainz (Germany)
Improving outcomes in firstline DLBCL
Matthew Matasar, New York, NY (USA)
Treatment choices in R/R DLBCL: What, why and when?
Christopher Fox, Nottingham (UK)
Experts in conversation Your questions answered
All faculty Live panel discussion and Q&A session
Is a cure within reach? A fiveyear countdown
Georg Hess, Mainz (Germany)
18:00 19:30 Channel 3 Lymphoma Hub
SEQUENCING OF THERAPIES IN HIGHRISK RELAPSED/REFRACTORY LYMPHOMA
AND CLL
Chair: Gilles Salles, New York, NY (USA)
The Lymphoma Hub Satellite Symposium, ‘Sequencing of therapies in highrisk relapsed/
refractory lymphoma and CLL,’ will be presented by an international speaker panel
chaired by Gilles Salles. The aim of the virtual symposium is to inform participants of
the therapeutic options and the data available to help guide treatment selection for
difficulttotreat relapsed/refractory disease, using case examples of ibrutinibresistant
CLL, earlyrelapsing FL, TP53mutated MCL, and primary refractory DLBCL. The
presentations will be followed by a live roundtable Q&A discussion with the chair and
speakers—Francesc Bosch, Loretta Nastoupil, Steven Le Gouill, and Andrew Davies.
Objectives and introductions
Gilles Salles, New York, NY (USA)
Treatment options for a patient with ibrutinibresistant CLL
Francesc Bosch, Barcelona (Spain)
How to treat early relapse in a patient with FL
Loretta J. Nastoupil, Houston, TX (USA)
Sequencing of therapy for a patient with TP53mutated MCL
Steven Le Gouill, Nantes (France)
Sequencing treatment options in primary refractory DLBCL
Andrew Davies, Southampton (UK)
Roundtable discussion
All faculty
18:00 19:30 Channel 4 Novartis
EXPERT PERSPECTIVES IN CART: IDENTIFICATION, REFERRAL AND MANAGEMENT
OF PATIENTS WITH LYMPHOMA
Chair: Anna Sureda, Barcelona (Spain)
This virtual symposium will discuss the current treatment landscape and unmet needs in
relapsed or refractory (R/R) diffuse large Bcell lymphoma (DLBCL) and follicular
lymphoma (FL), and future directions to optimize patient outcomes with CART cell
therapy. Key discussions will include expert guidance on patient identification, timely
492
-
(Continued)
Friday, June 18
Time Channel Session Article/ abstract nr.
use of CART therapy earlier in the thirdline setting, overcoming barriers to timely
referrals to CART centers, and management of longterm adverse events following
CART therapy. A review of the latest CART therapy trial data in R/R FL will also be
provided. There will be an opportunity for questions during the Live Q&A.
Introductions and opening remarks
Anna Sureda, Barcelona (Spain) and Natacha Bolaños, Madrid (Spain)
CART cell therapy for DLBCL: optimizing patient outcomes, and future directions
Paolo Corradini, Milan (Italy), Anna Sureda, Barcelona (Spain), Luca Arcaini, Pavia (Italy)
Expert panel discussion: Management of longterm adverse events following CART cell
therapy
Anna Sureda, Barcelona (Spain), Pier Luigi Zinzani, Bologna (Italy) and Paolo Corradini,
Milan (Italy)
CART cell therapy in R/R FL: current landscape and future directions
Pier Luigi Zinzani, Bologna (Italy)
Live Q&A and closing remarks
Anna Sureda, Barcelona (Spain), Paolo Corradini, Milan (Italy), Luca Arcaini, Pavia (Italy),
Pier Luigi Zinzani, Bologna (Italy) and Natacha Bolaños, Madrid (Spain)
Monday, June 20
Time Channel Session Article/ abstract nr.
19:00 20:00 Oncology Institute of Southern Switzerland (IOSI)
(supported by an unrestricted educational grant from Gilead Sciences Europe, Ltd, who
provided funding)
THE BIG DEBATE DLBCL: ONE DISEASE, ONE TREATMENT?
Chair: Emanuele Zucca, Bellinzona, Switzerland
DEBATE 1.
Are we ready to introduce genetic classification in routine diagnostics?
YES. Treatment improvement will not be possible otherwise.
Björn Chapuy, Göttingen (Germany)
NO. This is not yet feasible in everyday community settings.
Leticia QuintanillaFend, Tübingen (Germany)
DEBATE 2.
Is frontline RCHOP still the sole standard?
YES. RCHOP21 remains the standard of care.
Laurie Sehn, Vancouver, B.C., (Canada)
NO. We have already moved beyond RCHOP.
Grzegorz S. Nowakowski, Rochester, NJ (USA)
DEBATE 3.
Will targeted treatments soon inform frontline management?
YES. Precision medicine will allow patienttailored treatment.
Margaret Shipp, Boston, MA (USA)
NO. CART and agnostic immunotherapies will replace chemotherapy.
Stephen J. Schuster, Philadelphia, PA (USA)
-
493
DOI: 10.1002/hon.2883
SUPPLEMENT ABSTRACT
INDUSTRY PROGRAM SATELLITE SYMPOSIUM ABSTRACT
IP01
BayerSponsored Satellite Symposium at ICML 2021:
The Evolving Treatment Landscape and Emerging Novel Thera-
pies in Indolent NonHodgkin’s Lymphoma (iNHL)
NonHodgkin’s lymphoma (NHL) is the most common hemato-
logic malignancy, comprising several heterogeneous subtypes,
characterized as aggressive or indolent.
1,2
Indolent NHL (iNHL)
accounts for nearly 40% of all NHLs.
3,4
Despite advances in the
treatment of iNHL with the use of combination immunotherapy,
patients often experience relapse and progressive resistance to
treatment, underscoring the need to identify novel treatment op-
tions and rational combinations.
2,3,5
In addition, there is no uniform
standard of care beyond firstline treatment for patients with iNHL,
including both follicular lymphoma (FL) and marginal zone lym-
phoma (MZL).
3,5
Current therapies for patients with relapsed FL include standard
chemoimmunotherapies, immunemodulatory treatment, and various
targeted therapies, while treatment options for patients with MZL
are more limited and often extrapolated from the management of
FL.
6
Moreover, despite available treatment options, there is growing
interest in additional effective chemotherapyfree treatments with
limited side effects.
7,8
PI3K signaling is key to the proliferation and survival of indolent
Bcell lymphoma cells; its inhibition has emerged as a therapeutic
strategy for the treatment of iNHL.
914
While a few PI3K
inhibitors (oral and intravenous) are approved as monotherapy in the
relapsed/refractory setting, several oral PI3K inhibitors have
demonstrated severe adverse events that have precluded their
combination with other agents in earlier treatment lines.
12,13,15,16
Copanlisib is an intravenously administered, pan–class I PI3K inhibitor
that can be safely combined with other therapies in patients with
relapsed iNHL.
11,17
Recent data from the randomized phase 3
CHRONOS3 study supports the combination of copanlisib with
rituximab in relapsed iNHL, including FL and MZL, making it a
promising treatment option in the second line.
18,19
In addition, many novel agents, including CAR Tcells and
bispecific antibodies, show promise in patients with iNHL. The proper
treatment sequencing, dosing and scheduling, and rational combina-
tions warrant further investigation.
2,3,20
References
1. GLOBOCAN 2020 World Factsheet. Accessed February 24,
2020. https://gco.iarc.fr/today/data/factsheets/populations/
900worldfactsheets.pdf
2. JuarezSalcedo LM, et al. Drugs Context. 2020;9:201993.
3. Chao MP. Cancer Manag Res. 2013;5:251269.
4. Lunning M, Vose JM. Blood Rev. 2012;26(6):279288.
5. Matasar MJ, et al. Oncologist. 2019;24(11):e1236e1250.
6. National Comprehensive Cancer Network. BCell Lymphomas
V2.2021. Accessed March 14, 2021. https://www.nccn.org/pro-
fessionals/physician_gls/pdf/bcell.pdf
7. van Oers MHJ, et al. Blood. 2006;108(10):32953301.
8. Leonard JP, et al. J Clin Oncol. 2019;37(14):11881199.
9. Wiestner A. Haematologica. 2015;100:14951507.
10. Pongas G, Cheson BD. Semin Oncol. 2016;43:647654.
11. Aliqopa. United States prescribing information. Bayer AG; 2017.
12. Zydelig. United States prescribing information. Gilead Sciences;
2014.
13. Copiktra. United States prescribing information. Verastem;
2018.
14. Ukoniq. United States prescribing information. TG Therapeutics;
2021.
15. Casulo C, et al. Blood. 2016;128(22):2979.
16. Zelenetz AD, et al. Lancet Oncol. 2018;18(3):297311.
17. Dreyling M, et al. Am J Hematol. 2020; doi: 10.1002/ajh.25711.
18. Matasar MJ, et al. Lancet Oncol. 2021. In press.
19. Matasar MJ, et al. Presented at: American Association of Cancer
Research (AACR) Annual Meeting 2021; April 914, 2021. Ab-
stract CT001.
20. Freedman A, Jacobsen E. Am J Hematol. 2020;95(3):316327.
© 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
494
-
Hematological Oncology. 2021;39(S2):494. wileyonlinelibrary.com/journal/hon
DOI: 10.1002/hon.2884
AUTHOR INDEX
A
Abadi, U., 240
Abdo, A. N. R., 345
Abdulla, F., 213
Abouladzé, M., 366
Abraham, A., 168
Abramson, J. S., 067, 068, 072, 198, 371
Abrisqueta, P., 028, 135, 141, 179, 182, 243,
286
Ackermann, J., 082, 271
Adélaïde, J., 278
Adachi, N., 014
Adamis, H., 251
Addada, J., 174
Adhinaveni, R., 142
Advani, R. H., 94, 223
Aeppli, S., 201
Afonso, C., 172, 337, 339, 341, 350, 381
Aftab, B. T., 377
Agafonov, R. V., 233
Agarwal, A., 272
Agarwal, R., 081
Agarwal, S., 374
Agrawal, P., 157
Agrippino, R., 356, 382
Ahearne, M., 286 bis
Ahle, G., 161
Ahmadi, T., 365
Ahmed, S., 265
Ahn, J. R., 063, 310
Ai, W., 177
Aiken, L., 194
Aissat, A., 90
Akay, O. M., 164
Aktar, S., 116
Al Essa, W., 142
Al Moosawi, M., 290
Al Sawaf, O., 034
Al Tabaa, Y., 245
AlSawaf, O., 030, 031, 137, 139, 249
Albano, D., 204
Alcantara, M., 162
Alcoceba, M., 103, 115
Alderuccio, J. P., 177
Alduaij, W., 065, 290
Aleksik, O., 395
Alencar, A., 156
Alessandria, B., 059
Alessi, A., 277
Alfayate, A., 141
Alhaj Moustafa, M., 222
Ali, S., 373
Alig, S., 006, 023, 025, 046
Alinari, L., 180, 231
Aliste Santos, C., 167
Alizadeh, A. A., 006, 025, 046, 139
Alizadeh, A., 023
Alkodsi, A., 92
Alkorta Eizagirre, A., 387
Allan, J. N., 032
Allen, A., 99
Allen, P., 014
Allione, B., 181
Allocati, E., 392
AlonsoÁlvarez, S., 115
AlonsoAlonso, R., 98, 226, 228, 229, 300
AlonsoPrieto, C., 286
Alonso, C., 117
Alonso, R., 141, 292
Alperovich, A., 120
Althaus, B., 253
Altmüller, J., 155
Altuna Mongelos, A., 353, 387
Alvarez, I., 173
Alves, A., 355
Alves, D., 304
Alves, L. B. d. O., 313
Amaador, K., 294
Amador, C., 064, 065, 101
Ambarkhane, S., 028, 178
Ambati, S. R., 94
Ambrosoni, C., 358
Amdiev, A., 354
Amengual, J. E., 148
Amigó de Quesada, M., 302
Amorin, S., 189
Anastasia, A., 119
Anderson, J. K., 148
Ando, J., 209
Ando, K., 209, 210
Andorno, A., 142
Andorsky, D. J., 063, 310
André, M., 028, 237, 246, 307
Andre, M., 071, 203, 244
Andreadis, C., 085, 266
Andreou, E., 318
Andreu, R., 122, 135, 141, 182
Andriani, A., 319
Andrievskikh, M., 354
Angelillo, P., 154, 181
Angelopoulou, M., 164
Angrilli, F., 049, 079, 351
Anguita Velasco, J., 268
Annechini, G., 119, 356, 382
Annetta, I., 348
Annibali, O., 352
Annunziata, M. A., 392
Annunziata, S., 070
Anota, A., 379
Ansell, S. M., 003,041, 066, 074, 075, 171,
185, 186
Antelo Rodríguez, B., 167
Antier, C., 050
AntoinePoirel, H., 283, 344
Anyaegbu, G., 208
Arambarri Oyarzabal, A., 353, 387
Arat, M., 053
Arcaini, L., 043, 049, 077, 080, 119, 154,
312
Arcari, A., 173, 183, 204, 218, 352
Ardavan, A., 247
Ardeshna, K. M., 177, 197, 264
Ardeshna, K., 087, 194
Argiroffi, G., 277
Argnani, L., 127, 191, 205, 276
Armand, P., 074, 198
Armengol, M., 241
Arribas, A., 043
Arriola, J., 348
Artemyeva, A., 343
Arthur, C., 111
Ascani, S., 207
Asch, A. S., 113
Ashraf, K. K., 254
© 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Hematological Oncology. 2021;39(S2):495520. wileyonlinelibrary.com/journal/hon
-
495
Ashykhmin, A., 357
Asnafi, V., 152
Assanto, G. M., 119, 356, 382
Assouline, S., 109
Atalar, A. C., 164
Attarbaschi, A., 036
Attinger, A., 244
Auer, R., 174
Aurer, I., 071, 078, 203
Autore, F., 029, 133
Avigdor, A., 240, 270, 279
Avram, A., 346
Aymerich, M., 060
Ayuk, F., 082, 274
Azim Jr, H. A., 054
B
Bárcena, C., 228
Bárez, A., 141
Bæch, J., 89
Böhmer, L. H., 217
Böttcher, S., 031, 034, 062
Bücklein, V., 082, 271
Bühler, M. M., 058
Babali, V., 318
Babu, S., 240
Babuin, E., 298
Bachanova, V., 148, 157
Bachier, C., 273
Bachy, E., 015, 082, 084, 085, 107, 110, 145,
225, 238, 245, 266, 376
Badarau, A., 373
Baech, J., 147
BaezDuran, E., 300
Bagnardi, V., 178
Bagnato, G., 191
Bagot, M., 054
Bai, B., 215
Bai, O., 052
Baidoun, F., 222
Bailén, R., 268
Baile, M., 122, 141, 179, 286
Baillet, C., 245
Bailly, C., 245
Bailly, S., 050
Baiocchi, R. A., 180, 231
Bairey, O., 136
Baker, R., 112
Bakiri, M., 318
Bal, E., 004
Balagué, O., 069
Balague, O., 103
Balaguer Rosello, A., 122
Balari, A. S., 016, 250
Balbas, M., 129
Baldini, L., 079
Baldomero, H., 188
Baldus, C., 274
BalkeWant, H., 155
Ballerini, F., 121, 218
Ballester, C., 135
Baltadakis, I., 318
Baltasar, P., 135, 141
Balzarotti, M., 047, 048, 049, 173, 183, 255
Bamigbola, O., 140
Banchs, J., 265
Banerjee, L., 243
Bannerji, R., 032, 94, 111
Bao Pérez, L., 167
Bao, H., 216
Baptista, M. J., 043
Barbolini, E., 352
Barbui, A. M., 275
Barcena, C., 103, 229
Bardet, A., 278
Bargetzi, M., 201
Bari, A., 080, 352, 392
Barlow, B., 334
Barman, P., 041
Barnes, J. A., 198
Barnes, L., 232
Barone, M., 205
Barr, P. M., 032, 051, 136
Barraclough, A., 081
Barrans, S. L., 100
Barrans, S., 040
Barreau, S., 386
Barrington, S. F., 073
Barrington, S., 049, 071, 203, 247
Barrons, S., 99
Barros Lima, C., 172, 337, 339, 381
Barta, S. K., 148, 331
Bartlett, N. L., 038, 067, 068, 072, 075, 254
Baryakh, E., 354
Basso, K., 004, 042
Bassolli, L., 345
Bast, M., 148
Bastidas, G., 043
Bastie, J. N., 005
Bastos Oreiro, M., 126
BastosOreiro, M., 115, 117, 144, 243, 268,
286
Bastos, M., 179, 227
Batchelor, T., 156
Bates, A., 286 bis
Batlevi, C. L., 109, 120, 175
Batlevi, C., 375
Battistini, R., 019, 319
Baud, V., 017, 166
Baumann, T., 103
Baysal, B., 370
Beà, S., 058, 103
Bea, S., 043
Beauvais, D., 084
Beauverd, Y., 346
BechSerra, J. J., 241
Becker, S., 005, 050, 176
Becnel, M., 265
Beelen, D. W., 274
Beer, P., 040
Behan, S., 197
Beider, K., 279, 027, 064, 065, 101
Belén Vidriales, M., 135
Belada, D., 220, 237, 285, 330
Bellesso, M., 165, 345
Bello López, J. L., 167
Bello, C. M., 198
Bellosillo, B., 125
Belot, Aurél., 184
Belousov, A., 015
BenNeriah, S., 024, 064, 065, 101
Benedetti, F., 059, 218
Benesova, K., 220, 330
Benet, C., 122
Bengston, E. M., 198
Benjamin, R., 083
Benmaad, I., 90
Bento, L., 125, 144
Beraldo, J. I., 345
Berg, S., 157
Berger, C., 082
Bergesio, F., 019
Bergua Burgues, J. M., 227, 237
Bernard, S., 050
Berneman, Z., 307
Bernuzzi, P., 119
BerrioloRiedinger, A., 050
Bertolazzi, G., 96
Bertoni, F., 043, 059, 079
Besley, C., 087
Besser, M. J., 279
Besser, M., 270
Besson, C., 050, 278, 280
Besutti, G., 204
Betancor, I., 228
Bethge, W., 082, 274
Bethony, J., 067, 068
Beverstock, S. L., 335
Beygi, S., 006
Beylotbarry, M., 054
496
-
AUTHOR INDEX
Bhagat, G., 043
Bhella, S., 123, 158
Bhuller, K., 197
Bianchi, M. P., 319
Binder, M., 047
Biondi, A., 088
Bird, R., 076
Birnbaum, D., 278
Bishton, M., 212
Bisig, B., 044, 045, 225
Bittolo, T., 029
Björkholm, M., 92
Blaedel, J., 365
Blaise, D., 053
Blaker, Y. N., 92
BlancDurand, P., 90
Blanco Nuñez, O., 227
Blazevic, D., 333, 360
Blecua, P., 241
Bleul, S., 046
Block, A., 370
Bloehdorn, J., 030
Blonski, M., 162
Blouin, W., 056
Blumenberg, V., 082, 271
Bobillo, S., 114, 115
Boccomini, C., 062, 080, 119
Bodine, C. D., 334
Boegeholz, J., 023
Boellaard, R., 021, 190
Bogart, J. A., 072
Bohers, E., 91
Boldorini, R. L., 142
Boldorini, R., 043
Bolis, S., 019, 119, 121
Bollu, V., 266, 272
Bologna, S., 005, 044
Bommier, C., 314
Bond, D. A., 180
Bond, D. B., 157
Bond, D., 061, 147, 148
Bondarenko, I., 112
Bonfiglio, F., 043
Boni, J., 238
Bonifazi, F., 276
Bonnet, C., 005, 044, 050, 199, 225, 263
Bonomini, L., 043, 048
Bonzheim, I., 069
Boot, J., 156
Booth, S., 197, 214, 247
Borchmann, P., 155, 195, 267
Borchmann, S., 155
Borel, C., 189, 199
Bories, P., 084, 317
Borko Jovanovic, B., 055
Borregón, J., 228, 229
Borregon, J., 226, 300
Borsatti, E., 070
Borte, M., 305
Bosch, F., 135, 141, 241
Bosch, J., 103
Bosly, A., 150, 184
Bossard, C., 044, 225
Botin, T., 317
Bottelli, C., 173, 183
Botto, B., 048, 049, 121, 173, 352
Bouabdallah, K., 112, 176, 199, 225, 280
Bouabdallah, R., 91
Bouchard, S., 389
Boucher, L., 94
Boumendil, A., 053
Bounaix, L., 084
Bourgeois, H., 389
Bouscary, D., 189, 386
Boussen, I., 160
Bouzani, M., 318
Bowen, J., 067, 068
Boyer, M., 138
Boyle, M., 024
Bröckelmann, P. J., 074, 195
Brüggemann, M., 034
Brülisauer, D. M. A., 201
Brackertz, B., 237
Bradvica, V., 358
Bramanti, S., 275
Brammer, J., 180
Branagan, A., 373
Branco, B., 317
Brandão, A. A. G. S., 345
Breij, E., 365
Brescini, M., 382
Bret, C., 366
Brice, P., 051, 189, 190, 197, 199
Briere, J., 005
Brigidi, P., 205
Brink, M., 217
Broccoli, A., 043, 127, 191
Brodtkorb, M., 027
Bron, D., 307
Broom, A., 174
Brotelle, T., 044
Broussais, F., 084
Brousset, P., 008
BrouwerVisser, J., 94
Browett, P., 107
Brown, F., 231
Brown, P. d. N., 027
Brown, P., 89, 239
Brueggemann, M., 151
Brugger, W., 237
Bruna, R., 218
Bruneau, J., 225
Bruno, A., 022
Bruno, R., 077
Bruscaggin, A., 029, 043, 070, 133,
142
Bryan, A. C., 067
Bryan, A., 068
Bryan, L. J., 238
Buño, I., 126, 268
Buccheri, V., 193
Buchholz, T. A., 118
Buchholz, T. J., 376
Budde, E., 242
Buege, M. J., 147, 175, 281
Buie, L. W., 175
Bulian, P., 070, 133
Bullinger, L., 106
Burbelo, P. D., 284
Burda, D., 343
Burger, E., 047
Burger, J. A., 136
Burke, J. M., 130, 237
Burkhardt, B., 036
Burroni, B., 152, 189
Burton, C., 040, 99, 100, 174, 194, 247
Burton, K., 194
Busco, S., 391
Buske, C., 373
Butler, J., 085, 266
Buvat, I., 020
Buzzoni, C., 391
Byrd, J. C., 033
C
C Jin, M., 006
C Oliveira, A., 141
Córdoba, R., 98, 117, 135, 226, 227, 228,
229
Cañeque, T., 366
Caballero Barrigón, M. D., 182
Caballero, D., 115, 228, 229
Caballero, M. D., 144
Cabarrou, B., 317
Cabero, A., 117
Cabezudo, E., 227
Cabral, R., 342
AUTHOR INDEX
-
497
Cabras, G., 154, 173
Cabras, M. G., 047, 049, 079
Cabrejo, M., 196
Cabrera, M. E., 078
Caccavari, V., 392
Cacciapuoti, M. T., 102
Caddy, J., 100
Cai, A. R., 378
Cai, C., 282, 394
Cai, G., 052
Cai, J., 157
Cai, Q., 215
Cai, Y., 234, 362
Caimi, P. B., 148
Caimi, P. F., 075, 177
Cairoli, A., 044, 062
Cairoli, R., 128
Calay, F., 283
Calcinotto, A., 043
Caldarella, A., 391
Califano, C., 079, 080
Calimeri, T., 154, 156
Callanan, M., 152
Calvo, R., 146, 252
Calzada, O., 148
Camalori, M., 204
Cambalia, A., 054
Campana, F., 037
Campbell, N., 286 bis
Campbell, P. J., 040
Campbell, P., 109
Campo, E., 043, 058, 060, 064, 065, 069,
101, 103
Campostrini, G., 187
Campoy, F., 141
Campr, V., 220
Camus, V., 050, 184
Canales, M. A., 118
Cancelli, V., 284
Canioni, D., 152
CannataOrtiz, J., 286
Cantò, C., 351
Cantonetti, M., 019, 319, 352
Canzonieri, V., 043
Cao, A., 112
Cao, J., 057, 364
Capochiani, E., 079
Capra, M., 112
Carbonell, D., 126, 268
Carda, J. P., 339
Carda, J., 172, 337, 341, 381
Carda, J.P., 350
Carella, M., 191
Carlile, D., 015
CarloStella, C., 015, 070, 075, 177, 238,
251, 264
Carniti, C., 218, 275, 277
Caron, P. C., 120
Carpenter, B., 039
Carpio, C., 376
Carr, R., 039, 208
Carrabba, M., 275
Carrancio, S., 232, 376
Carreiro, M., 317
Carrozzi, G., 391
Carter, J., 157
Cartron, G., 079, 084, 91, 110, 145, 176,
189, 245, 261, 297, 366
Carty, S., 061
Caruso, L., 316
Casadei, B., 191, 205, 275, 276
Casado, L. F., 135
Casanova, M., 060
Casaroli, I., 059
Casasdel Pozo, E. M., 300
Casasnovas, O., 017, 079, 110, 146, 166,
176, 184, 189, 199, 245
Casasnovas, R.O., 025
Casasnovas, R., 91
Casasnovas, RenéO., 084
Cascavilla, N., 328
Cascione, L., 018, 022, 043, 059
Casella, C., 391
Caspar, C., 201
Casper, C., 067, 068
Cassiordor0, G., 332
Castagna, L., 053
Castellino, A., 154, 255
Castellino, C., 059, 218
Castillollanos, R., 363
Castillo, J. J., 373
CastrejondeAnta, N., 069
Castro, B., 342
Castro, F., 168
Catalani, O., 253
Cathcart, E., 056
Catovsky, D., 127
Cattaneo, C., 181, 284
Cavalieri, D., 044, 189, 225
Cavalli, F., 029, 043, 047, 049, 070, 079, 133
Cavalli, M., 119
Cavallo, F., 079, 107, 173, 183, 187, 218
Cavallo, R., 391
Cavallo, T., 385
Celades, C., 122
Celico, C., 047
Cen, H., 216
Cencini, E., 119, 173
Cenfra, N., 119
Cereceda, L., 98, 226, 228, 229
Cerhan, J. R., 041, 185, 186
Cerhan, J., 066
Ceriani, L., 018, 022, 043, 049, 070
Ceribelli, M., 011
Cernauskiene, S., 321
Cerroni, L., 226
Cerutti, A., 196
Chabay, P., 295
Chabon, J. J., 025
Chaganti, S., 087, 156, 258
Chahal, M., 200
ChaiAdisaksopha, C., 322
Chaidos, A., 109
Chalandon, Y., 188
Challenor, S., 174
Chamizo, C., 226, 300
Chamuleau, M. E.D., 016
Chan, E., 96, 97, 235
Chan, H., 107
Chan, J. Y., 235
Chan, K., 116
Chan, M., 200
Chan, W. C., 064, 065, 101
Chan, W., 231
ChananKhan, A., 033
Chang, S.T., 97
Chang, V., 354
Chang, Y., 269, 396
Chaoui, D., 199
Chapuis, N., 386
Chapuy, B., 106
Chartier, L., 017, 91, 152, 166
Chaturvedi, P., 233
Chatzidimitriou, C., 164
Chauchet, A., 050, 94, 189, 130
Chauvie, S., 019, 022, 070, 121, 246
Chavez, J. C., 085, 266
Chavez, J., 148, 242, 376
Cheah, C. Y., 236, 372
Cheah, D. M. Z., 235
Chebanov, D. K., 369
Chee, Y. L., 96, 97, 235
Cheminant, M., 152
Chen Liang, T., 122
ChenKiang, S., 231
Chen, D. Y., 130
Chen, D., 269
Chen, H., 364
Chen, J.M., 052
498
-
AUTHOR INDEX
Chen, J.Y., 052
Chen, K.M., 016
Chen, Q., 325
Chen, R., 336
Chen, S.J., 052
Chen, Y., 215, 269
Cheng, S., 026, 052
Cherel, L., 379
Cherkasova, E., 343
Cherrill, L. R., 214
Cherry, M., 273
Cheson, B. D., 072
Cheung, L. W.K., 143
Cheung, M., 116, 259
Cheung, S., 236
Chiappella, A., 048, 218, 255, 275, 277
Chiaravalloti, A., 356, 382
Chiarenza, A., 316
Chiattone, C. S., 223
Chicano, M., 126
Childs, B. H., 112
Chimienti, E., 077, 173
Chin, V., 327
Chin, Y. S., 108, 349
Chin, Y., 327
Ching, K., 393
Ching, T., 031
Chiu, C. W., 365
Chiusolo, P., 275
Chng, W. J., 96
Chng, W.J., 235
Chng, WeeJ., 97
Choi, H., 97
Choi, I., 209, 210
Choi, J. W., 011
Chong, E. A., 331
Chong, G., 081
Choquet, S., 050, 084, 160, 162, 258
Chow, E. K., 235
Christian, B., 180
Chuan, J., 377
Chuang, S.S., 97
Chudinovskikh, Y., 343
Chung, J., 231
Chung, M., 251
Churilov, L., 081
Churnetski, M., 148
Chyla, B., 138
Ciabatti, E., 119
Ciammella, P., 204
Ciancia, R., 218
Cibien, F., 134
Ciccone, G., 049, 218, 255
Cicinelli, E., 359
Cid López, M., 167
Cimminiello, M., 352, 385
Ciolli, S., 134
Ciotti, G., 356, 382
Cipriano, A., 172, 337, 339, 341, 350, 381
Cittone, M. G., 043, 133
Cittone, M., 070
Civallero, M., 223
ClémentFilliatre, L., 044
Clark, E., 015
Class, B., 233
Clausen, M. R., 016, 250
Claussen, C., 265
Clement, L., 189
Clerc, J., 386
Cleveland, J., 157
CliftonHadley, L., 071, 073, 203,
247
Climent, F., 103, 104, 227, 228, 229
Clot, G., 058
Co Ting Keh, L., 025
Co, M., 107
Cocito, F., 154
Cogliatti, S., 043
Cohen, A., 130
Cohen, J. B., 074
Cohen, J. I., 284
Cohen, J., 148
Coleman, A., 99
Coleman, H., 286 bis
Coleman, M., 063, 107, 310
Colin, F., 379
Collinge, B. J., 065, 101
Collinge, B., 024, 064
Collins, G. P., 038, 074, 075, 194, 197, 214,
247
Collins, G., 087, 286 bis
Colloca, G., 204
Colomo, L., 104, 125
Colton, M. D., 378
Columbié Molina, A., 302
Conconi, A., 048, 078, 079, 080
Condoluci, A., 029, 043, 070, 133
Connors, J., 200
Contreras, J., 122
Cook, J. R., 064, 065, 101
Cooke, S., 040
Cool, C., 393
Coombs, C. C., 129
Copie Bergman, C., 280
CopieBergman, C., 90
Copin, M. C., 044
Coppola, A., 204
Coppola, P. E., 191
Coralluzzo, G., 385
Corcoran, S., 011
Cordoba, R., 179
Corradini, P., 053, 111, 119, 218, 275, 277
Correa, J., 141
CortésRomera, M., 060
Cortés, M., 286
Cortelazzo, S., 059
Cortes Gomez, E., 102
Cortes, M., 122
Coscia, M., 128, 134
Cosman, G., 327
Coso, D., 005
Costa, M. J., 304
Costello, Rég., 107
Cottereau, A. Ségolèn., 020
Cottereau, A. S., 189
Cottereau, A.S., 017, 166, 386
Cottereau, A., 91
Counsell, N., 071, 203
Courreges, V., 348
Courtright, J., 273
Coutinho, J., 342
Coutinho, R., 342
Coutre, S. E., 136
Cowley, A., 174
Cox, M. C., 173, 183, 187
Cozens, K., 047, 049
Craig, A. F. M., 025
Craig, A., 023
Craig, J. W., 024
Craig, J., 290
Cramer, P., 034
Cranco, S., 298
Creasey, T., 197
Crocetti, E., 391
Croft, B., 111, 243
Crosbie, N., 147, 156
Cross, D., 076
Cross, M., 127
Crosswell, H. E., 038
Crouch, S., 040
Crump, M., 015, 123, 158, 201, 384
Cruz, H. G., 075
Crystal, A. S., 233
Cuadrado, M., 083
Cucco, F., 99, 100
Cuesta, A., 141
Cui, G.H., 052
Cultrera, J. L., 130
Cuneo, A., 134
AUTHOR INDEX
-
499
Cunningham, D., 016, 051, 262
Custidiano, M. R., 298
Cwynarski, K., 047, 049, 154, 156, 197,
214
Cygan, K. J., 94
Czerw, T., 311
D
D Phelan, J., 011
D'Addona, M., 390
d'Amore, F., 239
D'Elia, G. M., 356, 382
Díaz Arias, J. Án., 167
Díaz Crespo, F., 126, 268
DíezMartín, J. L., 268
Döhner, H., 030
Dörr, H., 155
Dührsen, U., 023, 025
DługoszDanecka, M., 236
Da Silva, M. G., 043
Dabrowska Iwanicka, A., 049
Dai, S., 136
Dai, V., 238, 264
Dal Maso, L., 391
DallaFavera, R., 004, 042
Dalle, S., 054
Dalmasso, F., 022
Daly, K., 149, 153
Damaj, G. L., 005
Damaj, G.L., 050
Damaj, G., 044, 91, 110, 145, 146, 225
Damiano, S., 358
Daneels, W., 344
Daniel, A., 044
Daniele, A., 392
Danilov, A., 061
Dantin, C., 188
Danylesko, I., 270, 279
Dao, P. H., 281
Darmani, I., 318
Darrall, A., 370
Dartigues, P., 278
Darzentas, N., 151
Davey, T., 056, 211
David, K. A., 157
Davies, A. J., 286 bis
Davies, A., 039, 049, 99, 100, 146, 154, 214
Davies, E., 174
Davies, J., 100
De Abreu Lima, L. B., 037
De Almeida, J. M., 355
De Beleyr, B., 307
De Boer, J. P., 074
de Boer, R., 294
De Bonis, C., 338
de Castro, N. S., 223
de Guibert, S., 238, 379
de Jong, B., 365
de Jong, D., 190
de la Cruz, F., 060, 104, 182
De la Fuente Burguera, A., 060
de la Fuente, A., 117, 182
de la Fuente, C., 329
De la Serna, J., 135
De la Torre, A., 158
De la Torre, C., 241
de Leval, L., 043, 044, 045, 225
de Long, L. M., 076
De Lorenzo, S., 312
De Luca, M. L., 356, 382
De Matteo, E., 295
De Mel, S., 96, 97, 235
De Novi, L. A., 119
de Oliveira, J. S. R., 193
De Paoli, L., 029, 142
de Ramon Ortiz, C., 346
De Renzis, B., 079
De Sanctis, V., 392
De Santis, G., 328
De Souza, C. A., 223
de Vet, H. C. W., 021
de Wilde, V., 044
De Wind, R., 044
Deambrogi, C., 029, 133
Dean, J. P., 032, 136
DeAnda, F., 143
Dearden, C., 127
DeauFischer, B., 386
Deau, B., 189
Decazes, P., 050
Dechmi, A., 386
Deckert, M., 047
Deering, R. P., 94
Degeyndt, A., 344
Deighton, K., 114
del Campo, R., 117, 286
Del Giudice, I., 080, 119, 382
Delabie, J., 064, 065, 101, 384
Delarue, R., 184, 261
Delfau Larue, M.H., 90
DelfauLarue, M., 91
Delfau, M.H., 151, 152
Delgado Trillo, I., 169, 170, 292
Delgado, J., 135
Della Gala, G., 276
Della Starza, I., 119
Dellatola, M., 318
Delmer, A., 199
Delwail, V., 238
DeMarco, D., 016
DeMarco, J., 370
Deng, L., 192
Deng, X., 057
Denis, F., 389
Denolf, P., 283
Deodato, M., 128, 133
Depaus, J., 238, 264
Derenzini, E., 043
Dereure, O., 054
Desai, S. H., 066
Desai, S., 171
Deschamps, P., 189, 386
Descroocq, J., 386
Deswal, A., 265
Deux, J.F., 017, 166
Devata, S., 061
Devereux, S., 136
Devin, J., 366
Devizzi, L., 043, 079
Dewhurst, F., 380
Dey, D., 178
Dhami, K., 143
Dhanik, A., 94
Di Blasi, R., 084
Di Molfetta, S., 392
Di Nicola, M., 351
Di Raimondo, F., 316
Di Rocco, A., 173, 255, 275, 319
Di Russo, A., 392
di Trani, M., 070
Diamanti, I., 301
Diaz Couselo, F., 298
Diaz Velez, N., 348
Dickinson, M. J., 015
Dickinson, M., 085, 109, 168, 193, 266
Dickson, S., 327
Diefenbach, C., 148, 242, 243
Diehn, M., 006, 023, 025, 046
Diepstra, A., 190
Dietrich, J., 156
Dietrich, S., 043, 053
Diez Martín, J. L., 126
DiezFeijoo Varela, R., 125
DiLiberto, M., 231
Dimitraki, E.K., 318
Dimopoulos, M., 373
Dimou, M., 154, 305
500
-
AUTHOR INDEX
Dinaro, Y. M., 391
Dinavahi, R., 258
Ding, C., 336
Ding, K., 131
Ding, M., 362
DirnbergerHertweck, M., 028
Dirnhofer, S., 018, 022, 043, 062, 105
Dlouhá, L., 285
Dlouha, J., 220
DlugoszDanecka, M., 146
Do Nascimiento, J., 141
Dobbs, K., 284
Dockter, T., 072
Dodero, A., 077, 218, 275, 277
Dogan, A., 056, 120
Dolnik, A., 106
Domingo Domenech, E., 333, 347, 360
Dominguez, M., 104
Donato, E., 106
Dondi, A., 119
Dong, C., 038
Dong, H., 114
Donovan, A., 148
Doorduijn, J. K., 146
Dorado, N., 268
Dorritie, K. A., 086
Dorritie, K., 242
Dotson, E., 180
Dreger, P., 034, 053, 274
Dren, N., 140
Dreval, K., 024, 067, 068
Dreyling, M., 028, 062, 082, 085, 150, 151,
266
Driessen, C., 062
Driessen, J., 021, 190
Drieux, F., 044,225
Drill, E., 056, 175, 281
Drott, K., 027
Drullinsky, P., 375
Dryer, M., 068
Du, G., 012
Du, M. Q., 99
Du, M., 100
Du, T., 192, 256
Du, Y., 267
Duarte, S., 172, 337, 339, 341, 350, 381
Dubois, J., 138
Dubovsky, J., 377
Duell, J., 028, 94
Duffles Amarante, G. B., 313
Duffles, G., 345
Dunne, B., 340
Dupont, E., 044
Dupuis, J., 146
DuranFerrer, M., 058
Duran, A., 313, 345
Duras, J., 220, 330
Durmo, R., 020, 121
Durot, E., 050
Duval, R., 042
Duvall, A., 393
Duyster, J., 046
Dyer, M., 067
Dymkowska, M., 244
E
E Busse, C., 106
Ebbesen, L. H., 89
Ebinger, M., 036
Ebnöther, M., 201
Eckert, K., 260
Eckhardt, K., 062
Eek, R., 146
Eertink, J. J., 021
Efremov, D., 029
Eichhorst, B., 030, 031, 034, 137, 138, 139,
249
Ekwede, I., 93
El Yamani, A., 044
ElGalaly, T. C., 89
ElGalaly, T., 147
ElGkotmi, N., 318
ElSharkawi, D., 174
Eldering, E., 294
Elemary, M., 259
Elemento, O., 95, 231
Eleta, M., 202
Elia, A. R., 043
Elliot, B., 365
Elliott, B., 016
Ellonen, P., 92
Else, M., 127
Emelina, E., 308, 309
Emmons, R., 111
Encuentra, M., 333, 347, 360
Endakova, A., 354
Engert, A., 074, 195
Enrico, A., 196
Eom, H. S., 209
Eom, H.S., 057
Epelman, S., 037
Epperla, N., 148, 157, 180
Eradat, H., 240
Erbella, F., 181
Ernst, M., 397
Eron, S. J., 233
ErvinHaynes, A., 238
Escoda, L., 286, 329, 333, 347, 360
Esfahani, M. S., 006, 046, 139
Espadana, A. I., 339, 350
Espadana, A., 172, 337, 341, 381
Espinet, B., 104, 125
Esposito, F., 022, 048, 049, 079
Essell, J., 273
Estcourt, L., 398
Esteller, M., 241
Esteve, A., 227
Esteves, G., 304
Etherington, A., 194
Evangelista, A., 059, 218
Evens, A. M., 157
Evens, A., 148
Eyre, T. A., 129
F
F García, J., 229
F Herrera, A., 053
F Seymour, J., 033
Fürstenau, M., 034
Fabbri, A., 047, 173, 183, 352
Fabiani, B., 005
Fabio, L., 385
Facchetti, F., 043, 181
Facco, M., 134
Fadeeva, N., 354
Faderl, M. R., 133
Faderl, M., 029, 043, 070
Fagerli, U. M., 239
Fagerli, UnnM., 027
Fagioli, F., 037
Fahrni, G., 133
Falautano, M., 047
Falchi, L., 056, 120, 175
Falcini, F., 391
Falconer, J., 286 bis
Falini, B., 080, 121, 207
Falini, L., 207
Fallanca, F., 121
Fan, L., 336
Fan, S., 96, 97
Fanale, M. A., 038
Fanale, M., 051
Fancourt, T., 081
Fanelli, F., 319
Fanetti, A. C., 391
AUTHOR INDEX
-
501
Fang, S., 056
Fang, X., 362
Fanning, S. R., 063
Fanning, S., 273
Fanti, S., 276
Farina, K. A., 175
Farina, L., 080, 121
Farinha, P., 024, 064, 065, 97, 101
Farolfi, A., 276
Farooq, U., 066, 185, 186
Fataccioli, V., 044, 225
Fathoala, D., 194
Faul, C., 082
Faust, S. N., 286 bis
Favero, F., 89
Favini, C., 059, 142
Favre Juilland, Mél., 045
Favre, C., 037
Fe', A., 385
Fedeli, U., 391
Federico, M., 071, 078, 080, 121, 203, 223,
395
Fehr, M., 062, 201
Fehse, B., 082
Feingold, J., 177
Feldman, A. L., 064, 065, 101
Feldman, A., 066
Feldman, T., 376
Fend, F., 069
Feng, C., 393
Feng, J., 112
Feng, L., 265
Feng, R., 215
Feng, S., 130
Feng, X., 361, 368
Fenske, T. S., 148
Fenton, K., 038
Ferguson, G., 194
Ferhanoglu, B., 164
Fernández de la Mata, M., 135
Fernández González, M., 122
FernándezIbarrondo, L., 125
FernándezMiranda, I., 228, 229
FernándezRodríguez, C., 125
FernandezMiranda, I., 104
FernandezSerrano, M., 241
Fernandez, I., 196
Ferrà, C., 135
Ferra, C., 144
Ferranti, A., 047
Ferrara, F., 154
Ferrara, I., 332, 390
Ferrari, A., 173
Ferrari, L., 196
Ferrari, S., 238, 376
Ferrario, A., 154
Ferreiro Ferro, R., 167
Ferreiro Martinez, J. J., 387
Ferrer, A., 125
Ferreri, A. J. M., 047, 154, 156, 181, 266
Ferreri, A. J., 119
Ferreri, A., 019
Ferreri, Andrés J. M., 077, 078, 048, 049
Ferrero, S., 059, 062, 080, 119, 173
Ferretti, S., 391
Ferri, V., 142
Feugier, P., 005, 079, 91, 110, 145, 176, 199
Fiaccadori, V., 071, 203
Fiad, L., 196, 202, 223
Fiaschi, N., 94
Ficola, U., 019
Fidalgo, J., 039, 208
Figuera, A., 316
Filatova, L., 343
Filippi, A., 246
Filonenko, K., 395
Finel, H., 053
Fink, A. M., 034
Fink, A.M., 030, 031, 137, 249
Finke, Jür., 047
Finke, J., 046
Fior, R., 162
Fioroni, F., 020
Fischer, K., 030, 031, 034, 137, 139, 249
Fischer, N., 201
Fisher, D. C., 056
Fisher, S. L., 233
Flavin, R., 340
Fleck, E., 044
Fleming, M., 180
Flenghi, L., 173, 218
Fleury, I., 267
Flink, D. M., 94
Flinn, I., 130, 248
Flospergher, E., 181
Flowers, C., 111
Fluge, Ø., 027
Flynn, C., 340
Foà, R., 119, 134
Fogliatto, L. M., 118
Follows, G. A., 197
Fomintseva, M., 388
Foncuberta, M. C., 298
Fontán, L., 012
Fontana, R., 332, 390
Fontanillo, C., 232
Foppoli, M., 154, 181
Forestieri, G., 029, 043, 070, 133, 142
Fornecker, L. M., 189
Fornecker, L.M., 161
Fornecker, LucM., 199
Fortpied, C., 071, 203
Fosså, A., 049
Foss, F. M., 014
Fouquet, G., 386
Fowler, N. H., 085, 266
Fox, C. P., 156, 174, 212, 214, 250, 261
Fox, C., 047, 286 bis
Fox, L., 329
Frölich, L., 082, 271
Fraga Rodríguez, M. F., 167
Franceschetti, S., 392
Franceschetto, A., 121
Franceschi, S., 391
FranchSarto, M., 179
Franch, M., 286, 333
Franchi, P., 189, 386
Francis, S., 051
Frank, M., 023
Franklin, A. R. K., 037
Frauenfeld, L., 069
Freeman, B., 130
Freeman, C. L., 150
Freeman, C., 024, 200
Fresa, A., 134
Fried, S., 270
Friedberg, J. W., 073
Friedman, J. D., 248
Frigola, G., 103
Fruchart, C., 184
Frustaci, A. M., 029, 128, 133
Frutos, L., 122
Fu, K., 064, 065, 101, 296
Fu, R. X., 324
Fu, X., 269, 323, 361, 396
Fuchs, M., 195
Fuente, M. L., 298
Furman, R. R., 033
Furtado, M., 197
Fusco, M., 391
Fylaktou, A., 301
G
Gámez Pérez, E., 302
GómezFernández, I., 268
GómezRoncero, M. I., 286
GómezRoncero, M
a
I., 141
502
-
AUTHOR INDEX
Gödel, P., 155
Güsewell, S., 201
Gac, A. C., 199
Gadacha, O., 366
Gadient, S., 062
GafterGvili, A., 164
Gaidano, G., 025, 028, 029, 043, 048, 059,
070, 078, 128, 133, 142
Gainaru, G., 164
Galasso, N., 056, 211
Galimberti, S., 059, 080, 119, 352
Galiulin, R., 112
Gallamini, A., 019, 246
Galli, G. R., 395
GallopEvans, E., 194, 247
Gambardella, L.M., 007
Gamelin, L., 258
Gan, Y., 224
Gandhi, M. D., 251
Gandhi, M. K., 076
Ganeev, I.I., 306
Ganesan, N., 056, 211
Ganzel, C., 164
Gao, F., 323
Gao, S., 131
Gao, Y., 215, 361, 367, 368, 372
García Belmonte, D., 117
García Marco, J. A., 170
García Vela, J. A., 169, 170, 292
GarcíaCosío Piqueras, M., 170
GarcíaCosio, M., 228, 229
GarcíaDíaz, N., 98
GarcíaMalo, M
a
D., 141
GarcíaMarco, J. A., 135
GarcíaPintos, M., 141
GarcíaSanz, R., 060
García, J. F., 98, 125, 228
Garcia de Paco, E., 366
GarciaArroyo, F. R., 104
GarciaCalduch, O., 179
GarciaCosio, M., 104
GarciaIbanez, L., 042
GarciaMarco, J. A., 033
Garcia, D., 179
Garcia, J. F., 043
Gardeli, D., 318
Garg, V., 373
Garofalo, A., 006
Garrido Castro, P., 365
Garthe, A.K., 036
Garzon, F., 373
Gasiorowski, R., 193
Gaspard, M.H., 317
Gasparotti, C., 391
GastierFoster, J. M., 067, 068
Gastinne, T., 084, 189, 190, 199
Gat, E., 084, 297
Gato, L., 227
Gattei, V., 029, 070, 080, 119, 133
Gaudio, F., 359
Gaulard, P., 044, 90, 225
Gauthier, M., 050
Gauthier, N., 162
Gavarotti, P., 019
Ge, J., 396
Ge, R. J., 324
Geissler, K., 112
Geller, S., 211
Gendlin, G., 308, 309
Genta, S., 018
Gentile, M., 134
Gentilini, M., 191
Gerardi, C., 392
Gerber, B., 029, 043, 070, 133
Gerhard, D. S., 067, 068
Gerrie, A. S., 024, 147, 148, 150
Gerrie, A., 200
Gerson, J. N., 148, 331
Geyer, J. T., 043
Ghanzin, M., 343
Gharibo, M., 063, 310
Ghenim, L., 317
Ghesquières, H., 184
Ghesquieres, H., 005, 079, 114, 189, 199
Ghia, P., 029, 032, 033, 043, 133, 136
Ghiggi, C., 121, 218
Ghilardi, G., 018, 043, 201
Ghione, P., 102, 114, 370
Ghobadi, A., 374
Ghosh, M., 085, 266
Ghosh, N., 242
Giannopoulos, K., 236, 240
Giatra, C., 318
Gibert, J., 125
Giebel, S., 311
Giezek, H., 193
Gigantes, S., 318
Gilbertson, M., 081, 326
Gille, R., 189
Gillenwater, H. H., 086
Gillessen Sommer, S., 070
Gillessen, S., 029, 133, 195
Gillings, M., 209, 210
Gimeno, E., 125, 141
Giné, E., 058, 060, 103, 115, 182
Gini, G., 019, 079, 080, 173, 183, 352, 392
Gioula, G., 301
Giovanella, L., 018, 022
Giudice, V., 390
Giuliani, F., 196
Giza, A., 034
Gkasiamis, A., 261
Glaisner, S., 044
Glantz, M., 157
Glass, B., 053
Glenn, M., 148
Glover, P., 040
Godwin, J. E., 273
Goh, J., 235
Goh, X., 235
Goldblatt, D., 286 bis
Goldkuhle, M., 397
Goldlust, S., 157
Golenkov, A.K., 306
Gomes, M., 172, 337, 339, 341, 350, 381
GomezEspuch, J., 144
Gomez, S., 104
Gong, L., 086
Gong, T., 394
González Barca, E. M., 286
González Madruga, T., 302
González Pérez, M. S., 167
González Rodríguez, A., 169
GonzálezBarca, E., 028, 060, 135, 227, 329,
333
GonzálezGonzález, B., 338
GonzálezLópez, T. J., 060
González, M., 135
Gonzalez Barca, E. M., 347
Gonzalez Barca, E., 360
Gonzalez de Villambrosia, S., 117
GonzalezBarca, E., 103, 179, 243
GonzalezMenendez, I., 106
GonzalezRincon, J., 104
Gonzalez, C. M., 196
Gonzalez, S., 179
Good, A., 233
Gopal, A. K., 263
Gorbach, O., 357
Gorbatchevsky, I., 113, 262
Goswami, B., 178
Goswami, R., 259
Gottardi, D., 019
Goy, A., 146
Goyal, G., 334
Grønbæk, K., 89
Graber, J., 157
Gracia Medina, E., 302
Grainge, M. J., 212
AUTHOR INDEX
-
503
Gramegna, D., 204
Grande, B. M., 064, 067, 068
Grande, B. M/c., 024
Grande, C., 182
Grandjean, B., 188
Grant, C., 340
Grapulin, L., 119
Grau, M., 103
Gravelle, P., 297
Gray, N., 012
Greco, A., 328
Gregor, M., 029, 133
Gregory, G. P., 253, 326
Greiner, T. C., 064, 065, 101
Greiner, T., 067
Gressin, R., 079, 110, 152, 245
Gribben, J., 114
Gricourt, G., 90
Grieve, C., 375
Griffiths, G., 99
Grigg, A. P., 038
Grigg, A., 081
Grigoriadou, G. I., 301
Grigoropoulos, N. F., 96, 97
Grimaldi, D., 059, 187
Griner, N. B., 067, 068
Griskevicius, L., 321
Gritti, G., 022, 043, 051, 111, 312
Groman, A., 370
Grommes, C., 156
Groocock, L., 232
Gros, FrançoisX., 084
Grosicki, S., 136
Gross, T. G., 067, 068
GrudevaPopova, Z., 244
Gu, J., 102
Guadagnuolo, S., 205, 276
Gualberto, A., 228
Guan, Q., 296
Guanchiale, L., 196
Guarda, L., 391
Guardalben, E., 312
Guariglia, R., 332, 390
Guarini, A., 119, 392
Guarinos, C., 376
Guerra, L., 019, 121
Guezennec, C., 073
Guidetti, A., 043, 275, 277
Guidetti, F., 043
Guidez, S., 110, 145, 245
GuillénGarcía, H., 286
Guille, A., 278
Gumpel, C., 196
Gunawardana, J., 076
Gupta, S. A., 108, 349
Gupta, S., 327
Gurion, R., 164
Gurung, B., 315
Gussetti, D., 133
Gustavo, T., 103
Guthrie, T. H., 130
Gutiérrez Aleaga, Z., 302
Gutiérrez, A., 182
Gutierrez, A., 117, 125, 144
Gutierrez, AntonioM., 179
Gutierrez, C., 265
Gutierrez, G., 144
Gutwein, O., 164
GuzmanBecerra, N., 258
Gyan, E., 079, 110, 245
H
H Walker, D., 013
Hájková, B., 285
Häupl, Björ., 011
Hübel, K., 118, 263
Hübschmann, D., 106
Hüttmann, A., 023, 025, 049
Haastrup, E. K., 89
Habermann, T. M., 041, 171, 185, 186
Habermann, T., 066
Habib, A., 157
Hadaya, K., 346
Hadigol, M., 004
Hagenbeek, A., 190
Haioun, C., 005, 015, 050, 079, 90, 91, 110,
184, 280
Hallek, M., 001, 030, 031, 034, 137, 139,
249
Halliday, S.J., 076
Halligan, S., 212
Hamadani, M., 053, 075, 177, 251
Hamed, A., 112
Hamilton, A., 120
Hamlin, P. A., 120
Hamlin, P., 375
Hammoud, M., 189
Hamon, M., 278
Hamon, S., 94
Hanáčková, V., 285
Han, X., 267
Han, Y., 234, 289, 291
Hanackova, V., 330
Hancock, H., 056, 211
Handorf, E., 148
Hansen, J., 232
Hantrakool, S., 322
Harigae, H., 085, 266
Harris, N. L., 067, 068
Hart, A. A., 233
Harvey, T., 340
Harwin, W. N., 254
Hatcher, J., 012
Hatic, H., 334
Hatzimichael, E., 164
Havenith, K., 238
Haverkos, B., 378
Hawkes, E. A., 081, 223
Hawking, J., 081
Hayden, A., 200
Hayoz, S., 018, 022
He, S., 177
He, X., 238
Hebart, H., 132
Heger, J.M., 155
Heiland, D. H., 046
HelmigMason, J., 231
Hemmaway, C., 047
Henderson, C., 233
Henderson, J. A., 233
Henry, L., 194
Herbaux, C., 110, 145, 245, 297
Heredia Manzano, L., 302
Hermann, C., 305
Hermine, O., 150, 151, 152
HernándezGarcía, M. T., 338
HernándezMohedo, F., 286
HernándezRivas, J. Án., 135
HernándezRivas, J. A., 141
HernándezRodríguez, I., 141
HernándezSánchez, E., 141
HernandezIlizaliturri, F., 102, 370
Hernandez, A., 076
Hernani, R., 144
Herrera, A. F., 075
Herrera, A., 061
Herrera, F., 169, 170, 292
Herrera, P., 144, 292
Hertenstein, B., 047
Hertzberg, M., 253
Hess, B. T., 264
Hess, B., 177
Hess, G., 047, 062
Hess, N., 317
Hidaka, M., 209
Hiemeyer, F., 112
Hiemstra, I. H., 365
504
-
AUTHOR INDEX
Higgins, K., 033
Hildebrandt, M., 271
Hilger, J., 372
Hill, B. T., 222
Hill, B., 148
Hillmen, P., 033, 136, 138
Hilton, L. K., 024, 064, 065, 067, 068
Hinterschied, C., 231
Hirata, J., 111, 243
Hirsch, C., 287, 397, 398
Hitz, F., 043, 201
Ho, L., 248
Ho, P. J., 266
Hoang Xuan, K., 156
HoangXuan, K., 161
Hoang, P. M., 97
Hoaus, S., 319
Hoda, D., 273
Hodgson, D., 049, 158, 201
Hodson, D. J., 040
Hoechstetter, M., 249
Hoekstra, O. S., 021
Hohaus, S., 070, 173
Holmes, A. B., 042
Holmes, A., 004
Holmes, H., 240
Holte, H., 027, 064, 065, 92, 101, 239
Holtick, U., 274
Hong, A., 179
Hong, Y., 296
Hopkins, L., 214
Hoppe, M. M., 96, 97
Hopper, M. A., 041
Horowitz, N., 164, 240
Horwitz, S. M., 056, 120, 219, 281
Horwitz, S., 014, 211, 371
Hossain, N., 157
Hoster, E., 082, 150, 151, 271
Hou, M., 052
Houdyk, K., 081
Houillier, C., 161, 162
Houot, R., 050, 079, 084, 110, 145, 245, 379
Hristopoulos, M., 242
Hsi, E. D., 072
Hu, B., 107
Hu, D., 364
Hu, J.D., 052
Hu, J., 131, 325, 234, 362, 289, 291, 303,
052, 131
Huang, D. W., 011
Huang, D., 178, 235
Huang, H.Y., 052
Huang, H., 215
Huang, J., 107, 130, 372
Huang, L., 052
Huang, W., 262
Huang, X.B., 052
Huang, X., 057, 143
Huang, Y., 180
Hubareva, A., 395
Hue, S. S.S., 97
Huelsenbeck, J., 132
Hughes, M. E., 331
Huguet, M., 115
Huls, G. A., 217
Humpe, A., 271
Humphrey, K., 015
Husainova, G., 354
Husby, S., 89
Huscher, D., 305
Hutchings, M., 015, 016, 190
Hutson, A., 370
Huw, LingY., 242
Hwang, I., 231
I
I Gordon, L., 055
Iacoboni, G., 015
Iacovacci, S., 391
Iannitto, E., 154
Idoine, A., 130
Ielmini, N., 047, 049, 079
Ikonopoulou, D., 318
Ilariucci, F., 047, 218
Illerhaus, G., 046, 047
Illes, A., 033
Illidge, T., 071, 203
Ilyin, N., 388
Imaizumi, Y., 014, 210
Infante, M. S., 227
Infante, M., 117, 286
Inghirami, G., 043, 064, 065, 101, 102
Inwards, D. J., 148, 185, 186
Inwards, D., 171
Ionescu, C., 049
Ionova, T., 354
Iorio, J., 202
Irigoin, V., 358
Iriondo Alzola, J., 353, 387
Irvin, J. D., 067, 068
Isasa, M., 233
Isenberg, G., 164
Ishikawa, T., 118
Ishitsuka, K., 014, 209
Ishizawa, K., 209
Ishmatova, I., 343
Isufi, I., 111
Itchaki, G., 156
Itti, E., 90
Ivanov, V., 354
Iyengar, S., 087, 107, 197
Izutsu, K., 014, 118, 209, 210, 252
Izuzquiza, M., 286
J
J Davies, A., 174
J Frank, M., 006
J HernandezIlizaliturri, F., 148
J Luck, T., 106
Jäger, U., 249
Jørgensen, G. Ø., 89
Jørgensen, J., 027, 92, 239
Jackson, S., 032
Jacobs, R., 032
Jacobsen Pulczynski, E., 047
Jacobsen, E. D., 014, 056
Jacobsen, E., 054, 146, 198
Jacoby, E., 270, 279
Jacque, N., 162
Jaeger, U., 074, 267
Jaffe, E. S., 064, 065, 101
Jaffe, E., 067, 068
Jagadeesh, D., 113, 219, 222, 244
Jahan, R., 042
Jain, M. D., 384
Jain, M., 082
Jain, P., 146
Jain, S., 076
Jais, J. P., 225
Jakob, T., 398
Jallades, L., 082
Janíková, A., 285
Janakiram, M., 238
Janardhanan, P., 232
Jani Sait, S., 370
Janikova, A., 049, 078, 220, 330
Jankeel, D., 232
Jankovic, V., 94
Janssen, P. M., 217
Janssens, A., 307
Janus, A., 127
Jardin, F., 050, 91, 235, 280
Jaynes, P., 96, 97
Jehng, T., 377
Jenner, R., 247
AUTHOR INDEX
-
505
Jentzsch, L., 082
Jeong, S., 94
Jeréz Cayuela, A., 122
Jerkeman, M., 049, 92
Jesús Peñarrubia, M., 286
Jeyasekharan, A. D., 96, 97, 235
Ji, C., 131, 299
Ji, D., 057
Jiang, A., 147, 200
Jiang, L., 151
Jiang, X.F., 052
Jiang, Y.J., 052
Jiang, Y., 030, 031, 137, 138, 362
Jiménez Galainena, J. J., 302
Jiménez Ubieto, A., 060
JiménezUbieto, A., 115, 182, 286
JimenezUnieto, A., 117
Jimenez, O., 295
Jin, J., 057, 107, 112, 216
Jin, M. C., 025, 046
Jin, M., 368
Jindra, P., 285
Jing, H., 057
Jo, T., 210
Jodon, G., 378
Joffe, E., 120, 257
Johansson, P., 249
John, L., 287
Johnson, M., 286 bis, 370
Johnson, N. A., 051, 193
Johnson, N., 259
Johnson, P. W., 047, 073, 286 bis
Johnson, P., 016, 049, 99, 100, 247
Johnston, P. B., 171, 185, 186
Jones, C., 087
Jones, S. G., 197
Joris, M., 084
José Kersten, M., 085, 266
José Lis, M
a
., 141
José Terol, M., 135, 182
Josefsson, Pär L., 89
JosephPietras, D., 286 bis
Joseph, A., 375
Joubert, Clém., 184
Jozami, A. C., 348
Judet, A., 017, 166
Julião, M. J., 172, 339, 350, 381
Julião, M., 337
Junior, W. F. S., 345
Jurczak, W., 028, 033, 109, 112, 129, 236,
240, 244, 260, 262
JureKunkel, M., 365
Juskevicius, D., 018, 105
Jyrkkiö, S., 027
K
K Hilton, L., 101
Kühnle, I., 036
Kaźmierczak, M., 109
Kabíčková, E., 036
Kader, A., 370
Kadnikova, T., 395
Kahl, B. S., 177
Kahl, B., 157, 252, 315
Kalpadakis, C., 164
Kaltenbach, S., 152
Kamdar, M., 242, 378
Kaminski, M., 061
Kanellias, N., 164
Kanellis, G., 318
Kanoun, S., 189, 245, 114, 315
Kaouranis, K., 318
Kaplan, J. B., 148
Kaplanov, K., 354
Kara, M., 347
Karakasis, D., 318
Karakatsanis, S., 164
Karaolidou, F., 318
Karban, J., 330
Karianakis, G., 164
Karihtala, K., 027, 206
Karim, R., 174
Karimi, Y., 061
Karimzad, K., 265
KarjalainenLindsberg, ML., 027
KarjalainenLindsberg, M.L., 206
Karlen, J., 377
Karmali, R., 055, 148, 157
Karmiris, T., 164, 318
Karnabeda, O., 357
Karnik, R., 013
Karpha, I., 174
Karpova, O., 357
Karschnia, P., 082
Kasibhatla, S., 376
Kaskel, P., 195
Kataeva, E.V., 306
Kater, A. P., 033, 138, 146, 294
Kato, K., 014, 085, 210, 266
Katodritou, E., 164, 301
Kaverina, O., 354
Kawamata, T., 014
Kay, N., 033
Kaynar, L., 164
Ke, X., 107
Keane, C., 076, 081
Keating, M. M., 259
Kehden, B., 151
Kelleger, N., 333
Kelleher, N., 103, 329, 347, 360
Keller, U., 047
Kenkre, V. P., 113
Kennedy, H., 380
Kersten, M. J., 021, 190, 217, 272, 294
Kesanakurthy, V., 261
Kessler, L., 228
Khan, N., 211
Khan, S., 041
Kharabi, B., 393
KharfanDabaja, M., 053, 185, 186
Kheterpal, M., 211
Khiabanian, H., 004, 029, 043
Khodadoust, M. S., 006, 056, 211
Khoury, J. D., 97
Kim, E., 211
Kim, J. S., 107, 209
Kim, M. S., 157
Kim, S. Y., 030, 250
Kim, S.H., 157
Kim, S., 031, 137
Kim, W. S., 209
Kim, W.S., 057
Kim, Y. H., 056, 211
Kim, Y., 054
Kimball, A., 374
Kindrakevych, O., 357
King, R. L., 041
King, R., 066, 171
Kingsley, E., 130, 264
Kipps, T. J., 032, 136
Kipps, T., 138
Kirby, R. J., 233
Kirkwood, A. A., 073, 087, 194
Kirkwood, A., 247
Kiseleva, M., 354
Klöpfer, P., 237
Klapper, W., 035, 036, 150
Klaus, C., 013
Klein, A., 148
Kline, J., 051, 075
Klingbiel, D., 118
Klitochenko, T., 354
KluinNelemans, H., 151
Kmetyuk, Y., 357
Knörr, F., 036
Kneba, M., 034
Knopp, M. V., 073
506
-
AUTHOR INDEX
Knowles, S., 219
Kořen, J., 285
Kobayashi, R., 037
Koch, R., 029, 043, 070, 133
Koenecke, C., 274
Koeppel, L., 195
Kogarko, B.S., 306
Kogarko, I., 306
Koh, L. P., 235
Koh, Y., 057, 209
Koldej, R., 081
Kolla, B., 148
Kollar, P., 358
Kolstad, A., 085, 266
Konstantinidou, P., 301
Kopeckova, K., 237
Korin, L., 298
Kosmas, P., 318
Kostakoglu, L., 072
Kostrewa, J., 370
Kothari, S., 148
Kotrova, M., 151
Koumarianou, A., 164
Koutroumpakis, E., 265
Kovach, A. E., 148
Kovalchuk, S., 173
Koviazin, A., 343
Kozlov, V., 357
Krčméryová, M., 285
Krampera, M., 047
Krasniqi, F., 201
Krause, S., 047
Kreger, B. T., 233
Kreuz, M., 106
Kreuzer, K. A., 034
Kreuzer, K.A., 030, 031, 137, 249
Kriachok, I., 357, 395
Kridel, R., 123, 158, 201, 384
Krug, L. T., 93
Krull, J., 041
Kryachok, I., 049, 223
Ku, M., 253
Ku, N. C., 129
Kugathasan, L., 147
Kuhnl, A., 083, 087, 174
Kuittinen, O., 383
Kuitunen, H., 383
Kukreti, V., 123, 158, 201, 384
Kulis, M., 058
Kumar, A., 056, 120, 147, 149, 153, 175,
375
Kumar, P., 157
Kumar, R., 004
Kunz, W., 271
Kurakin, V., 354
Kurgansky, N., 196
Kurlapski, M., 070
Kuroda, J., 209
Kurosawa, M., 209, 210, 025, 046, 139
Kurtz, D. M., 006
Kurtz, D., 023
Kuruvilla, J., 051, 074, 123, 158, 193, 201,
259, 374, 376, 384
Kushchevyi, Y., 395
Kuss, B., 032
Kusumoto, S., 014, 210
Kutsch, N., 155
Kuzan, D., 272
Kwak, J.Y., 057
Kweekel, C., 365
Kwon, M., 126, 268
L
L Mackall, C., 006
L OrtizRomero, P., 054
L Shaffer III, A., 011
López Jiménez, F. J., 169, 170
López Jiménez, J., 060, 122
LópezGarcía, A., 141
LópezGarcía, P., 338
LópezGuillermo, A., 060, 103, 115
LópezJiménez, J., 141
LópezRubio, M., 141
López, C., 058, 103, 169, 170, 292
La Rosée, P., 047
La Rosa, E., 328
Labrador, J., 141
LaCasce, A. S., 038, 072, 198
Lacerda, J. F., 304
Lacy, S., 040
Laddaga, F. E., 359
Ladetto, M., 043, 059, 080, 119, 312
Lafuente, M., 125
Lage, L. A. P. C., 345
Lahiry, A., 237
Lai, A. C., 172, 350, 381
Lai, A., 337, 339, 341
Laister, R. C., 384
Laister, R., 259
Lakhwani, S., 338
Lamadrid García, J., 302
Lamanna, N., 129
Lamb, M., 039
Lambert, J., 314
Lamy, T., 146, 199, 379
Landau, D.A., 009
Landoni, A. I., 358
Landsburg, D. J., 148, 331
Lang, N., 158, 201
Langer, P., 287
Langerak, A. W., 138
Langerbeins, P., 034
Lansigan, F., 063, 148, 198, 310
Lapalombella, R., 231
Lapietra, G., 356, 382
Laplant, B., 171
Laraque, L., 375
Lares, A., 211
Laribi, K., 050
Larionova, O., 354
Larouche, J. F., 259
Larsen, T. S., 027, 89, 239
Larson, M. C., 041
Lasica, M., 236
Latif, A.L., 087
Laubach, C., 073
Lauer, E. M., 046
Laurenge, A., 156
Laurent Damaj, G., 109
Laurent, C., 110, 145, 152, 278, 297, 317
Laurenti, L., 029, 133, 134
Lauritzsen, G. F., 239
Lavaud, A., 160
Law, P., 076
Law, SoiC., 076
Lawrence, M., 99
Lawrie, E., 247
Lazareva, D., 354
Lazaroiu, M., 112
Lazarovici, J., 050, 189, 199
le Blanc, M., 073
Le Bras, F., 084, 199
Le Bris, Y., 152
Le Cann, M., 162
Le Dû, K., 389
Le Dieu, R., 194
Le Du, K., 050
Le GarffTavernier, M., 162
Le Garff, M., 160
Le Goff, E., 90
Le Goff, M., 389
Le Gouill, S., 079, 084, 110, 145, 146, 152,
245, 280
Leal, F., 067, 068
Lebel, E., 384
Leblond, v., 160
Lebras, L., 005, 050
AUTHOR INDEX
-
507
LechMaranda, E., 129
LedouxPilon, A., 044
Lee, C. Y., 221
Lee, H. G., 209
Lee, H. J., 074, 248
Lee, J. H., 209
Lee, J.S., 057
Lee, J., 96, 97, 235
Lee, S. T., 081
Lee, W. S., 209
Lee, W.S., 057
Lefebure, M., 138
Leitch, H., 290
Leivonen, S.K., 206, 239
Lema, V., 358
Lemmonier, F., 044
Lemonnier, F., 90, 225
Lengerke, C., 274
Lentz, G., 252
Leonard, E. J., 037
Leonard, J. P., 072
Leonidopoulou, T., 164
Lepik, K., 354
Lepistö, M., 92
Leppä, S., 027, 92, 206, 239
Lepretre, S., 033
Lequesne, J., 050
Leslie, L., 257
Letailleur, V., 044
Leveneur, Y., 317
Levi, I., 240
LeVoir, A., 281
Levy, M. Y., 130, 244
Lewis, D. J., 016
Lewis, D., 129, 147, 214
Lewis, K. L., 236
Lhomme, F., 044
Li, B., 052
Li, D., 263
Li, F., 052, 216
Li, H., 073, 368
Li, J., 057, 063, 113, 131, 136, 215, 261, 269,
310, 336
Li, L., 269, 293, 296, 323, 361, 396
Li, M., 364
Li, S., 97, 148, 376
Li, W., 112, 215, 293
Li, X., 269, 323, 361, 396
Li, Y., 131, 296
Li, Z.F., 052
Li, Z., 215, 216, 269, 368, 396
Liao, M. Z., 031
Liardo, E. V., 187
Liberati, A. M., 028, 079, 107, 119
Liberatore, C., 181
Liestøl, K., 239
Ligdi, L., 318
Lim, S. T., 96, 97, 235
Lim, S.H., 286 bis
Lima, C. B., 341, 350
LimbrickOldfield, E. H., 114, 315
Limongello, R., 207
Lin, J., 260
Lin, N., 192, 256
Lin, T., 112
Lin, Y.L., 366
Lin, Y., 157
Linhares, Y., 251
Link, B. K., 041, 185, 186
Linton, K. M., 047
Linton, K., 016, 107, 214
Litovich, C., 053
Liu, C. L., 006, 025, 046
Liu, J., 052, 234, 282, 362, 394
Liu, L., 052, 131
Liu, M., 303
Liu, N., 116
Liu, R. D., 190
Liu, T., 131
Liu, W., 192, 282, 364, 394
Liu, X., 96, 97, 215, 235, 293, 296
Liu, Y.H., 052
Liu, Y.Y., 052
Liu, Y., 168
Llamas Gutierrez, F., 044
Llanos, M., 104
Lleshi, A., 173, 181
LlorinSangalang, J., 113
Lo, A., 200
Lobetti Bodoni, C., 078
Locatelli, F., 037
Locke, F., 082
Loh, J. W., 029
Lohrmann, E., 237
Loi, HoiY., 235
Lolli, G., 191
LomeMaldonado, C., 363
Long, M., 231
Lopes, C., 304
LopezGirona, A., 232
LopezGodino, O., 144
LopezGuillermo, A., 043, 078, 243
Lopez, A., 179
Lorente, S., 286
Lorenzano, F., 316
Lorenzoni, A., 277
Lorne, B., 379
Loscertales, J., 141
Losem, C., 132
Loseto, G., 392
Lossos, I. S., 242
Loutsidi, A., 318
Lown, R., 286 bis
Lowy, I., 94
Loyaux, R., 90
Lu, F., 299
Lu, T., 031, 362
Lucchini, E., 043
Luchetta, P., 348
Luciani, S., 351
Lucioni, M., 043
Lue, J. K., 148
Lugtenburg, P. J., 190
Lugtenburg, P., 016, 239, 250
Luisi, F. A. V., 037
Luizaga, L., 103, 115
Luminari, S., 020, 077, 078, 079, 080, 119,
121, 173, 183, 223, 263, 352
Lund, I., 370
Lundberg, L., 015
Lunning, M., 257
Luponio, S., 332, 390
Lurain, K., 93
Luther, S., 371
Luzardo Henriquez, H. D., 227
Luzardo, H. D., 179
Luzardo, H., 286
Lv, F., 112
Lymboussakis, A., 223
Lymp, J., 273
Lysenko, I., 354
M
Müller, H., 195
Müller, N., 271
M
a
Vale, A., 141
Ma, J., 282, 394
Ma, L., 114
Ma, X.J., 052
Macaulay, C. W., 046
Macaulay, C., 023
Maccaro, C., 056
Mach, N., 062
Machan, S., 226
Maciel, F. V. R., 345
Macintyre, E., 151, 152
Mackensen, A., 082
508
-
AUTHOR INDEX
MacManus, M. P., 326
Macon, W., 171
Macq, G., 344
Maddocks, K. J., 028, 072, 148
Maddocks, K., 061, 075, 180
MaeckerKolhoff, B., 036
Maerevoet, M., 176
Magnano, L., 103, 115
Mahajan, N., 375
Mahler, M., 233
Maier, S., 373
Maierhofer, B., 373
Maiolo, E., 319
Maiorana, A., 043
Maisonneuve, H., 050
Maitre, E., 127
Major, A., 157
Majzner, R., 006
Makita, S., 014, 210
Malak, S., 280
Malecek, M.K., 157
Maliske, S., 185, 186
Malizia, C., 276
Malkowski, B., 049
Malladi, R., 266
Maloisel, F., 389
Maly, J., 238
Mammi, C., 173, 183, 018, 022
Mancino, S., 385
Mancuso, S., 183
Mangone, L., 391
Mangusan, R., 93
Manicone, M., 204
Manji, F., 123
Mankel, B., 069
Mannarella, C., 119
Manni, M., 080, 121, 223, 395
Mannina, D., 080, 119, 187, 352
Mannisto, S., 027, 239
Manos, K., 081
Manske, M. K., 041
MansoAlonso, R., 228
Manso, R., 226, 229, 300
Mantoan, B., 119
Manzke, O., 263
Mapar, P., 92
María Arguiñano, J., 286
María RodríguezPinilla, S., 226
Marín Niebla, A., 060
Maradei, J., 196
Marasca, R., 043, 107
Marcheselli, L., 077, 080, 121, 173, 183,
187, 204, 352
Marchetti, M., 134, 134
Marcial Martínez, W., 302
Marcus, R., 107
Margiotta Casaluci, G., 142
Maria Arguinano Perez, J., 243
Mariani, S., 319
Mariano, R., 196
Marinello, P., 195
Marino, D., 079, 173
Maris, M., 273
Marks, R., 274
Marlton, P., 111
Marouf, A., 189
Marques, B., 172, 337, 339, 341, 350, 381
Marquet Palomanes, J., 169, 170
Marquet, J., 122, 292
Marquez, M., 348
Marra, A., 207
Marra, M. A., 024, 067, 068
Martín GarcíaSancho, A., 060, 182, 227,
286
Martín Moro, F., 169, 170, 292
Martín Rojas, R., 126
Martín Rubio, I., 292
Martín Santos, T., 122
MartínMartitegui, X., 286
MartínSubero, J. I., 058
Martín, A., 122
Martín, R., 117
Martín, S., 333
Martínez Lorca, A., 170
MartínezLaperche, C., 126, 268
Martínez, A.B., 122
Martelli, M. P., 207
Martelli, M., 049, 356
Martens, A. W. J., 294
Martignetti, R., 198
Martin GarcíaSancho, A., 103
MartinAcosta, P., 104, 228, 229
Martin, A., 179
Martin, C., 144
Martin, J. P., 067
Martin, J.P., 068
Martin, M.R., 067, 068
Martin, P., 149, 153, 157, 261
Martin, S., 103, 329
Martines, C., 029
MartinezCalle, N., 194, 197, 212
MartinezLopez, J., 085, 266
MartinezPrieto, M., 267, 272
Martinez, E., 257
Martinez, G., 313
Martinez, X., 213
Martino, M., 275
Martins, C., 304
Martorelli, C., 332, 390
Martus, P., 274
Martynchyk, A., 395
Maruyama, D., 014
Masciopinto, P., 359
Masood, A., 266
MasouridiLevrat, S., 188
Massaro, F., 352
Mata, A. V., 304
Matasar, M. J., 112, 120, 281
Matasar, M., 168, 252, 371, 375
Mateos Mazón, J. J., 141
Mato, A. R., 129
Mato, A., 033
Matous, J., 373
Mattar, B., 273
Mattarucchi, R., 133
Mattioli, V., 391
Mattlener, J., 155
Matturro, A., 385
Matutes, E., 043
Maurer, M. J., 041, 147, 185
Maurer, M., 066
Mauro, F. R., 134
Mavis, C., 102, 370
Mayer, A., 069
Maynard, B., 286 bis
Mayo, M., 013
Mayo, S., 259
Maziarz, R. T., 272
Mazzoleni, G., 391
Mazzucchelli, L., 043, 078
Mazzucco, W., 391
MBoumbae, D. L., 90
Mbulaiteye, S. M., 067, 068
McCarthy, H., 136
McCarthy, M., 340
McCord, R., 240
McCulloch, R., 147
McDonald, A., 013, 193
McGuirk, J. P., 266, 267
McKay, P., 99, 107, 109, 174, 194, 197
McKinney, M., 240
McMillan, A. K., 197
McMillan, A., 087, 243
McNally, D. R., 95
McWhite, K., 370
Mead, M. D., 257, 374
Medeiros, J., 304
Mederios, J., 148
Medina, A., 060
AUTHOR INDEX
-
509
Medinger, M., 188
Meeuwes, F. O., 217
Megalakaki, E., 164
Mehra, A., 112
MehtaShah, N., 051, 056
Mehta, A., 148, 242, 334
Meignan, M., 017, 020, 91, 166, 189, 199,
246
Meignin, V., 043
Meissner, B., 024
Melear, J. M., 063
Mell, T., 100
Mellink, C., 138
Mellios, Z., 164, 318
Melnichenko, V., 354
Melnick, A., 012, 95
Melo, R. B., 345
Menárguez, J., 126
Menarguez, J., 268
Mendibil Esquisabel, B., 353, 387
Mendy, D., 232
Menendez, P., 241
Meng, H., 269
Meng, L., 384
Menna, P., 239
Menne, T. F., 197
Menne, T., 028, 083, 087, 380
Menter, T., 062, 105
Mercadal, S., 104, 115
Mercer, K., 99, 100
Meriranta, L., 92
Merli, F., 020, 048, 049, 079, 173, 183, 187,
204, 352
Merli, M., 029, 043, 077, 079, 080, 121, 133,
173
Mescam, L., 278
Mesquita, I. P., 304
Messmer, M., 148
Metser, U., 049
Mettivier, L., 332, 390
Metz, C., 162
Metzler, S. R., 198
Mey, U. J., 201
Mey, U., 062
Meyer, P., 239
Mi, H., 336
Mi, L., 192, 282, 364, 394
Mi, X., 055
Miall, F., 99, 194, 243
Mian, M., 059, 078
Miao, H. H., 038
Micallef, I. N., 185, 186
Micallef, I., 171
Micallef, S., 244
Miceli, R., 275
Michieli, M., 187
Michot, J.M., 376
Michot, JeanM., 184
MierHicks, A., 157
Mikhaeel, G., 049
Mikhailova, N., 354
Mikhaylova, I. N., 369
Miklos, D. M., 006
Miklos, D., 023
Milan, L., 022
Miles, D., 031
Miller, J. H., 326
Milner, S. G., 207
Minami, H., 209
Mingrone, W., 201
Minguez, P. A., 300
Minoia, C., 223, 392
Minotti, G., 239
Minullina, R., 354
Mirás, F., 141
Mironov, O., 354
Miskin, H. P., 236
Miskin, H., 241
Misleh, J., 130
Missiaglia, E., 045
Missiglia, E., 044
Misyurina, E., 354
Mitschke, J., 046
Miyagi, T., 210
MiyataTakata, T., 064, 065
Mo, Z., 232
Moatti, H., 199
Moccia, A., 043, 048, 070, 201, 246
Mochkin, N., 354
Mociková, H., 107
Mocikova, H., 220, 330
Mohr, A., 370
Mohty, M., 084
Moia, R., 029, 059, 070, 133, 142
Moignet, A., 379
Moja, L., 397
MolesMoreau, MarieP., 050
Moles, M.P., 161, 389
Molica, S., 134
Molina, T. J., 184
Molinari, A. L., 079, 119, 218
Molinari, A., 111, 173
Mollejo, M., 043, 104, 228, 229
MoluçonChabrot, C., 161
Mondéjar, R., 228
Mondoulet, L., 366
Monegier, A., 314
Mongay Soler, L., 112
Monjanel, H., 044, 050
Monsalvo, S., 268
Montalbán, C., 179
Montalban, C., 043
Monter, A., 227
MontesMoreno, S., 182
Montillo, M., 029, 128
Montoro, J., 144
Montoto, S., 053, 078
Moore, S. G., 310
Mora, R. F., 174
Moreaux, J., 366
Morel, P., 044
Morel, V., 160, 162
Moreno Jiménez, G., 169
Moreno, C., 032, 135, 136
Moreno, M., 179
Morgan, R., 378
Morigi, A., 191
Morillo, D., 376
Morin, R. D., 024, 064, 065, 067, 068, 101
Morin, R., 259
Morineau, N., 110, 145, 245
Morishima, S., 014
Morisse, M. C., 085
Morland, C., 214
Morschhauser, F., 005, 015, 079, 084, 91,
109, 110, 145, 146, 176, 190, 245, 261
Mortier, L., 054
Moskowitz, A. J., 021, 051, 056, 120, 221
Moskowitz, A., 211
Moskowitz, C. H., 021
Mosquera Orgueira, A., 167
Motalkina, M., 343
Motta, G., 316
Motta, M., 077, 128
Mottok, A., 97
Mougiakakos, D., 082, 274
Mounier, N., 280
Mous, R., 016
Mozas, P., 103, 115
Mozos, A., 227
Muñiz, P., 126
Muñoz, C., 268
Mucientes, J., 122
Muiña, B., 141
Mulè, A., 352
Mulholland, N., 083
Muller, D., 286 bis
Mullighan, C. G., 067, 068
Mundy, C., 286 bis
510
-
AUTHOR INDEX
Mungall, A. J., 064, 065, 067, 068, 101
Mungall, K., 067, 068
Munksgaard, L., 027
Munoz, J., 086
Munson, D., 377
Muntañola, A., 103, 115, 141, 286
Muntanola Prat, A., 060
Murphy, A. J., 94
Murru, R., 134
Musick, L., 111, 243
Musolino, A., 391
Musso, M., 352
Musto, P., 359
Musulen, E., 241
Musuraca, G., 079, 080, 119, 121, 173, 187,
218
Mutsaers, P. G.N.J., 217
Mutter, J. A., 046
Muxi, P., 358
Muzi, C., 154, 204
Mwangi, R., 066
Mykhalska, L., 357
Myskowski, P., 056, 211
N
Nørgaard, P., 027
Nabergoj, M., 188
Nadeu, F., 058, 103
Nagai, H., 209
Nagler, A., 270, 279
Nagumantry, S. K., 197
Nagy, E., 214
Nahar, A., 193
Naik, S., 157
Nair, B. C., 129
Nair, R., 223
Nakamura, H., 259
Namirembe, C., 067, 068
Nan, F. F., 324
Nan, F., 269, 396
Nanni, L., 191
Narayana Rao Gari, S., 148
Nardelli, C., 359
Narkhede, M., 334
Narla, R. K., 232
Narni, F., 059
Nassi, L., 119, 173, 392
Nasta, S. D., 331
Nasta, S., 244
Nastoupil, L. J., 266
Nastoupil, L., 265, 376
Nasveschuk, C. G., 233
Nath, K., 076
Natkunam, Y., 006
Nauwelaerts, H., 244
Navarro, A., 058
Navarro, B., 104, 117
Navarro, J.L., 122
Navarro, W., 258
Nazario Dolz, M., 302
Neelapu, S., 265
Negievich, Y., 075
Negri, F., 196
Negri, P., 196
Negricea, R., 242
Neidert, N. N., 046
Neuenburg, J. K., 260
Neven, A., 071, 203
Neves, D. S., 341
Neves, D., 172, 337, 339, 350, 381
Ney, D., 157
Ng, S.B., 97
Ng, SiokB., 96, 235
Ngoya, M., 053
NguyenQuoc, S., 162
Nichols, J., 370
Nicolas Virelizier, E., 110, 245
NicolasVirelizier, E., 91
Nicoletti, A., 385
Nielsen, A. F., 89
Nielsen, C., 89
Nielsen, L., 307
Niemann, C. U., 249
Nijland, M., 190, 217
Nikitin, I., 308, 309
Nikitina, T., 354
Nikolaenko, L., 371
Ninomoto, J., 032
Nioche, C., 020
Nistal, S., 286
Niu, T., 052
Noël, R., 044
Noesslinger, T., 132
Nogueira, F. L., 154
Nonis, A., 047
Noor, S., 211
Norasetthada, L., 322
Norman, J., 087
Normant, E., 236, 241
Norol, F., 162
Norris, R. E., 037
Northend, M., 174, 194, 247
Nosaka, K., 014
Notarangelo, L. D., 284
Novak, A. J., 041
Novak, J. P., 041
Novak, U., 043, 062, 201
Novelli, S., 144, 286
Novikov, M., 357
Novo, M., 255
Novoa, A., 298
Novosad, O., 357, 395
Nowakowski, G. N., 066
Nowakowski, G. S., 063, 171, 178, 185, 186,
237, 254, 261, 310
Nowakowski, G., 078, 257
Noy, A., 056, 067, 068, 120, 175, 371
Nuccorini, R., 385
Nunn, L., 99
Nyamutswa, L., 393
O
O'Brien, S., 033
O'Callaghan, A., 286 bis
O'Connor, O. A., 236
O'Hear, C., 240, 242
O'Mahony, D., 197
O'Reilly, M., 087
Oña, R., 117, 227
Oak, J., 006
Oarbeascoa, G., 268
Oberic, L., 146, 152, 184, 317
Obr, A., 028, 330
Occhini, U., 079
Ocheni, S., 398
Ochoa, P., 298
OdoneFilho, V., 037
Oellerich, T., 011
Offner, F. C., 015
Offner, F., 136, 266, 307, 344
Ogasawara, K., 086
Ogna, A., 284
Ogwang, M. D., 067, 068
Ohtsuka, E., 210
Oki, Y., 168, 242
Okwali, M., 120
Oleinik, Y., 343
Oliinichenko, O., 357
Oliva, S., 392
Oliveira, A. C., 333, 347
Oliveira, A., 360
Oliver, A. C., 358
Oliver, R., 194
Oliveri, R. S., 365
Olivier, P., 005
AUTHOR INDEX
-
511
Ollila, T., 157
Olsen, M., 006, 046
Olszewski, A. J., 240
Ondarra Segurola, L., 353
Ong, C. K., 96, 97, 235
Onofrillo, D., 154
Onogi, H., 209, 210
Oostvogels, R., 217
Opat, S. S., 326
Opat, S., 032, 107, 109, 372
Oppi, S., 019
Orem, J., 067, 068
Orme, J., 185
Orsucci, L., 047, 048, 077, 079, 218
Ortiz Romero, P., 98
Ortuño, F., 122
Osborne, W., 083, 087, 99, 174, 194, 197,
380
Oschlies, I., 036
Oscier, D. G., 043
Osipov, Y., 354
Osorio, S., 141
Osovská, M., 285
Östman, A., 206
Özcan, M., 112
Ostrovsky, O., 279
Ott, G., 064, 065, 101
Otto, F., 069
Ouyang, B., 052
Owen, C., 136, 138
Owen, M., 194
Owens, C., 120, 371
Ozcan, M., 193
Ozgur, M., 164
P
Pérez Buira, S., 226
Pérez Ceballos, E., 122
Pérez Corral, A., 268
Pérez Encinas, M. M., 167
Pérez Persona, E., 237
PérezFernández, I., 141
PérezSimón, J. A., 258
Pérez, N., 300
Pérez, S., 141
Paccagnella, A., 276
Pagani, C., 181, 183, 187, 284
Pagel, J., 113
Paget, J., 280
Paik, J., 231
Painter, D., 040
Pak, T., 281
Palaskas, N., 265
Palassopoulou, M., 164
Pallasch, C., 249
Palmer, B., 055
Palmer, J., 213
Palomba, L. M., 120
Palomba, M. L., 114, 175
Palombi, F., 079, 319
Paludo, J., 147, 186
Pan, G., 269
Panchal, A., 031, 137
Paneesha, S., 263
Pang, W. L., 235
Pang, Y., 299
Pangalis, G. A., 078
Panizo, C., 146, 243
Panse, J., 047
Panzarella, T., 384
Paolani, G., 276
Papa, E., 319
Papageorgiou, S. G., 154
Papageorgiou, S., 164
Papavasiliou, F N., 106
Parameswaran, V., 310
Pardee, T. S., 371
Parisi, L., 149, 153
Parody, R., 144, 329
Parreira, J., 118
Parrens, M., 044, 225, 278
Partesotti, G., 119
Pasanen, A., 027, 92
Pascale, S. P., 385
Pasero, P., 366
Pasqualucci, L., 004, 042
Passamonti, F., 029, 043, 133
Passweg, J., 029, 133, 188
Pastano, R., 053
Pastushenko, I., 357
Pastushenko, Y., 395
PaszkiewiczKozik, E., 193, 311
Patah, P., 261, 376
Patel, A. R., 114, 315
Patel, A., 087
Patel, P., 033
Patmore, R., 040
Patriarca, A., 142
Patten, P. E. M., 266
Patten, P., 083
Patterson, V., 198
Patti, C., 019, 218, 312, 352
Paulli, M., 043, 077
Paunescu, A.C., 280
Pavlovsky, A., 196, 202, 223
Pavlovsky, S., 196
Pavone, V., 059, 328, 352
Pavoni, C., 019
Paydas, S., 164
Peñalver, F. J., 286
Peñalver, F.J., 179
Peñarrubia, M., 182
Peano, S., 121
Pecciarini, L., 181
Pedrosa, C. L., 342
Pedrosa, L., 104
Peggs, K., 247
Peixeiro, R. P., 342
Peleteiro Raindo, A., 167
Pellegrini, C., 191
Pelliccia, S., 187, 319
Pellinen, T., 206
Penack, O., 274
Peng, C., 336
Peng, S., 232
Peng, Y. Y., 174
Peng, Y., 96, 97
Pennese, E., 047, 173, 312, 351
Peraza Bordao, J., 302
Perbellini, O., 077
Pereira, J., 165, 223, 313, 345
Pereyra, P., 223
Perez de Oteyza, J., 117
PerezCallejo, D., 015
Perez, A., 082, 144
Perez, L., 056, 211
Perini, G. F., 193
Perino, S., 233
Peron, M., 389
Perrone, T., 080, 119
Peterson, T. J., 281
Petrello, H., 067, 068
Petrides, G., 083
Petrova, T., 354
Petrucci, L., 154, 319
Pettirossi, V., 207
Petzer, A., 266
Peyrade, F., 005
Peyre, M., 152
Pezzullo, L., 332, 390
Pham, S., 242
Phillips, B., 247
Phillips, E. H., 174, 203
Phillips, E., 071, 194
Phillips, N., 174
Phillips, T. J., 061, 238
Phillips, T., 109, 111
512
-
AUTHOR INDEX
Piñana, J. L., 144
Pianovski, M. A., 037
Piazza, F., 043, 077, 134
Piccione, E., 015
Pichler, P., 237
Pickles, T., 200
Piechotta, V., 287, 397, 398
Pietrantuono, G., 079, 121, 352
Pietrasanta, D., 128, 134
Piffaretti, D., 029, 043, 070, 133
Piffer, S., 391
Pike, L. C., 073
Pike, L., 247
Pileckyte, R., 321
Pileri, S. A., 043, 218
Pilz, V., 195
Pimentel, A., 141
Ping, L., 192
Pini, K., 029, 043, 070, 133
PinillaIbarz, J., 033
Pinna, P., 391
Pinnix, C., 265
Pinto, A., 070, 121, 218, 312, 376
Pinyol, M., 069
Pinzón, S., 125
Piparo, C., 312
Piperidou, A., 164
Piras, D., 391
Piris Pinilla, M. Án., 98
Piris Villaespesa, M., 170
Piris, M. Án., 043, 226, 228
Piris, M. A., 104, 227, 229, 300
Piriyakhuntorn, P., 322
Pirosa, M. C., 043, 070, 079, 133
Pisani, F., 047
Pitkänen, E., 92
Pittaluga, S., 064, 065, 101
Pittrow, D., 305
Pizzamiglio, s., 277
Pizzolitto, S., 043
Pizzolo, G., 134
Plates, V., 202
Plattel, W. J., 190
Pokala, S., 118
Poliatskin, I., 343
Politi, L. S., 047
Pollock, R. M., 233
Polo, B., 304
Ponzoni, M., 043, 047, 154, 181
Poon, D., 073
Poon, L., 96, 97, 235
Popplewell, L. L., 374
Popplewell, L., 061, 085, 266
Porcu, P., 014, 054
Porfirieva, N., 354
Porrata, L. F., 171, 185, 186
Porro Lura, M., 030
Portell, C., 107
Porter, R., 130
Portugues, C., 91
Pott, C., 151
Potter, V., 083
Pottinger, B., 99
Poullot, E., 044, 90
Pourdehnad, M., 376
Pourpe, S., 94
Prates, V., 196
Pravato, S., 134
Preau, M., 280
Preciado, M. V., 295
Prete, E., 328, 352
Prica, A., 116, 123, 158, 201, 384
Prince, H. M., 223
Prinz, M., 046
Pro, B., 055, 078
Prochazka, V., 220, 330
ProfitosPeleja, N., 241
Proia, D. A., 233
Prouty, A., 231
Provencio, M., 074, 104
Przespolewski, E., 370
Publicover, A., 380
Pucciarini, A., 207
Puccini, B., 173, 183
Pukrop, T., 047
Pulsoni, A., 077, 079, 080, 119, 121, 352,
356, 382
Pupo, L., 319
Puzzovivo, A., 392
Pylypenko, H., 244
Pytlik, R., 220
Q
Qayum, N., 240
Qi, F., 364
Qi, K., 149, 153
Qian, L., 224
Qian, W.B., 052
Qian, Z., 293, 296
Qiao, Q., 012
Qin, Y., 177
Qiu, J., 336
Qiu, L., 216, 293, 296
Quaglia, F. M., 134
Quaresima, V., 284
Quartara, A., 196
Queizán, J.A., 179
Queizan, J. A., 227
Querfeld, C. S., 213
Queru, K., 044
QuintanillaMartinez, L., 069, 106
Qureshi, I., 174
R
R Thompson, S., 108
Ríos, E., 135, 141
Röth, A., 047
Rütti, M., 201
Radford, J. R., 109
Radford, J., 071, 075, 114, 177, 203
Raemaekers, J., 071, 203
Raess, P. W., 064, 065, 101
Rafferty, J., 99
Rai, S., 209
Rajakumar, P., 157
Rajamäki, A., 383
Rajarethinam, A., 109
Rajguru, S., 148
Ramírez Páyer, Án., 135
RamírezIbarguen, A. F., 363
RamírezPáyer, Án., 182
RamírezPayer, Á., 286
RamírezPayer, A., 141
Ramírez, M., 182
Ramadan, S., 062
Ramakrishnan, P., 154
Ramaswami, R., 93
Rambaldi, A., 019, 022, 246
Ramchandren, R., 193, 257
Ramirez, A., 078
RamisZaldivar, J. E., 069
Ramos, R., 125
Rao, S. S., 130
Raposo, J., 304
Rashid, M. B. M. A., 235
Rasi, S., 029, 142
Rattanathammethee, T., 322
Rattarittamrong, E., 322
Rattotti, S., 077, 119
Rau, R., 393
Raus, N., 189
Raut, M., 193, 195
Ravichandran, H., 95
Raya, J.M., 338
Re, A., 173, 181, 183, 187, 218
AUTHOR INDEX
-
513
Re, F., 059, 077, 079, 080, 119, 173, 187,
218
Rebaud, L., 020
Rebmann Chigrinova, E., 188
RechaviRobinson, D., 244
Reda, G., 134
Redd, R., 198
Reddy, N., 113, 148, 157
Rees, G., 214
Regadas, L., 342
Reguilón Gallego, L., 122
Reinacher, P. C., 046
Reinhardt, H. C., 155
Rejeski, K., 082, 271
Relander, T., 239
Relf, J., 015
Remaggi, G., 196
Remedi, A., 358
Ren, M., 106
Ren, S., 234
Renaud, L., 91
Reneau, J., 180
Renner, C., 062
Renzi, D., 119
Requena, L., 226
Restuccia, F., 351
Rey Búa, B., 182, 286
ReyesGarau, D., 241
Reyes, C. D., 338
Reynolds, C. M., 310
Reynolds, S. J., 067, 068
Riaza, R., 141
Ribeiro, M. L., 241
Ribera, J. M., 329, 333, 347, 360
Riberio, M. T., 114
Ribrag, V., 005, 91, 109, 151, 152, 262, 280
Ricardi, U., 049, 119
Ricart, A. D., 236
Ricciuti, G., 351
Richter, P., 201
Riddick, M., 196, 202
Riedell, P. A., 085, 266, 267
Rietveld, J. M., 294
Rigacci, L., 173
Rigolin, G. M., 134
Rimsza, L. M., 064, 065, 101
Rimsza, L., 041
Rimza, L., 069
Rinaldi, A., 059
Ringeleviciute, U., 321
Ristow, K., 148
Ritchie, D., 081
Ritgen, M., 031, 137, 249
Ritter, K., 188
RivasDelgado, A., 103, 115
Rivas, A., 179
Rivero, A., 103, 115
Robak, T., 033, 127, 136, 146
Robe, C., 90
Robinson, K. W., 331
Robrecht, S., 030, 031, 034, 137, 249
Rocha, V. G., 313
Rocha, V., 165, 345
Rocquet, M., 189
Rodari, M., 070
Roddie, C., 174
Rodin, D., 158, 201
Rodríguez Martín, E., 170
RodríguezFernández, A., 141
RodríguezPeralto, J. L., 226
RodríguezPinilla, S. M., 228
RodríguezSalazar, M.J., 338
Rodríguez, M., 228, 329
RodriguezGonzalez, F. G., 89
RodriguezLuaces, M., 360
RodriguezPeralto, J. L., 98
RodriguezPinilla, S. M., 98, 229, 300
RodriguezRivera, I., 120, 371
RodriguezSevilla, J. J., 125
Rodriguez, G., 144
Rodriguez, M.J., 179
Rodriguez, M., 98, 226, 227, 229, 300, 333
Rodriguez, R., 366
Roig, M., 227
Rois Pego, N. F., 353, 387
Rojo, F., 300
Roldán Santiago, E., 170
RoldánPérez, A., 286
Roman, E., 040
Romano Gargarella, L., 134
Romano, A., 019, 316
Romanowicz, G., 070
RomejkoJarosińska, J., 311
Romero, P., 141
Ronan, R., 373
Rontogianni, D., 318
RoosWeil, D., 160, 162
Roque, A., 172, 339, 341, 350, 381
Rosamilio, R., 332
Roschewski, M., 025
Rosen, S. T., 213
Rosenberg, E., 279
Rosenthal, A. C., 185, 186
Rosenthal, A., 257, 064, 065, 101
Roshan, R., 93
Rossi, A., 352
Rossi, C., 050, 246, 025, 029, 043, 059, 070,
079, 128, 132, 133, 142, 246
Rossi, F. G., 218
Rossi, G., 181, 183, 187, 284
Rosskamp, M., 344
Rosso, S., 391
Rotger, A., 060
Rotolo, F., 054
Roue, G., 241
Rouits, E., 244
Roulin, L., 90
Roumelioti, A., 318
Roveri, E., 196
Rovira, J., 115, 329, 333, 347, 360
Rovo, A., 188
Ruan, J., 055
Rubenstein, J., 157
Rubio, L., 201
Rubio, M. T., 189
Rubio, M.T., 162
Rubio, MarieThérès., 084
Rudge, J. F., 197
Rudiuk, T., 357
Rudoy, S., 196
Ruf, S., 036
Ruffini, A., 020
Ruggiu, M., 314
RuizCamps, I., 141
Ruiz, C., 122
Ruiz, F., 377
Ruiz, M
a
E., 141
Rukavitsyn, O., 354
Rule, S., 146, 147
Rummel, M. J., 047,063, 310
Rumpold, G., 280
Ruppert, A., 072
Rusconi, C., 049
Rushton, C. K., 024, 065, 101
Russell, K., 032
Russo, A. G., 391
Russo, F., 077
Ruzicka, M., 271
Ruzickova, L., 172, 337, 339, 341, 350, 381
Ryan, G., 078
Ryu, S., 056, 211
S
Sánchez Blanco, J. J., 182, 227
Sánchez Blanco, J.J., 122
SánchezBeato, M., 228, 229
SánchezGonzález, B., 286
514
-
AUTHOR INDEX
SánchezRamírez, M., 141
Sánchez, M
a
J., 141
Sønderskov Gørløv, J., 047
Sørensen, B., 89
Saadoon, E., 344
Sabattini, E., 043
Sabdia, M. B., 076
Sabell, S., 268
Sacchetti, G. M., 070
Sacchi, M., 074
Sackman, F., 196
Sadullah, S., 174
Safin, R., 354
Sagiraju, S., 142
Saha, S., 111, 243
Sahaf, B., 006
Sakellariou, K., 318
Salanoubat, C., 162
Salar, A., 104, 117, 122, 125, 179, 263
Salas, Q., 144
Salaverria, I., 069
Sale, B., 99
Salles, G., 028, 043, 082, 91, 109, 120, 149,
153, 175, 178
Salman, H., 113
Salman, S., 157
SalmerónVillalobos, J., 069
Salvador Chalup, M. M. B., 154
Salvino, M. A., 037
Samii, K., 346
Samoylova, A., 354
Sampol, A., 144
Sanchez Avalos, J. C., 298
SanchezBeato, M., 104
SanchezGonzalez, B., 125
Sancho Cia, J. M., 360
Sancho, J. M., 103, 115, 117, 286, 329, 333,
347
Sancho, J.M., 179
Sander, S., 106
Sanderson, R., 083, 087
Santambrogio, E., 043
Santarosa, A., 211
Santarsieri, A., 197
Santi, A., 207
Santiago, R., 141
Santoro, A., 051, 074, 077, 193, 275
Santoro, M., 276
Santos, J. C., 241
Santuccio, G., 316
SanzPamplona, R., 227
SanzVillanueva, L., 126
Sapunarova, K., 112
Sarangi, V., 041
Saretsky, T., 193
Sarouei, K., 240
Sartori, R., 173, 183
Sasaki, O., 210
Sasser, A.K., 365
Sassone, M. C., 156, 181
Sauter, C., 053
Savage, K. J., 024, 038, 064, 065, 074, 075,
101, 150
Savage, K., 200
Sawalha, Y., 148, 180
Sawicki, W., 311
Sayas, M. J., 227
Saydam, G., 112
Scalzulli, P. R., 154, 328, 352
Scarfò, L., 029, 128, 133, 134
Scarfó, L., 043
Schär, S., 018, 022, 062
Schöberl, F., 271
Schöder, H., 021, 072, 073
Schachter, J., 279
Schanz, U., 188
Scheich, S., 011
Scheid, C., 287
Scherer, F., 025, 046
Scherle, P., 231
Schetelig, J., 034
Scheubeck, G., 062
Schiano de Colella, J. M., 110, 145, 245
Schiano De Colella, J.M., 278
Schiavoni, G., 207
Schiavotto, C., 019
Schilhabel, A., 034, 139, 151
Schipani, M., 059, 142
Schmidt Jespersen, J., 89
Schmidt, A., 201
Schmidt, B., 132
Schmidt, C., 082, 271
Schmitt, A., 109, 389
Schmitt, M., 274
Schmitt, T., 274
Schmitz, N., 053
Schmoll, H. J., 047
Schneider, C., 030, 034
Schoder, H., 120
Schoen, F., 151
Scholz, C. W., 263
Scholz, C., 228
Schorb, E., 046, 047
SchroersMartin, J., 006
Schroers, R., 274
Schultz, A., 025
Schuster, S. J., 085, 266, 272, 331
Schuurhuis, D., 365
Schwaner, I., 132
Schwieterman, J., 056
Sciabolacci, S., 207
Scott, D. W., 024, 064, 065, 067, 068, 95, 97,
101, 150, 259
Scott, D., 012, 200
Scott, F. M., 335
Seguy, F., 263
Sehgal, L., 231
Sehn, L. H., 024, 064, 065, 150, 252, 263
Sehn, L., 200
Sekiguchi, N., 193
Sellam, G., 240
Selleri, C., 332, 390
Semiglazova, T., 343
Septans, A.L., 389
Sequero, S., 104
Serbest, G., 014
Seregni, E., 277
Seri, C., 141
Serio, B., 332, 390
Serraino, D., 391
Serres, M. R., 041
Seshadri, M. R., 012
Seshan, V. E., 120
Sesques, P., 050, 082, 084
Setoain, X., 060
Sevastoudi, A., 301
Seyffert, S., 373
Seymour, E., 243
Seymour, J. F., 111, 138
Sha, F., 120
Sha, Y., 336
Shadman, M., 130
Shah, B., 146, 148, 198
Shah, N. N., 129
Shah, N., 174, 197, 237
Shalaev, S., 343
Shanavas, M., 076
Shang, G., 109
Shao, S. H., 310
Sharma, K., 013
Sharman, J. P., 063, 130, 310
Sharman, J., 273
Shaughnessy, P., 273
Shaw, J., 380
Shcolnik, R., 345
Shelekhova, T., 354
ShemTov, N., 270
Shen, W., 364
Shenderova, I., 388
AUTHOR INDEX
-
515
Sherstnev, D., 354
Sheybani, N., 006
Shi, C., 367
Shi, Y., 112
Shiano del colella, J. M., 199
Shibayama, H., 209, 210
Shimoda, K., 210
Shimoni, A., 270, 279
Shin, H.J., 057
Shindo, T., 209
Shipp, M. A., 074
Shotton, R., 194
Shouval, R., 270
Shpall, E., 265
Shrubsole, C., 194
Shu, S., 364
Shu, Y., 216
Shudrak, N., 395
Shukla, N., 006
Siakantaris, M., 164
Sibon, D., 005, 044, 110, 184, 189, 225, 280
Sicard, G., 189
Siddiqi, T., 032, 086
Sidi, Y., 037
Sidiropoulou, E., 106
Siebert, R., 106
Sieg, A., 157
Sieg, N., 155
Silva, P., 268
Silva, W. F., 165
Simón, J. A. P., 266
Sim, H. W., 174
Simashova, P., 354
Simko, S., 253
Simpson, D., 136, 372
Sims, R. B., 254
Singer, S., 157
Singh, A., 029
Singh, V., 174
Siqueira, S. A. C., 345
Sirulnik, A., 94
Siyu, Q., 399
Skoetz, N., 287, 397, 398
Skrypets, T., 223, 392, 395
Slack, G. W., 024, 064, 065, 101
Slade, D., 214
Sloan, S., 231
Smet, A., 307
Smirnova, E., 354
Smith, A. G., 040
Smith, C. D., 349
Smith, C., 081, 108
Smith, J., 047
Smith, S. D., 146
Smith, S. M., 157
Snauwaert, S., 307
SnijdewintNkairi, R., 365
Soares, I. C., 345
SobierajTeague, M., 107
Soehlbrand, A., 151
Soh, T. G., 235
Sohail, S., 211
Sohoni, S., 033
Sokol, L., 198
SoléRodríguez, M., 286
Soler, J. A., 141
Solh, M., 177
Solomon, S., 086
Solorzano, S., 160
Somasundaram, N., 235
Song, J. Y., 064, 065, 101
Song, W., 367, 368
Song, Y.P., 052
Song, Y., 057, 131, 192, 256, 282, 364
Song, Z., 293
Soo, J., 025
Sopena Novales, P., 122
Sorasio, R., 019
Sorigue, M., 383
Sorio, M., 352
Sotttini, A., 284
Souchet, L., 162
Soumerai, J. D., 113
Souravla, K., 318
Soussain, C., 156, 161, 162
Speletas, M., 305
Spina, M., 077, 079, 173, 181, 183, 255
Spina, V., 029, 043, 070, 133, 142
Spindler, T., 377
Sportoletti, P., 134, 207
Spurgeon, S., 157
Sreevatsan, P., 012
Stüssi, G., 029, 043, 070, 133
Staber, P., 249
Stafford, G., 197
Stakia, P., 188
Stamatoullas, A., 189, 199
Stanton, l., 99, 100
Stasia, A., 070
Stathis, A., 043, 070, 079, 113, 177
Staudt, L. M., 011, 064, 065, 067, 068, 101
Stefani, P. M., 059, 080, 121, 352
Steffanoni, S., 156
Stefoni, V., 191, 218
Steidl, C., 024, 064, 065, 95, 101
Steimle, T., 152
Steiner, R., 265, 371
Steinerová, K., 285
Steinerova, K., 220, 330
Steinhilber, J., 069
Stelitano, C., 059, 119
Stelljes, M., 274
Stenner, F., 201
Stenson, C., 380
Stepanishyna, Y., 395
Stephens, D. M., 086
Stern, A., 188
Sternberg, A., 197
Stevens, D. A., 273
Stevens, K., 208
Stieglmaier, J., 374
Stilgenbauer, S., 030, 031, 033, 034, 047,
137, 139, 249
Stocker, R., 380
Storozhenko, L., 388
Storti, S., 183
Stracci, F., 391
Strati, P., 265
Straus, D. J., 038, 175
Straus, D., 056, 120, 371, 375
Streich, S., 069
Strigari, L., 276
Strolin, S., 276
Strouse, C., 157
Stumpf, J., 249
Sturgess, K., 197
SuárezGonzález, J., 126
Suarez, M., 122
Subklewe, M., 082, 271, 374
Sudhindra, A., 114, 315
Sujobert, P., 278
Sukor, S., 340
Suleman, A., 116
Sun, C. Z., 324
Sun, C., 143
Sun, M., 107
Sun, X., 303
Sun, Y., 258
Sun, Z., 269, 323, 361, 396
Sundaram, S., 102, 157, 370
Sunela, K., 383
Sureda, A., 015, 053, 179, 246, 329, 333,
347, 360
Svoboda, J., 331
Svobodová, E., 285
Swanink, R., 074
Swaroop, A., 055
Swerdlow, S. H., 067, 068
Sworder, B., 006, 023
516
-
AUTHOR INDEX
Sykorova, A., 220, 330
Symeonidis, A., 164
Syrykh, C., 278, 297
Szablewski, V., 176
SzaferGlusman, E., 032, 365
SzlauerStefańska, A. T., 311
Szoke, A., 136
Szomor, Á., 112
Szor, R. S., 313
Szymczyk, M., 150
T
Tabbo', F., 102
Tadmor, T., 164
Tafuri, A., 319, 352
Tagliabue, G., 391
Taguchi, J., 210
Takamatsu, Y., 210
Takano, K., 210
Takvorian, T., 198
Talaulikar, D., 076, 107
Talotta, D., 142
Tam, C. S. L., 032
Tam, C. S., 236, 372
Tam, C., 260
Tam, W., 95
Tamayo, P., 122
Tamburini, J., 189
Tambuyzer, T., 283
Tan, D., 235
Tan, L. K., 235
Tan, S.Y., 97
Tandon, M., 030, 031, 137
Tang, J.P., 236
Tang, T., 96, 97, 235
Tang, W., 272, 373
Tang, Y., 192, 256
Tani, M., 048, 079, 119, 121, 154, 173, 187,
218, 238
TansleyHancock, O., 99
Tantiworawit, A., 322
Tao, L., 146, 252
Tapia, G., 043
Tarantini, G., 173, 328
Tarantino, V., 121, 154
Tardy, M., 050
Tartas, N., 298
Tarte, K., 110, 145, 297
Tasakis, R. N., 106
Tasselli, L., 207
Tatevosova, N. S., 369
Tausch, E., 030, 031, 034, 137, 139, 249
Taveras, A., 373
Tchernonog, E., 044
Tedeschi, A., 029, 032, 107, 128, 133, 136
Teihman, S., 270
Templeton, A. J., 201
Tempra, P., 298
ten Hagen, W., 365
Terdi Di Bergamo, L., 142
Terol, M. J., 060
Terol, M.J., 122
Terol, M
a
J., 141
Teruel, A.I., 122
Terzi di Bergamo, L., 029, 043, 070
TerzidiBergamo, L., 133
Tesei, C., 319
Teshima, T., 266
Tessoulin, B., 199
ThadaniMulero, M., 138
Thanarajasingam, G., 147
Theurich, S., 398
Thieblemont, C., 005, 017, 043, 079, 084,
085, 91, 107, 110, 145, 152, 166, 176,
184, 250, 266, 314
Tholouli, E., 087
Thomas, C., 011
Thomas, N., 067, 068
Thomas, R.N., 370
Thomas, S., 274, 373
Thome Miazza, M., 045
Thompson, C. A., 185
Thompson, C., 066
Thompson, M. C., 129
Thompson, S. R., 349
Thompson, S., 327
Thornton Snider, J., 114, 315
Thorpe, J., 086
Thorsgaard, M., 89
Thota, V., 377
Thurner, L., 047
Thurston, G., 94
Tiacci, E., 207
Tian, Z., 289, 291
Tilly, H., 005, 017, 050, 079, 91, 109, 110,
145, 166, 176, 184, 245
Timothy, G., 068
Tisi, M. C., 154, 275
Tissino, E., 029
Tiwari, R., 266
To, I., 242
Tobin, J. W., 076
Tobinai, K., 014, 209, 210
Toffanin, S., 244
Toffolutti, F., 391
Toldbod, H., 239
Tomás Navarro, J., 122
TomásRoca, L., 98, 228
Tomás, L., 227
TomasRoca, L., 229
Tomei, G., 319
Tomiczek, M., 118
Tomlinson, E., 398
Tomuleasa, C., 223
Tong, Y., 052
Tonialini, L., 328
Tonino, S. H., 190, 294
Tonnelet, D., 050
Tonseth, P., 259
Tooze, R., 040, 100
Topp, M. S., 94
Topp, M., 274
Torka, P., 102, 157, 370
Torres, A., 141
Tosti, M. E., 119
Touat, M., 156
Tounta, G., 318
Tournilhac, O., 044, 225
Tousseyn, T., 043
Townsend, W., 174
Traverse Glehen, A., 199
TraverseGlehen, A., 043, 050, 067, 068
Trede, N. S., 273
Trenina, N., 354
Trentim, L., 134
Trentin, L., 019, 032
Treon, S., 373
Triantafyllou, T., 301
Trichelair, P., 010
Tripodo, C., 96, 97
Trněný, M., 285
Trneny, M., 074, 078, 220, 244, 263, 330
Trotman, J., 076, 107
Troussard, X., 127
Trumpp, A., 106
Tsai, D. E., 129
Tsai, N.C., 213
Tsang, H., 076
Tsang, M., 157
Tsang, R., 078, 158, 201
Tsinaris, Z., 301
Tsirigotis, P., 164
Tsirogianni, M., 164
Tsirou, K., 301
Tsonis, I., 318
Tsukamoto, N., 209
Tsukasaki, K., 014, 209, 210
AUTHOR INDEX
-
517
Tu, G., 364
Tu, M., 192
Tucci, A., 043, 047, 048, 049, 080, 154, 173,
183, 187, 204, 284
Tudesq, J. J., 084
Tuglular, T., 164
Tuglus, C., 374
Tulstrup, M. R., 89
Tumino, R., 391
Tun, A. M., 185, 186
Tun, H. W., 222, 257
Turba, E., 198
Turner, G., 214
Turroni, S., 205
Tytorenko, I., 395
Tzankov, A., 018, 043, 105
Tzenou, T., 318
U
Uña, J., 122
Uchida, T., 112, 209
Uldrick, T. S., 93
Ultimo, S., 207
Umyarova, E., 148
Ungar, D., 177, 251, 264
Unterhalt, M., 150
Us, I., 012
Usai, S. V., 080, 173, 218
Utsunomiya, A., 014, 210
Uttenthal, B. J., 197
Uttenthal, B., 039
Uzunov, M., 160, 162
V
Vaca, R., 157
Vacca, M. P., 359
Vaccarella, S., 391
Vacková, B., 285
Vaddi, K., 231
Vaillant, W., 317
Vallisa, D., 077, 187, 044, 045
Van Bogaert, C., 307
van de Brug, T., 021
van den Berg, A., 190
van der KevieKersemaekers, A., 138
van der Poel, M. W.M., 217
Van Eycken, L., 283
van Hoppe, M., 100
van Hoppe, S., 040
Vanazzi, A., 048
Vander Borght, T., 005
Vannata, B., 078
Vanquaethem, H., 389
VanSchoiack, A., 96
Vaqué, J. P., 98
VardaBloom, N., 270
Vardhana, S. A., 221
Varela, A., 196
Varela, J. C., 273
Varela, M. R., 144
Varettoni, M., 218
Varvarà, M., 391
Vasiliev, E., 354
Vasilieva, A., 388
Vassilakopoulos, T. P., 154
Vassilakopoulos, T., 164
Vega, F., 265
Vela, V., 105
Velasques, R. D., 165, 345
Velasquez, C. A., 141
Venanzi, A., 207
Vendiola, J. A., 157
Venegas, M. B., 298
Venugopal, P., 157
Vercellino, L., 017, 91, 166
Verderio, P., 277
Verdesoto, S., 360
Verga, L., 181
Vermaat, J. S.P., 217
Verner, E., 372
Verrou, E., 301
Versari, A., 020, 049, 080, 121
Veyrune, J.L., 366
Viailly, P., 91
Viardot, A., 266
Vicent, A., 329
Vidal, M
a
J., 141
Vidrine, J., 380
Viennot, M., 91
Vignon, M., 386
Viguria Alegria, M. C., 227
Viguria, M. C., 144
Viguria, M., 182
Vijnovich Baron, A., 298
Villa, D., 024, 147, 148, 150, 200, 259
Villacampa, G., 141
Villaescusa, T., 228, 229
Villalón, L., 141
Villamor, N., 103
Villarese, P., 151
Villarreal, J. A., 333
Villarroel, J., 329
Villarrubia Espinosa, J., 169
Villasboas, J. C., 186
Villemagne, B., 044
Vindelov, S. D., 250
Vinogradova, Y., 388
Vinyoles, M., 241
Visco, C., 043, 077, 078, 147, 167
Visentin, A., 134, 352
Visnadi, H., 345
Visser, L., 190
Visser, O., 217
Viswanathan, H., 393
Vitale, C., 128, 134
Vitolo, U., 043, 048, 255
Vitriu, A., 298
Viviani, S., 019, 246, 392
Vlasevska, S., 042
Vodička, P., 285
Vodicka, P., 330
Voegeli, M., 062, 201
VoevodaDimenshtein, V., 279
Volchenkov, S., 343
Volodicheva, E., 354
Volpetti, S., 218
von Baumgarten, L., 271
von BergweltBaildon, M., 082
von Bergwelt, M., 271
von Bonin, M., 274
von Keudell, G., 074, 120
von Roemeling, R., 257
von Tresckow, B., 155, 195, 266, 274
Vorozheikina, E., 118
Vos, J. M. I., 294
Vose, J. M., 148
Vrakidou, E., 164
Vucinic, V., 274
W
W Macauley, C., 006
W Wright, G., 011
Wößmann, W., 036
Wade, S. W., 114
Wade, S., 393
WagnerDrouet, E. M., 274
WagnerJohnston, N. D., 072
WagnerJohnston, N., 238
WagnerJohntson, N., 148
Wahlin, B. E., 263
Walewski, J., 236, 246
Waller, E. K., 267
Wan, W., 396
518
-
AUTHOR INDEX
Wang, A., 377
Wang, B., 011
Wang, C.F., 052
Wang, D., 129, 364
Wang, J., 102
Wang, L.Q., 052
Wang, L., 026, 052, 075, 264, 282, 394
Wang, M. L., 260
Wang, M.C., 112
Wang, M., 057, 146, 148, 149, 153, 265, 269
Wang, S., 131
Wang, T., 131, 261
Wang, W., 159, 224
Wang, X., 052, 131, 192, 215, 234, 256, 269,
282, 289, 291, 293, 296, 303, 323, 325,
361, 362, 364, 396
Wang, Y., 066, 171, 185, 186, 269, 269, 320
Wang, Z., 216, 336
Wapenaar, R., 307
Warbey, V., 247
Wartski, M., 386
Warwick, L., 140
Waultier Rascalou, A., 162
Waultier, A., 161
Webster, N., 040
Wehrle, J., 046
Weiß, A., 151
Wei, J.Y., 052
Weigert, O., 082
Weinreich, D. M., 94
Weinstock, D., 056
Weirather, J., 028
Weischenfeldt, J. L., 89
Weisenburger, D. D., 064, 065, 101
Weiss, J., 155, 384
Weiss, M., 013
Wendtner, C. M., 034
Wendtner, C., 031, 137, 249
Wenzl, K., 041
Westhead, D., 100
Westin, J. R., 025
Westin, J., 265
Wetherall, N., 286 bis
Whitby, D., 93
Wickham, N., 236
Widell, A., 93
WielgosBonvallet, M., 365
Wierda, W. G., 032, 086, 129
Wiesinger, A., 315
Wilcox, R., 061
Willaume, A., 050
Willems, L., 161, 162, 386
Willenbacher, W., 074
Williams, C., 174
Willimott, V., 286 bis
Wills Sanin, B., 221
Wilson, W. H., 025, 067, 068
Wilson, W., 174
Winderlich, M., 178
Winkelmann, M., 271
Winter, J., 055
Wirth, A., 326
Witzig, T. E., 066, 171, 185, 186
WoeiAJin, F. J. S. H., 244
WoeiAJin, S., 217
Wold, B., 027
Wolff, D., 274
Wolff, T., 132
Wondergem, Mariël., 217
Wong, J., 065, 067, 101, 370
Wood, S., 232
Worel, N., 258, 267
Woszczyk, D., 240
Woyach, J., 129
Wróbel, T., 236
Wrench, D., 174
Wu, C.Y., 052
Wu, D.P., 052
Wu, F., 376
Wu, H., 012, 215
Wu, J. Q., 138
Wu, J., 323, 361
Wu, M., 192
Wu, T., 216
Wu, W., 029, 043, 336
Wu, X., 213, 215, 396
Wuerthner, J., 075
Wulf, G., 274
Wynn, T., 286 bis
X
Xerri, L., 044, 278, 297
Xia, M., 012
Xia, Y., 396
Xia, Z., 131
Xian, D., 261
Xiang, S., 269
Xiao, R., 052
Xiao, Y., 215
Xie, Y., 192, 240, 256
Xiong, J., 052
XuMonette, Z., 167
Xu, B., 052, 131
Xu, D., 396
Xu, H., 269
Xu, J.Y., 052
Xu, P.P., 052
Xu, P., 026
Xu, W., 131, 215, 336
Xu, X., 216
Xu, Z., 216
Xudong, Z., 399
Xue, H., 320
Y
Y Spiegel, J., 006
Yáñez, L., 135, 141
Yañez, E., 112
Yañez, L., 144
Yacoub, A., 063, 310
Yahalom, J., 120
Yallop, D., 083
Yamauchi, N., 014
YanLi, L., 288
Yan, F., 052
Yan, J., 269, 396
Yan, X., 364
Yancopoulos, G. D., 94
Yang, D. H., 209
Yang, H., 057, 216, 272
Yang, J., 234
Yang, L., 086, 269
Yang, S., 131
Yang, X., 195
Yang, Y., 011, 114, 336
Yang, Z., 041, 057
Yanguas, N., 104
Yannakou, C. K., 236
Yap, C., 214
Yarchoan, R., 93
Yasenchak, C. A., 254
Yavrom, S., 262
Ye, J., 299
Ye, Y., 364
Yedwabnick, M., 377
Yenerel, M. N., 033
Yerushalmi, R., 270
Yi, H.M., 052
Yimer, H. A., 130
Yimer, H., 273
Yin, M., 129
Yin, Z., 303
Ying, Z., 192, 256, 364
Yoffe, L., 102
Yokoyama, M., 209
AUTHOR INDEX
-
519
Yonekura, K., 210
Yoon, D. H., 209
Yoon, D.H., 057
Yoshida, S., 209, 210
Yosifov, D., 030
You, F., 269
Younes, A., 120
Young, J., 171
Young, K., 167
Youssef, M., 273
Youssef, Y., 231
Ysebaert, L., 110, 145, 245, 317, 379
Yu, H., 269, 364, 396
Yu, J., 293
Yu, L., 052
Yu, X., 011
Yuen, S., 111
Yuen, Y. C., 235
Yun, X., 303
Z
Zabaljauregui, S., 196
Zabalza, A., 141
Zaccaria, G. M., 059
Zafar, S. F., 130
Zain, J. M., 055
Zain, J., 213
Zaja, F., 080
Zamprogna, G., 128
Zanabilli, J., 144
Zanatta, A., 133
Zander, T., 062, 201
Zangrilli, I., 070
Zanni, M., 047, 059, 079, 119, 173, 187, 218
Zaucha, J. M., 070, 246
Zayac, A., 157
Zeberio Etxetxipia, I., 182, 353, 387
Zeberio, I., 286
Zecca, M., 037
Zektser, M., 164
Zelenetz, A. D., 113, 120, 175
Zelenetz, A., 375
Zenz, T., 043, 128
Zhang, B., 131, 269
Zhang, C., 030, 031, 137, 139, 192
Zhang, H., 052, 131, 293, 296, 303
Zhang, J., 266, 272
Zhang, L., 163, 215, 269, 323, 361, 396
Zhang, M., 026, 269, 269, 323, 324, 325,
361, 368, 396
Zhang, Meif., 163
Zhang, Q., 112
Zhang, S., 293
Zhang, T., 293
Zhang, W., 94, 131, 159, 163, 224, 364
Zhang, X. Y., 235
Zhang, X., 052, 130, 163, 289, 291, 303, 323,
325
Zhang, Y., 159, 163, 224, 231, 289, 291, 303
Zhao, D., 159, 282
Zhao, J., 293
Zhao, R., 131
Zhao, W.L., 052
Zhao, W., 026, 049, 252
Zhao, Y., 234, 299
Zhelyazkova, A., 99
Zheng, W., 192
Zheng, X.Y., 052
Zhong, H.J., 052
Zhou, C., 032
Zhou, D., 159, 163, 224
Zhou, J., 131
Zhou, K., 107, 216
Zhou, S., 293, 296
Zhou, W., 107
Zhou, X., 052, 234, 362
Zhou, Z., 269, 396
Zhu, A., 149, 153
Zhu, E. Y., 129
Zhu, H., 336
Zhu, J., 057, 192, 256, 282, 364
Zhu, Z., 131
Zhu, ZunM., 052
Zia, A., 085
Ziegelbauer, J. M., 93
Zignego, A. L., 077
Zijlstra, J. M., 021, 190
Zikos, P., 164
Zilioli, V. R., 049, 119, 173, 183, 187, 204,
218, 352
Zimmermann, M., 036
Zinger, M., 389
Zinzani, P. L., 038, 043, 051, 054, 074, 075,
107, 112, 127, 128, 146, 154, 177, 191,
193, 205, 238, 250, 252, 262, 264, 266,
276, 312
Zinzani, P., 275
Zmajkovicova, K., 373
Zoppegno, L., 196
Zorzi, M., 391
Zou, Dongm., 163
Zucca, E., 018, 022, 029, 043, 047, 048, 049,
062, 070, 078, 079, 133, 246,
314
Zuccaro, V., 077
Zucchetto, A., 029
Zucenka, A., 321
Zukotynski, K., 259
Zumalde Murua, A., 353, 387
Zverkova, A., 343
Zwezerijnen, G. J. C., 021
Zwezerijnen, G. J., 190
Zyuzgin, I., 343
520
-
AUTHOR INDEX